<HTML><HEAD><TITLE>Gene Ontology Results</TITLE></HEAD><BODY>
<H1>Gene Ontology Enrichment Results</H1>
<A HREF="homerResults.html">Homer <i>de novo</i> Motif Enrichment Results</A><BR/>
<A HREF="knownResults.html">Known Motif Enrichment Results</A><BR/>
<H4>Text file version of complete results (i.e. open with Excel)
<UL>
<LI><A HREF="biological_process.txt">biological process</A>: Functional groupings of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="molecular_function.txt">molecular function</A>: Mechanistic actions of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="cellular_component.txt">cellular component</A>: Protein localization (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="chromosome.txt">chromosome location</A>: Genes with similar chromosome localization (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="kegg.txt">KEGG pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.genome.jp/kegg/pathway.html">KEGG</A>)</LI>
<LI><A HREF="interactions.txt">protein interactions</A>: "Proteins interacting with a common protein (BIND, EcoCyc, HPRD)" (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="interpro.txt">interpro domains</A>: Proteins with similar domains and features (<A HREF="http://www.ebi.ac.uk/interpro/">Interpro</A>)</LI>
<LI><A HREF="pfam.txt">pfam domains</A>: Proteins with similar domains and features (<A HREF="http://www.sanger.ac.uk/Software/Pfam/">Pfam</A>)</LI>
<LI><A HREF="smart.txt">smart domains</A>: Proteins with similar domains and features (<A HREF="http://smart.embl-heidelberg.de/">SMART</A>)</LI>
<LI><A HREF="gene3d.txt">gene3d domains</A>: Proteins with similar domains and features (<A HREF="http://cathwww.biochem.ucl.ac.uk:8080/Gene3D">Gene3D</A>)</LI>
<LI><A HREF="prosite.txt">prosite domains</A>: Proteins with similar domains and features (<A HREF="http://ca.expasy.org/prosite/">Prosite</A>)</LI>
<LI><A HREF="prints.txt">prints domains</A>: Proteins with similar domains and features (<A HREF="http://www.bioinf.manchester.ac.uk/dbbrowser/PRINTS/">PRINTS</A>)</LI>
<LI><A HREF="msigdb.txt">MSigDB lists</A>: "Genes sets for pathways, factor/miRNA target predictions, expression patterns, etc." (<A HREF="http://www.broadinstitute.org/gsea/msigdb/index.jsp">MSigDB</A>)</LI>
<LI><A HREF="biocyc.txt">BIOCYC pathways</A>: Groups of proteins in the same pathways (<A HREF="http://biocyc.org/">BIOCYC</A>)</LI>
<LI><A HREF="cosmic.txt">COSMIC cancer mutations</A>: Genes mutated in similar cancers (<A HREF="http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/">COSMIC</A>)</LI>
<LI><A HREF="gwas.txt">GWAS genes</A>: Genes mutated in similar diseases (<A HREF="http://www.genome.gov/26525384">GWAS Catalog</A>)</LI>
<LI><A HREF="lipidmaps.txt">Lipid Maps pathways</A>: Groups of proteins in the same lipid pathways (<A HREF="http://www.ncbi.nlm.nih.gov/biosystems/">Lipid Maps/Biosystems</A>)</LI>
<LI><A HREF="pathwayInteractionDB.txt">Pathway Interaction DB</A>: Groups of proteins in the same pathways (<A HREF="http://pid.nci.nih.gov/">Pathway Interaction Database</A>)</LI>
<LI><A HREF="reactome.txt">REACTOME pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.reactome.org/PathwayBrowser/">REACTOME</A>)</LI>
<LI><A HREF="smpdb.txt">SMPDB pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.smpdb.ca/">SMPDB</A>)</LI>
<LI><A HREF="wikipathways.txt">WikiPathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.wikipathways.org/index.php/Special:BrowsePathwaysPage">Wikipathways</A>)</LI>
</UL>
<H2>Enriched Categories</H2>
<TABLE border="1" cellpading="0" cellspacing="0">
<TR><TH>P-value</TH><TD>ln(P)</TD><TD>Term</TD><TD>GO Tree</TD><TD>GO ID</TD><TD># of Genes in Term</TD><TD># of Target Genes in Term</TD><TD># of Total Genes</TD><TD># of Target Genes</TD><TD>Common Genes</TD></TR>
<TR><TD>1.771e-07</TD><TD>-15.55</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>691</TD><TD>11</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,IGF1R,MAP2,ATP9A,TSC22D3,FRAS1,ATP2C2,AIM1,COL4A5,FAM198B,SYTL2</TD></TR>
<TR><TD>2.893e-07</TD><TD>-15.06</TD><TD>extracellular matrix component</TD><TD>cellular component</TD><TD>GO:0044420</TD><TD>127</TD><TD>6</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5,TIMP2,SLC1A3,HSPG2,FRAS1,COL12A1</TD></TR>
<TR><TD>9.890e-06</TD><TD>-11.52</TD><TD>proteinaceous extracellular matrix</TD><TD>cellular component</TD><TD>GO:0005578</TD><TD>357</TD><TD>7</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5,TIMP2,SLC1A3,CTGF,HSPG2,FRAS1,COL12A1</TD></TR>
<TR><TD>1.336e-05</TD><TD>-11.22</TD><TD>AACTTT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AACTTT_UNKNOWN</TD><TD>1782</TD><TD>14</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,HSPG2,PDLIM3,FRAS1,TOX2,NETO2,TRPC1,COL4A5,SLC1A3,FAM198B,CNTNAP2,PDE4D,SYTL2,MECOM</TD></TR>
<TR><TD>2.502e-05</TD><TD>-10.60</TD><TD>WANG_SMARCE1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>WANG_SMARCE1_TARGETS_UP</TD><TD>270</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,CD55,ATP9A,FRAS1,COL12A1,TOX2</TD></TR>
<TR><TD>2.908e-05</TD><TD>-10.45</TD><TD>extracellular matrix</TD><TD>cellular component</TD><TD>GO:0031012</TD><TD>422</TD><TD>7</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5,TIMP2,SLC1A3,CTGF,HSPG2,FRAS1,COL12A1</TD></TR>
<TR><TD>3.222e-05</TD><TD>-10.34</TD><TD>REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION</TD><TD>MSigDB lists</TD><TD>REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION</TD><TD>83</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TIMP2,PLOD2,COL12A1</TD></TR>
<TR><TD>3.354e-05</TD><TD>-10.30</TD><TD>YAMAZAKI_TCEB3_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>YAMAZAKI_TCEB3_TARGETS_UP</TD><TD>170</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,COL4A5,HSPG2,PLOD2,NR4A1</TD></TR>
<TR><TD>4.189e-05</TD><TD>-10.08</TD><TD>KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3</TD><TD>MSigDB lists</TD><TD>KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3</TD><TD>791</TD><TD>9</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,CD55,MFI2,CTGF,PLOD2,IL18,TAGLN2,SLC1A3,COL12A1</TD></TR>
<TR><TD>4.548e-05</TD><TD>-10.00</TD><TD>ONDER_CDH1_TARGETS_2_DN</TD><TD>MSigDB lists</TD><TD>ONDER_CDH1_TARGETS_2_DN</TD><TD>445</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,IL18,CNTNAP2,CD55,SLC1A3,AIM1,MECOM</TD></TR>
<TR><TD>4.768e-05</TD><TD>-9.95</TD><TD>LEF1_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>LEF1_UP.V1_DN</TD><TD>183</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,CTGF,MYRIP,PLOD2,AIM1</TD></TR>
<TR><TD>4.933e-05</TD><TD>-9.92</TD><TD>basement membrane</TD><TD>cellular component</TD><TD>GO:0005604</TD><TD>94</TD><TD>4</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5,TIMP2,HSPG2,FRAS1</TD></TR>
<TR><TD>5.224e-05</TD><TD>-9.86</TD><TD>PASINI_SUZ12_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>PASINI_SUZ12_TARGETS_DN</TD><TD>308</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,COL4A5,TAGLN2,TIMP2,PDLIM3,PLOD2</TD></TR>
<TR><TD>5.308e-05</TD><TD>-9.84</TD><TD>LIU_PROSTATE_CANCER_DN</TD><TD>MSigDB lists</TD><TD>LIU_PROSTATE_CANCER_DN</TD><TD>456</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,ALDH2,MFI2,LONRF3,HSPG2,TSC22D3,MECOM</TD></TR>
<TR><TD>5.554e-05</TD><TD>-9.80</TD><TD>chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>3677</TD><TD>19</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,HSPG2,ATP9A,NR4A1,ATP2C2,COL4A5,CNTNAP2,SLC1A3,COL12A1,SYTL2,GALNT3,IGF1R,MAP2,FRAS1,AIM1,TOX2,PDE4D,SOX8,MYRIP</TD></TR>
<TR><TD>5.554e-05</TD><TD>-9.80</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>3677</TD><TD>19</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,HSPG2,ATP9A,NR4A1,ATP2C2,COL4A5,CNTNAP2,SLC1A3,COL12A1,SYTL2,GALNT3,IGF1R,MAP2,FRAS1,AIM1,TOX2,PDE4D,SOX8,MYRIP</TD></TR>
<TR><TD>6.092e-05</TD><TD>-9.71</TD><TD>endomembrane system</TD><TD>cellular component</TD><TD>GO:0012505</TD><TD>3658</TD><TD>19</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,HSPG2,ATP9A,NR4A1,ATP2C2,COL4A5,CNTNAP2,FAM198B,SYTL2,COL12A1,MECOM,GALNT3,CTGF,PLOD2,MAP2,SUN3,PDE4D,MYRIP,SULT2B1</TD></TR>
<TR><TD>6.932e-05</TD><TD>-9.58</TD><TD>GSE24634_TREG_VS_TCONV_POST_DAY7_IL4_CONVERSION_DN</TD><TD>MSigDB lists</TD><TD>GSE24634_TREG_VS_TCONV_POST_DAY7_IL4_CONVERSION_DN</TD><TD>198</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,SLC1A3,TIMP2,ALDH2,AIM1</TD></TR>
<TR><TD>7.099e-05</TD><TD>-9.55</TD><TD>PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP</TD><TD>MSigDB lists</TD><TD>PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP</TD><TD>199</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,FAM198B,SLC1A3,HSPG2,COL12A1</TD></TR>
<TR><TD>7.511e-05</TD><TD>-9.50</TD><TD>SUNG_METASTASIS_STROMA_UP</TD><TD>MSigDB lists</TD><TD>SUNG_METASTASIS_STROMA_UP</TD><TD>103</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,HSPG2,PLOD2,COL12A1</TD></TR>
<TR><TD>7.800e-05</TD><TD>-9.46</TD><TD>LEE_RECENT_THYMIC_EMIGRANT</TD><TD>MSigDB lists</TD><TD>LEE_RECENT_THYMIC_EMIGRANT</TD><TD>203</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,TIMP2,PDE4D,SYTL2,TOX2</TD></TR>
<TR><TD>8.030e-05</TD><TD>-9.43</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN</TD><TD>MSigDB lists</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN</TD><TD>487</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,CTGF,MAP2,TSC22D3,FRAS1,SYTL2,MECOM</TD></TR>
<TR><TD>9.801e-05</TD><TD>-9.23</TD><TD>INGRAM_SHH_TARGETS</TD><TD>MSigDB lists</TD><TD>INGRAM_SHH_TARGETS</TD><TD>7</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1,TSC22D3</TD></TR>
<TR><TD>1.068e-04</TD><TD>-9.14</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_3_DN</TD><TD>MSigDB lists</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_3_DN</TD><TD>217</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,PDE4D,IGF1R,SYTL2,MECOM</TD></TR>
<TR><TD>1.180e-04</TD><TD>-9.04</TD><TD>BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B</TD><TD>MSigDB lists</TD><TD>BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B</TD><TD>518</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,COL4A5,TIMP2,FAM198B,CTGF,IGF1R,NR4A1</TD></TR>
<TR><TD>1.216e-04</TD><TD>-9.02</TD><TD>BASAKI_YBX1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>BASAKI_YBX1_TARGETS_DN</TD><TD>359</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,CD55,PLOD2,TSC22D3,SYTL2,AIM1</TD></TR>
<TR><TD>1.403e-04</TD><TD>-8.87</TD><TD>INGRAM_SHH_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>INGRAM_SHH_TARGETS_UP</TD><TD>121</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,CTGF,NR4A1,TSC22D3</TD></TR>
<TR><TD>1.444e-04</TD><TD>-8.84</TD><TD>auditory behavior</TD><TD>biological process</TD><TD>GO:0031223</TD><TD>8</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2,SLC1A3</TD></TR>
<TR><TD>1.564e-04</TD><TD>-8.76</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2B</TD><TD>MSigDB lists</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2B</TD><TD>376</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,TIMP2,ALDH2,CTGF,NR4A1,TSC22D3</TD></TR>
<TR><TD>1.683e-04</TD><TD>-8.69</TD><TD>SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION</TD><TD>MSigDB lists</TD><TD>SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION</TD><TD>49</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,CTGF,PLOD2</TD></TR>
<TR><TD>1.698e-04</TD><TD>-8.68</TD><TD>extracellular matrix disassembly</TD><TD>biological process</TD><TD>GO:0022617</TD><TD>121</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>COL4A5,TIMP2,HSPG2,COL12A1</TD></TR>
<TR><TD>1.846e-04</TD><TD>-8.60</TD><TD>extracellular matrix organization</TD><TD>biological process</TD><TD>GO:0030198</TD><TD>369</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>COL4A5,TIMP2,HSPG2,CTGF,PLOD2,COL12A1</TD></TR>
<TR><TD>1.873e-04</TD><TD>-8.58</TD><TD>extracellular structure organization</TD><TD>biological process</TD><TD>GO:0043062</TD><TD>370</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>COL4A5,TIMP2,HSPG2,CTGF,PLOD2,COL12A1</TD></TR>
<TR><TD>2.147e-04</TD><TD>-8.45</TD><TD>FORTSCHEGGER_PHF8_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>FORTSCHEGGER_PHF8_TARGETS_UP</TD><TD>252</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,CTGF,IGF1R,MAP2,NR4A1</TD></TR>
<TR><TD>2.248e-04</TD><TD>-8.40</TD><TD>REACTOME_COLLAGEN_FORMATION</TD><TD>MSigDB lists</TD><TD>REACTOME_COLLAGEN_FORMATION</TD><TD>54</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,PLOD2,COL12A1</TD></TR>
<TR><TD>2.325e-04</TD><TD>-8.37</TD><TD>MODULE_122</TD><TD>MSigDB lists</TD><TD>MODULE_122</TD><TD>138</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,COL4A5,CTGF,COL12A1</TD></TR>
<TR><TD>2.376e-04</TD><TD>-8.34</TD><TD>soft_tissue</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue</TD><TD>6065</TD><TD>24</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,CD55,MFI2,HSPG2,ATP9A,NR4A1,TSC22D3,COL4A5,CNTNAP2,SLC1A3,COL12A1,SYTL2,MECOM,GALNT3,IGF1R,PLOD2,MAP2,FRAS1,TOX2,AIM1,NETO2,TRPC1,SOX8,MYRIP</TD></TR>
<TR><TD>2.549e-04</TD><TD>-8.27</TD><TD>Laminin_G</TD><TD>interpro domains</TD><TD>IPR001791</TD><TD>58</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>CNTNAP2,HSPG2,COL12A1</TD></TR>
<TR><TD>2.707e-04</TD><TD>-8.21</TD><TD>NABA_MATRISOME</TD><TD>MSigDB lists</TD><TD>NABA_MATRISOME</TD><TD>1010</TD><TD>9</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,CTGF,HSPG2,PLOD2,FRAS1,IL18,COL4A5,FGF19,COL12A1</TD></TR>
<TR><TD>2.824e-04</TD><TD>-8.17</TD><TD>mechanosensory behavior</TD><TD>biological process</TD><TD>GO:0007638</TD><TD>11</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2,SLC1A3</TD></TR>
<TR><TD>2.884e-04</TD><TD>-8.15</TD><TD>Rab_BD</TD><TD>interpro domains</TD><TD>IPR010911</TD><TD>12</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>3.004e-04</TD><TD>-8.11</TD><TD>NABA_CORE_MATRISOME</TD><TD>MSigDB lists</TD><TD>NABA_CORE_MATRISOME</TD><TD>271</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,CTGF,HSPG2,FRAS1,COL12A1</TD></TR>
<TR><TD>3.474e-04</TD><TD>-7.97</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5</TD><TD>MSigDB lists</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5</TD><TD>436</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,ZNF432,TIMP2,FAM198B,CD55,ATP2C2</TD></TR>
<TR><TD>3.527e-04</TD><TD>-7.95</TD><TD>bone</TD><TD>COSMIC cancer mutations</TD><TD>bone</TD><TD>8539</TD><TD>29</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ALDH2,MFI2,LONRF3,HSPG2,NR4A1,TSC22D3,ATP2C2,COL4A5,CNTNAP2,SLC1A3,FAM198B,FGF19,COL12A1,SYTL2,MECOM,GALNT3,ZNF432,CTGF,IGF1R,PLOD2,MAP2,FRAS1,AIM1,TRPC1,SUN3,PDE4D,SOX8,SULT2B1</TD></TR>
<TR><TD>3.687e-04</TD><TD>-7.91</TD><TD>regulation of cell proliferation</TD><TD>biological process</TD><TD>GO:0042127</TD><TD>1479</TD><TD>11</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,TIMP2,CTGF,MFI2,IGF1R,NR4A1,IL18,PDE4D,SOX8,FGF19,MECOM</TD></TR>
<TR><TD>3.710e-04</TD><TD>-7.90</TD><TD>GSE6269_HEALTHY_VS_E_COLI_INF_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE6269_HEALTHY_VS_E_COLI_INF_PBMC_DN</TD><TD>156</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TAGLN2,PDE4D,MFI2</TD></TR>
<TR><TD>3.980e-04</TD><TD>-7.83</TD><TD>large_intestine-colon</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-colon</TD><TD>1346</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,HSPG2,FRAS1,TSC22D3,AIM1,NETO2,CNTNAP2,MYRIP,SYTL2,COL12A1</TD></TR>
<TR><TD>4.039e-04</TD><TD>-7.81</TD><TD>positive regulation of cell proliferation</TD><TD>biological process</TD><TD>GO:0008284</TD><TD>800</TD><TD>8</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,CTGF,IGF1R,NR4A1,IL18,PDE4D,SOX8,FGF19</TD></TR>
<TR><TD>4.297e-04</TD><TD>-7.75</TD><TD>IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM</TD><TD>MSigDB lists</TD><TD>IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM</TD><TD>293</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,IGF1R,FGF19,ATP2C2,MECOM</TD></TR>
<TR><TD>4.502e-04</TD><TD>-7.71</TD><TD>bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>6295</TD><TD>24</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ALDH2,LONRF3,HSPG2,NR4A1,TSC22D3,ATP2C2,COL4A5,SLC1A3,FAM198B,FGF19,COL12A1,SYTL2,MECOM,GALNT3,ZNF432,CTGF,IGF1R,MAP2,FRAS1,TRPC1,SUN3,PDE4D,SOX8</TD></TR>
<TR><TD>4.587e-04</TD><TD>-7.69</TD><TD>VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP</TD><TD>MSigDB lists</TD><TD>VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP</TD><TD>165</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,SLC1A3,PLOD2,COL12A1</TD></TR>
<TR><TD>4.642e-04</TD><TD>-7.68</TD><TD>DELPUECH_FOXO3_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>DELPUECH_FOXO3_TARGETS_UP</TD><TD>69</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,CD55,IGF1R</TD></TR>
<TR><TD>4.651e-04</TD><TD>-7.67</TD><TD>manganese ion transport</TD><TD>biological process</TD><TD>GO:0006828</TD><TD>14</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,ATP2C2</TD></TR>
<TR><TD>4.693e-04</TD><TD>-7.66</TD><TD>MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP</TD><TD>166</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,TIMP2,HSPG2,PLOD2</TD></TR>
<TR><TD>4.699e-04</TD><TD>-7.66</TD><TD>regulation of JNK cascade</TD><TD>biological process</TD><TD>GO:0046328</TD><TD>158</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,IGF1R,FGF19,MECOM</TD></TR>
<TR><TD>4.726e-04</TD><TD>-7.66</TD><TD>LIM_MAMMARY_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>LIM_MAMMARY_STEM_CELL_UP</TD><TD>462</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,SLC1A3,CTGF,HSPG2,COL12A1,NETO2</TD></TR>
<TR><TD>4.824e-04</TD><TD>-7.64</TD><TD>anatomical structure morphogenesis</TD><TD>biological process</TD><TD>GO:0009653</TD><TD>2356</TD><TD>14</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,CTGF,HSPG2,MAP2,NR4A1,FRAS1,TRPC1,IL18,COL4A5,SLC1A3,SOX8,FGF19,COL12A1,MECOM</TD></TR>
<TR><TD>4.842e-04</TD><TD>-7.63</TD><TD>SESTO_RESPONSE_TO_UV_C1</TD><TD>MSigDB lists</TD><TD>SESTO_RESPONSE_TO_UV_C1</TD><TD>70</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,CTGF,SULT2B1</TD></TR>
<TR><TD>5.139e-04</TD><TD>-7.57</TD><TD>MYO7A (myosin VIIA)</TD><TD>protein interactions</TD><TD>4647</TD><TD>16</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>MAP2,MYRIP</TD></TR>
<TR><TD>5.141e-04</TD><TD>-7.57</TD><TD>RTAAACA_V$FREAC2_01</TD><TD>MSigDB lists</TD><TD>RTAAACA_V$FREAC2_01</TD><TD>871</TD><TD>8</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,CTGF,IGF1R,HSPG2,PDLIM3,NR4A1,TSC22D3,MECOM</TD></TR>
<TR><TD>5.166e-04</TD><TD>-7.57</TD><TD>RABBD</TD><TD>prosite domains</TD><TD>PS50916</TD><TD>12</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>5.249e-04</TD><TD>-7.55</TD><TD>GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_6H_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_6H_CD4_TCELL_UP</TD><TD>171</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,PDE4D,TSC22D3,SYTL2</TD></TR>
<TR><TD>5.509e-04</TD><TD>-7.50</TD><TD>upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma</TD><TD>7269</TD><TD>26</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ALDH2,CD55,MFI2,LONRF3,HSPG2,ATP9A,NR4A1,ATP2C2,COL4A5,CNTNAP2,FAM198B,COL12A1,MECOM,GALNT3,ZNF432,IGF1R,PLOD2,MAP2,FRAS1,AIM1,NETO2,TRPC1,TAGLN2,SOX8,MYRIP</TD></TR>
<TR><TD>5.560e-04</TD><TD>-7.49</TD><TD>system development</TD><TD>biological process</TD><TD>GO:0048731</TD><TD>4011</TD><TD>19</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,HSPG2,NR4A1,IL18,COL4A5,CNTNAP2,SLC1A3,FGF19,COL12A1,MECOM,IGF1R,PDLIM3,CTGF,MAP2,FRAS1,TOX2,TRPC1,PDE4D,SOX8</TD></TR>
<TR><TD>5.700e-04</TD><TD>-7.47</TD><TD>PID_AVB3_INTEGRIN_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_AVB3_INTEGRIN_PATHWAY</TD><TD>74</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,IGF1R,COL12A1</TD></TR>
<TR><TD>5.866e-04</TD><TD>-7.44</TD><TD>acute_lymphoblastic_B_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>acute_lymphoblastic_B_cell_leukaemia</TD><TD>3979</TD><TD>18</TD><TD>17775</TD><TD>38</TD>
<TD>MFI2,LONRF3,ATP9A,TSC22D3,COL4A5,CNTNAP2,SLC1A3,COL12A1,GALNT3,PDLIM3,IGF1R,CTGF,PLOD2,MAP2,FRAS1,TOX2,TRPC1,MYRIP</TD></TR>
<TR><TD>5.866e-04</TD><TD>-7.44</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia</TD><TD>3979</TD><TD>18</TD><TD>17775</TD><TD>38</TD>
<TD>MFI2,LONRF3,ATP9A,TSC22D3,COL4A5,CNTNAP2,SLC1A3,COL12A1,GALNT3,PDLIM3,IGF1R,CTGF,PLOD2,MAP2,FRAS1,TOX2,TRPC1,MYRIP</TD></TR>
<TR><TD>6.632e-04</TD><TD>-7.32</TD><TD>Furin_repeat</TD><TD>interpro domains</TD><TD>IPR006212</TD><TD>18</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>IGF1R,FRAS1</TD></TR>
<TR><TD>7.092e-04</TD><TD>-7.25</TD><TD>TGTTTGY_V$HNF3_Q6</TD><TD>MSigDB lists</TD><TD>TGTTTGY_V$HNF3_Q6</TD><TD>696</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,TAGLN2,CNTNAP2,PDE4D,CTGF,LONRF3,TSC22D3</TD></TR>
<TR><TD>7.179e-04</TD><TD>-7.24</TD><TD>Collagen biosynthesis and modifying enzymes</TD><TD>REACTOME pathways</TD><TD>R-HSA-1650814</TD><TD>64</TD><TD>3</TD><TD>8202</TD><TD>23</TD>
<TD>COL4A5,PLOD2,COL12A1</TD></TR>
<TR><TD>7.197e-04</TD><TD>-7.24</TD><TD>RAF_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>RAF_UP.V1_DN</TD><TD>186</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,TSC22D3,AIM1,SYTL2</TD></TR>
<TR><TD>7.317e-04</TD><TD>-7.22</TD><TD>Extracellular matrix organization</TD><TD>REACTOME pathways</TD><TD>R-HSA-1474244</TD><TD>267</TD><TD>5</TD><TD>8202</TD><TD>23</TD>
<TD>COL4A5,TIMP2,HSPG2,PLOD2,COL12A1</TD></TR>
<TR><TD>7.343e-04</TD><TD>-7.22</TD><TD>GSE31082_CD4_VS_CD8_SP_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE31082_CD4_VS_CD8_SP_THYMOCYTE_UP</TD><TD>187</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,NR4A1,SYTL2,AIM1</TD></TR>
<TR><TD>7.423e-04</TD><TD>-7.21</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP</TD><TD>MSigDB lists</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP</TD><TD>81</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,FAM198B,MECOM</TD></TR>
<TR><TD>7.775e-04</TD><TD>-7.16</TD><TD>positive regulation of alpha-beta T cell proliferation</TD><TD>biological process</TD><TD>GO:0046641</TD><TD>18</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>7.793e-04</TD><TD>-7.16</TD><TD>CAMP_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>CAMP_UP.V1_DN</TD><TD>190</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,TIMP2,MAP2,ATP9A</TD></TR>
<TR><TD>7.947e-04</TD><TD>-7.14</TD><TD>PEREZ_TP53_AND_TP63_TARGETS</TD><TD>MSigDB lists</TD><TD>PEREZ_TP53_AND_TP63_TARGETS</TD><TD>191</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>SOX8,IGF1R,LONRF3,TSC22D3</TD></TR>
<TR><TD>8.541e-04</TD><TD>-7.07</TD><TD>BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN</TD><TD>MSigDB lists</TD><TD>BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN</TD><TD>85</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,TSC22D3,SYTL2</TD></TR>
<TR><TD>8.585e-04</TD><TD>-7.06</TD><TD>GSE20366_CD103_POS_VS_CD103_KLRG1_DP_TREG_DN</TD><TD>MSigDB lists</TD><TD>GSE20366_CD103_POS_VS_CD103_KLRG1_DP_TREG_DN</TD><TD>195</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,TRPC1,IL18,SYTL2</TD></TR>
<TR><TD>8.677e-04</TD><TD>-7.05</TD><TD>response to auditory stimulus</TD><TD>biological process</TD><TD>GO:0010996</TD><TD>19</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2,SLC1A3</TD></TR>
<TR><TD>8.709e-04</TD><TD>-7.05</TD><TD>ZHAN_MULTIPLE_MYELOMA_SPIKED</TD><TD>MSigDB lists</TD><TD>ZHAN_MULTIPLE_MYELOMA_SPIKED</TD><TD>20</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,CTGF</TD></TR>
<TR><TD>9.219e-04</TD><TD>-6.99</TD><TD>Deregulation of Rab and Rab Effector Genes in Bladder Cancer</TD><TD>WikiPathways</TD><TD>WP2291</TD><TD>16</TD><TD>2</TD><TD>4455</TD><TD>13</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>9.567e-04</TD><TD>-6.95</TD><TD>regulation of stress-activated MAPK cascade</TD><TD>biological process</TD><TD>GO:0032872</TD><TD>191</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,IGF1R,FGF19,MECOM</TD></TR>
<TR><TD>9.613e-04</TD><TD>-6.95</TD><TD>GAVIN_PDE3B_TARGETS</TD><TD>MSigDB lists</TD><TD>GAVIN_PDE3B_TARGETS</TD><TD>21</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,SYTL2</TD></TR>
<TR><TD>9.699e-04</TD><TD>-6.94</TD><TD>MASSARWEH_TAMOXIFEN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>MASSARWEH_TAMOXIFEN_RESISTANCE_UP</TD><TD>530</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,TIMP2,FAM198B,CD55,PDE4D,ATP2C2</TD></TR>
<TR><TD>9.754e-04</TD><TD>-6.93</TD><TD>regulation of stress-activated protein kinase signaling cascade</TD><TD>biological process</TD><TD>GO:0070302</TD><TD>192</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,IGF1R,FGF19,MECOM</TD></TR>
<TR><TD>9.788e-04</TD><TD>-6.93</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>MSigDB lists</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>202</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,FAM198B,MAP2,PLOD2</TD></TR>
<TR><TD>9.794e-04</TD><TD>-6.93</TD><TD>YCATTAA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YCATTAA_UNKNOWN</TD><TD>531</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,CD55,PDE4D,COL12A1,SYTL2,MECOM</TD></TR>
<TR><TD>1.015e-03</TD><TD>-6.89</TD><TD>CAIRO_HEPATOBLASTOMA_CLASSES_DN</TD><TD>MSigDB lists</TD><TD>CAIRO_HEPATOBLASTOMA_CLASSES_DN</TD><TD>204</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,ALDH2,MYRIP,TSC22D3</TD></TR>
<TR><TD>1.074e-03</TD><TD>-6.84</TD><TD>FBLN2 (fibulin 2)</TD><TD>protein interactions</TD><TD>2199</TD><TD>23</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>COL4A5,HSPG2</TD></TR>
<TR><TD>1.075e-03</TD><TD>-6.84</TD><TD>MODULE_1</TD><TD>MSigDB lists</TD><TD>MODULE_1</TD><TD>359</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,TIMP2,HSPG2,PDLIM3,NR4A1</TD></TR>
<TR><TD>1.090e-03</TD><TD>-6.82</TD><TD>diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_adenocarcinoma</TD><TD>4562</TD><TD>19</TD><TD>17775</TD><TD>38</TD>
<TD>MFI2,LONRF3,HSPG2,ATP9A,ATP2C2,COL4A5,SLC1A3,CNTNAP2,COL12A1,SYTL2,MECOM,PDLIM3,IGF1R,PLOD2,MAP2,FRAS1,AIM1,TOX2,MYRIP</TD></TR>
<TR><TD>1.090e-03</TD><TD>-6.82</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>4562</TD><TD>19</TD><TD>17775</TD><TD>38</TD>
<TD>MFI2,LONRF3,HSPG2,ATP9A,ATP2C2,COL4A5,SLC1A3,CNTNAP2,COL12A1,SYTL2,MECOM,PDLIM3,IGF1R,PLOD2,MAP2,FRAS1,AIM1,TOX2,MYRIP</TD></TR>
<TR><TD>1.114e-03</TD><TD>-6.80</TD><TD>chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>chondroblastoma</TD><TD>560</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,CTGF,IGF1R,PLOD2,FRAS1,ATP2C2</TD></TR>
<TR><TD>1.120e-03</TD><TD>-6.79</TD><TD>basal lamina</TD><TD>cellular component</TD><TD>GO:0005605</TD><TD>23</TD><TD>2</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5,HSPG2</TD></TR>
<TR><TD>1.129e-03</TD><TD>-6.79</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_1_DN</TD><TD>MSigDB lists</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_1_DN</TD><TD>363</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,TAGLN2,SLC1A3,TIMP2,NR4A1</TD></TR>
<TR><TD>1.143e-03</TD><TD>-6.77</TD><TD>CAHOY_OLIGODENDROCUTIC</TD><TD>MSigDB lists</TD><TD>CAHOY_OLIGODENDROCUTIC</TD><TD>94</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CNTNAP2,SOX8,CTGF</TD></TR>
<TR><TD>1.154e-03</TD><TD>-6.76</TD><TD>ITGB1 (integrin beta 1)</TD><TD>protein interactions</TD><TD>3688</TD><TD>98</TD><TD>3</TD><TD>16036</TD><TD>34</TD>
<TD>TIMP2,IGF1R,HSPG2</TD></TR>
<TR><TD>1.233e-03</TD><TD>-6.70</TD><TD>RIGGINS_TAMOXIFEN_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>RIGGINS_TAMOXIFEN_RESISTANCE_DN</TD><TD>215</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,PDLIM3,ATP2C2,AIM1</TD></TR>
<TR><TD>1.252e-03</TD><TD>-6.68</TD><TD>WINZEN_DEGRADED_VIA_KHSRP</TD><TD>MSigDB lists</TD><TD>WINZEN_DEGRADED_VIA_KHSRP</TD><TD>97</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,TRPC1,CTGF</TD></TR>
<TR><TD>1.328e-03</TD><TD>-6.62</TD><TD>KANG_IMMORTALIZED_BY_TERT_DN</TD><TD>MSigDB lists</TD><TD>KANG_IMMORTALIZED_BY_TERT_DN</TD><TD>99</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,NR4A1,ATP9A</TD></TR>
<TR><TD>1.346e-03</TD><TD>-6.61</TD><TD>FU</TD><TD>smart domains</TD><TD>SM00261</TD><TD>18</TD><TD>2</TD><TD>9131</TD><TD>28</TD>
<TD>IGF1R,FRAS1</TD></TR>
<TR><TD>1.360e-03</TD><TD>-6.60</TD><TD>Ricin_B_lectin</TD><TD>pfam domains</TD><TD>PF00652</TD><TD>24</TD><TD>2</TD><TD>16629</TD><TD>38</TD>
<TD>GALNT3,AIM1</TD></TR>
<TR><TD>1.365e-03</TD><TD>-6.60</TD><TD>V$FOXJ2_02</TD><TD>MSigDB lists</TD><TD>V$FOXJ2_02</TD><TD>221</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,MAP2,FRAS1,MECOM</TD></TR>
<TR><TD>1.372e-03</TD><TD>-6.59</TD><TD>anatomical structure development</TD><TD>biological process</TD><TD>GO:0048856</TD><TD>4662</TD><TD>20</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,HSPG2,NR4A1,IL18,COL4A5,SLC1A3,CNTNAP2,FGF19,COL12A1,MECOM,CTGF,IGF1R,PDLIM3,MAP2,FRAS1,TOX2,TRPC1,TAGLN2,PDE4D,SOX8</TD></TR>
<TR><TD>1.390e-03</TD><TD>-6.58</TD><TD>regulation of alpha-beta T cell proliferation</TD><TD>biological process</TD><TD>GO:0046640</TD><TD>24</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>1.421e-03</TD><TD>-6.56</TD><TD>acute_myeloid_leukaemia_therapy_related</TD><TD>COSMIC cancer mutations</TD><TD>acute_myeloid_leukaemia_therapy_related</TD><TD>1584</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>GALNT3,MFI2,MAP2,FRAS1,AIM1,TRPC1,SLC1A3,CNTNAP2,MYRIP,COL12A1</TD></TR>
<TR><TD>1.421e-03</TD><TD>-6.56</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related</TD><TD>1584</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>GALNT3,MFI2,MAP2,FRAS1,AIM1,TRPC1,SLC1A3,CNTNAP2,MYRIP,COL12A1</TD></TR>
<TR><TD>1.434e-03</TD><TD>-6.55</TD><TD>V$SOX9_B1</TD><TD>MSigDB lists</TD><TD>V$SOX9_B1</TD><TD>224</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2,NR4A1,TSC22D3,SYTL2</TD></TR>
<TR><TD>1.477e-03</TD><TD>-6.52</TD><TD>DAZARD_UV_RESPONSE_CLUSTER_G24</TD><TD>MSigDB lists</TD><TD>DAZARD_UV_RESPONSE_CLUSTER_G24</TD><TD>26</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,SULT2B1</TD></TR>
<TR><TD>1.486e-03</TD><TD>-6.51</TD><TD>CUI_TCF21_TARGETS_2_DN</TD><TD>MSigDB lists</TD><TD>CUI_TCF21_TARGETS_2_DN</TD><TD>790</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,COL4A5,CD55,PDE4D,CTGF,PLOD2,COL12A1</TD></TR>
<TR><TD>1.500e-03</TD><TD>-6.50</TD><TD>insulin-like growth factor binding</TD><TD>molecular function</TD><TD>GO:0005520</TD><TD>25</TD><TD>2</TD><TD>16491</TD><TD>38</TD>
<TD>IGF1R,CTGF</TD></TR>
<TR><TD>1.524e-03</TD><TD>-6.49</TD><TD>human chr16q11</TD><TD>chromosome location</TD><TD>human chr16q11</TD><TD>1</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>NETO2</TD></TR>
<TR><TD>1.524e-03</TD><TD>-6.49</TD><TD>human chr2q24-q31</TD><TD>chromosome location</TD><TD>human chr2q24-q31</TD><TD>1</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>GALNT3</TD></TR>
<TR><TD>1.524e-03</TD><TD>-6.49</TD><TD>human chr1q21-q25</TD><TD>chromosome location</TD><TD>human chr1q21-q25</TD><TD>1</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.524e-03</TD><TD>-6.49</TD><TD>human chr1p36.1-p34</TD><TD>chromosome location</TD><TD>human chr1p36.1-p34</TD><TD>1</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>HSPG2</TD></TR>
<TR><TD>1.562e-03</TD><TD>-6.46</TD><TD>MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>1033</TD><TD>8</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,CTGF,PLOD2,SLC1A3,TAGLN2,FGF19,COL12A1,MECOM</TD></TR>
<TR><TD>1.593e-03</TD><TD>-6.44</TD><TD>rhabdomyosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>rhabdomyosarcoma</TD><TD>4310</TD><TD>18</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,CD55,MFI2,HSPG2,NR4A1,COL4A5,SLC1A3,CNTNAP2,COL12A1,SYTL2,IGF1R,PLOD2,MAP2,FRAS1,AIM1,TOX2,NETO2,SOX8</TD></TR>
<TR><TD>1.593e-03</TD><TD>-6.44</TD><TD>KAMIKUBO_MYELOID_CEBPA_NETWORK</TD><TD>MSigDB lists</TD><TD>KAMIKUBO_MYELOID_CEBPA_NETWORK</TD><TD>27</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,ALDH2</TD></TR>
<TR><TD>1.605e-03</TD><TD>-6.43</TD><TD>MASSARWEH_TAMOXIFEN_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>MASSARWEH_TAMOXIFEN_RESISTANCE_DN</TD><TD>231</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,IGF1R,MAP2,FRAS1</TD></TR>
<TR><TD>1.616e-03</TD><TD>-6.43</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4</TD><TD>MSigDB lists</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4</TD><TD>106</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,TIMP2,COL12A1</TD></TR>
<TR><TD>1.632e-03</TD><TD>-6.42</TD><TD>negative regulation of myoblast differentiation</TD><TD>biological process</TD><TD>GO:0045662</TD><TD>26</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,SOX8</TD></TR>
<TR><TD>1.694e-03</TD><TD>-6.38</TD><TD>Collagen formation</TD><TD>REACTOME pathways</TD><TD>R-HSA-1474290</TD><TD>86</TD><TD>3</TD><TD>8202</TD><TD>23</TD>
<TD>COL4A5,PLOD2,COL12A1</TD></TR>
<TR><TD>1.705e-03</TD><TD>-6.37</TD><TD>CERVERA_SDHB_TARGETS_2</TD><TD>MSigDB lists</TD><TD>CERVERA_SDHB_TARGETS_2</TD><TD>108</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,MFI2,AIM1</TD></TR>
<TR><TD>1.722e-03</TD><TD>-6.36</TD><TD>VWC</TD><TD>pfam domains</TD><TD>PF00093</TD><TD>27</TD><TD>2</TD><TD>16629</TD><TD>38</TD>
<TD>CTGF,FRAS1</TD></TR>
<TR><TD>1.754e-03</TD><TD>-6.35</TD><TD>circulatory system development</TD><TD>biological process</TD><TD>GO:0072359</TD><TD>774</TD><TD>7</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CTGF,HSPG2,PDLIM3,NR4A1,FGF19,MECOM</TD></TR>
<TR><TD>1.754e-03</TD><TD>-6.35</TD><TD>cardiovascular system development</TD><TD>biological process</TD><TD>GO:0072358</TD><TD>774</TD><TD>7</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CTGF,HSPG2,PDLIM3,NR4A1,FGF19,MECOM</TD></TR>
<TR><TD>1.770e-03</TD><TD>-6.34</TD><TD>response to hormone</TD><TD>biological process</TD><TD>GO:0009725</TD><TD>1003</TD><TD>8</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,CTGF,IGF1R,PLOD2,MAP2,NR4A1,TOX2,FGF19</TD></TR>
<TR><TD>1.818e-03</TD><TD>-6.31</TD><TD>VERHAAK_AML_WITH_NPM1_MUTATED_DN</TD><TD>MSigDB lists</TD><TD>VERHAAK_AML_WITH_NPM1_MUTATED_DN</TD><TD>239</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,HSPG2,ATP9A,MECOM</TD></TR>
<TR><TD>1.829e-03</TD><TD>-6.30</TD><TD>RAB27A (RAB27A, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>5873</TD><TD>30</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>1.838e-03</TD><TD>-6.30</TD><TD>DORN_ADENOVIRUS_INFECTION_12HR_UP</TD><TD>MSigDB lists</TD><TD>DORN_ADENOVIRUS_INFECTION_12HR_UP</TD><TD>29</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1,TSC22D3</TD></TR>
<TR><TD>1.869e-03</TD><TD>-6.28</TD><TD>Degradation of the extracellular matrix</TD><TD>REACTOME pathways</TD><TD>R-HSA-1474228</TD><TD>89</TD><TD>3</TD><TD>8202</TD><TD>23</TD>
<TD>TIMP2,HSPG2,COL12A1</TD></TR>
<TR><TD>1.879e-03</TD><TD>-6.28</TD><TD>Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>7783</TD><TD>26</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ALDH2,MFI2,LONRF3,HSPG2,NR4A1,TSC22D3,ATP2C2,COL4A5,SLC1A3,FAM198B,FGF19,COL12A1,SYTL2,MECOM,GALNT3,ZNF432,CTGF,IGF1R,MAP2,FRAS1,TRPC1,SUN3,PDE4D,SOX8,SULT2B1</TD></TR>
<TR><TD>1.893e-03</TD><TD>-6.27</TD><TD>metanephros morphogenesis</TD><TD>biological process</TD><TD>GO:0003338</TD><TD>28</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,FRAS1</TD></TR>
<TR><TD>1.909e-03</TD><TD>-6.26</TD><TD>cell differentiation</TD><TD>biological process</TD><TD>GO:0030154</TD><TD>3353</TD><TD>16</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,HSPG2,NR4A1,COL4A5,CNTNAP2,SLC1A3,FGF19,COL12A1,MECOM,CTGF,IGF1R,MAP2,TRPC1,PDE4D,TAGLN2,SOX8</TD></TR>
<TR><TD>1.931e-03</TD><TD>-6.25</TD><TD>JOHNSTONE_PARVB_TARGETS_3_UP</TD><TD>MSigDB lists</TD><TD>JOHNSTONE_PARVB_TARGETS_3_UP</TD><TD>410</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,TIMP2,MFI2,FRAS1,TOX2</TD></TR>
<TR><TD>1.932e-03</TD><TD>-6.25</TD><TD>KAAB_HEART_ATRIUM_VS_VENTRICLE_UP</TD><TD>MSigDB lists</TD><TD>KAAB_HEART_ATRIUM_VS_VENTRICLE_UP</TD><TD>243</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,TAGLN2,CTGF,HSPG2</TD></TR>
<TR><TD>1.941e-03</TD><TD>-6.24</TD><TD>WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP</TD><TD>MSigDB lists</TD><TD>WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP</TD><TD>113</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,NR4A1,MECOM</TD></TR>
<TR><TD>1.944e-03</TD><TD>-6.24</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.60.120.200</TD><TD>93</TD><TD>3</TD><TD>9988</TD><TD>27</TD>
<TD>CNTNAP2,HSPG2,COL12A1</TD></TR>
<TR><TD>1.967e-03</TD><TD>-6.23</TD><TD>RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_UP</TD><TD>MSigDB lists</TD><TD>RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_UP</TD><TD>30</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,CTGF</TD></TR>
<TR><TD>1.967e-03</TD><TD>-6.23</TD><TD>SIMBULAN_PARP1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SIMBULAN_PARP1_TARGETS_UP</TD><TD>30</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TIMP2</TD></TR>
<TR><TD>1.967e-03</TD><TD>-6.23</TD><TD>transition metal ion transport</TD><TD>biological process</TD><TD>GO:0000041</TD><TD>108</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,MFI2,ATP2C2</TD></TR>
<TR><TD>1.981e-03</TD><TD>-6.22</TD><TD>Ricin_B_lectin</TD><TD>interpro domains</TD><TD>IPR000772</TD><TD>31</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>GALNT3,AIM1</TD></TR>
<TR><TD>1.990e-03</TD><TD>-6.22</TD><TD>FOSTER_KDM1A_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>FOSTER_KDM1A_TARGETS_UP</TD><TD>245</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CNTNAP2,MAP2,SULT2B1,AIM1</TD></TR>
<TR><TD>1.999e-03</TD><TD>-6.21</TD><TD>TGANTCA_V$AP1_C</TD><TD>MSigDB lists</TD><TD>TGANTCA_V$AP1_C</TD><TD>1074</TD><TD>8</TD><TD>17758</TD><TD>39</TD>
<TD>LONRF3,HSPG2,MAP2,PDE4D,CNTNAP2,FAM198B,TAGLN2,MECOM</TD></TR>
<TR><TD>2.003e-03</TD><TD>-6.21</TD><TD>striated_muscle</TD><TD>COSMIC cancer mutations</TD><TD>striated_muscle</TD><TD>4392</TD><TD>18</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,CD55,MFI2,HSPG2,NR4A1,COL4A5,SLC1A3,CNTNAP2,COL12A1,SYTL2,IGF1R,PLOD2,MAP2,FRAS1,AIM1,TOX2,NETO2,SOX8</TD></TR>
<TR><TD>2.035e-03</TD><TD>-6.20</TD><TD>Ion channel transport</TD><TD>REACTOME pathways</TD><TD>R-HSA-983712</TD><TD>198</TD><TD>4</TD><TD>8202</TD><TD>23</TD>
<TD>TRPC1,ATP9A,TSC22D3,ATP2C2</TD></TR>
<TR><TD>2.051e-03</TD><TD>-6.19</TD><TD>membrane region</TD><TD>cellular component</TD><TD>GO:0098589</TD><TD>1097</TD><TD>8</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,CD55,IGF1R,TRPC1,SLC1A3,CNTNAP2,PDE4D,MYRIP</TD></TR>
<TR><TD>2.099e-03</TD><TD>-6.17</TD><TD>GROWTH_FACTOR_BINDING</TD><TD>MSigDB lists</TD><TD>GROWTH_FACTOR_BINDING</TD><TD>31</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,CTGF</TD></TR>
<TR><TD>2.099e-03</TD><TD>-6.17</TD><TD>VALK_AML_CLUSTER_3</TD><TD>MSigDB lists</TD><TD>VALK_AML_CLUSTER_3</TD><TD>31</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,AIM1</TD></TR>
<TR><TD>2.118e-03</TD><TD>-6.16</TD><TD>angiosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>angiosarcoma</TD><TD>2284</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>GALNT3,IGF1R,MAP2,FRAS1,TSC22D3,TOX2,TRPC1,SLC1A3,CNTNAP2,MYRIP,COL12A1,MECOM</TD></TR>
<TR><TD>2.118e-03</TD><TD>-6.16</TD><TD>soft_tissue-blood_vessel-angiosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-blood_vessel-angiosarcoma</TD><TD>2284</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>GALNT3,IGF1R,MAP2,FRAS1,TSC22D3,TOX2,TRPC1,SLC1A3,CNTNAP2,MYRIP,COL12A1,MECOM</TD></TR>
<TR><TD>2.120e-03</TD><TD>-6.16</TD><TD>SLC23A3 (solute carrier family 23, member 3)</TD><TD>protein interactions</TD><TD>151295</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.120e-03</TD><TD>-6.16</TD><TD>COL12A1 (collagen, type XII, alpha 1)</TD><TD>protein interactions</TD><TD>1303</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>COL12A1</TD></TR>
<TR><TD>2.120e-03</TD><TD>-6.16</TD><TD>Slc23a3 (solute carrier family 23 (nucleobase transporters), member 3)</TD><TD>protein interactions</TD><TD>22626</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.120e-03</TD><TD>-6.16</TD><TD>IL1RL2 (interleukin 1 receptor-like 2)</TD><TD>protein interactions</TD><TD>8808</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IL18</TD></TR>
<TR><TD>2.120e-03</TD><TD>-6.16</TD><TD>NLRP14 (NLR family, pyrin domain containing 14)</TD><TD>protein interactions</TD><TD>338323</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.120e-03</TD><TD>-6.16</TD><TD>ABCC13 (ATP binding cassette subfamily C member 13, pseudogene)</TD><TD>protein interactions</TD><TD>150000</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.120e-03</TD><TD>-6.16</TD><TD>KL (klotho)</TD><TD>protein interactions</TD><TD>9365</TD><TD>1</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>TIMP2</TD><TD>interpro domains</TD><TD>IPR015613</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>SUN3</TD><TD>interpro domains</TD><TD>IPR030274</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SUN3</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>ATP2C2</TD><TD>interpro domains</TD><TD>IPR030334</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>IL-18</TD><TD>interpro domains</TD><TD>IPR015529</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>MDS1</TD><TD>interpro domains</TD><TD>IPR026710</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>FGF15/FGF19</TD><TD>interpro domains</TD><TD>IPR028303</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>FGF19</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>MAP2</TD><TD>interpro domains</TD><TD>IPR030797</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>Caspr2</TD><TD>interpro domains</TD><TD>IPR029831</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>TRPC1_channel</TD><TD>interpro domains</TD><TD>IPR005457</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TRPC1</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>MAP2_projctn</TD><TD>interpro domains</TD><TD>IPR013588</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>Nuc_orp_HMR_rcpt</TD><TD>interpro domains</TD><TD>IPR003071</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>ATP9A</TD><TD>interpro domains</TD><TD>IPR030356</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ATP9A</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>SYTL2</TD><TD>interpro domains</TD><TD>IPR027006</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SYTL2</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>SOX-8</TD><TD>interpro domains</TD><TD>IPR031265</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SOX8</TD></TR>
<TR><TD>2.132e-03</TD><TD>-6.15</TD><TD>NETO2</TD><TD>interpro domains</TD><TD>IPR028868</TD><TD>1</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>NETO2</TD></TR>
<TR><TD>2.146e-03</TD><TD>-6.14</TD><TD>BAELDE_DIABETIC_NEPHROPATHY_DN</TD><TD>MSigDB lists</TD><TD>BAELDE_DIABETIC_NEPHROPATHY_DN</TD><TD>420</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,CTGF,PLOD2,ATP9A,TSC22D3</TD></TR>
<TR><TD>2.163e-03</TD><TD>-6.14</TD><TD>sublamina densa</TD><TD>cellular component</TD><TD>GO:0061618</TD><TD>1</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>FRAS1</TD></TR>
<TR><TD>2.163e-03</TD><TD>-6.14</TD><TD>collagen type XII trimer</TD><TD>cellular component</TD><TD>GO:0005595</TD><TD>1</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>COL12A1</TD></TR>
<TR><TD>2.173e-03</TD><TD>-6.13</TD><TD>V$OCT1_Q6</TD><TD>MSigDB lists</TD><TD>V$OCT1_Q6</TD><TD>251</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,MAP2,TSC22D3,COL12A1</TD></TR>
<TR><TD>2.176e-03</TD><TD>-6.13</TD><TD>ductolobular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ductolobular_carcinoma</TD><TD>1676</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ZNF432,LONRF3,HSPG2,MAP2,FRAS1,TSC22D3,AIM1,SYTL2,COL12A1</TD></TR>
<TR><TD>2.176e-03</TD><TD>-6.13</TD><TD>breast-carcinoma-ductolobular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma-ductolobular_carcinoma</TD><TD>1676</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ZNF432,LONRF3,HSPG2,MAP2,FRAS1,TSC22D3,AIM1,SYTL2,COL12A1</TD></TR>
<TR><TD>2.206e-03</TD><TD>-6.12</TD><TD>tibia</TD><TD>COSMIC cancer mutations</TD><TD>tibia</TD><TD>871</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>CTGF,MFI2,IGF1R,FRAS1,NR4A1,COL12A1,SYTL2</TD></TR>
<TR><TD>2.243e-03</TD><TD>-6.10</TD><TD>Cytokine_IL1-like</TD><TD>interpro domains</TD><TD>IPR008996</TD><TD>33</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>IL18,FGF19</TD></TR>
<TR><TD>2.266e-03</TD><TD>-6.09</TD><TD>blood_vessel</TD><TD>COSMIC cancer mutations</TD><TD>blood_vessel</TD><TD>2302</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>GALNT3,IGF1R,MAP2,FRAS1,TSC22D3,TOX2,TRPC1,SLC1A3,CNTNAP2,MYRIP,COL12A1,MECOM</TD></TR>
<TR><TD>2.285e-03</TD><TD>-6.08</TD><TD>MAP2_projctn</TD><TD>pfam domains</TD><TD>PF08377</TD><TD>1</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>MAP2</TD></TR>
<TR><TD>2.302e-03</TD><TD>-6.07</TD><TD>LU_AGING_BRAIN_UP</TD><TD>MSigDB lists</TD><TD>LU_AGING_BRAIN_UP</TD><TD>255</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,COL4A5,PDLIM3,PLOD2</TD></TR>
<TR><TD>2.302e-03</TD><TD>-6.07</TD><TD>V$AP1_Q6_01</TD><TD>MSigDB lists</TD><TD>V$AP1_Q6_01</TD><TD>255</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,LONRF3,HSPG2,MAP2</TD></TR>
<TR><TD>2.304e-03</TD><TD>-6.07</TD><TD>high-affinity glutamate transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0005314</TD><TD>1</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>2.311e-03</TD><TD>-6.07</TD><TD>chemokine biosynthetic process</TD><TD>biological process</TD><TD>GO:0042033</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>2.311e-03</TD><TD>-6.07</TD><TD>granulocyte macrophage colony-stimulating factor biosynthetic process</TD><TD>biological process</TD><TD>GO:0042253</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>2.311e-03</TD><TD>-6.07</TD><TD>interleukin-13 biosynthetic process</TD><TD>biological process</TD><TD>GO:0042231</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>2.311e-03</TD><TD>-6.07</TD><TD>interleukin-13 production</TD><TD>biological process</TD><TD>GO:0032616</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>2.311e-03</TD><TD>-6.07</TD><TD>adrenergic receptor signaling pathway involved in positive regulation of heart rate</TD><TD>biological process</TD><TD>GO:0086024</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.311e-03</TD><TD>-6.07</TD><TD>inactivation of MAPKK activity</TD><TD>biological process</TD><TD>GO:0051389</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.311e-03</TD><TD>-6.07</TD><TD>granulocyte macrophage colony-stimulating factor production</TD><TD>biological process</TD><TD>GO:0032604</TD><TD>1</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>2.358e-03</TD><TD>-6.05</TD><TD>MISSIAGLIA_REGULATED_BY_METHYLATION_UP</TD><TD>MSigDB lists</TD><TD>MISSIAGLIA_REGULATED_BY_METHYLATION_UP</TD><TD>121</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,MFI2,MYRIP</TD></TR>
<TR><TD>2.377e-03</TD><TD>-6.04</TD><TD>REACTOME_ION_TRANSPORT_BY_P_TYPE_ATPASES</TD><TD>MSigDB lists</TD><TD>REACTOME_ION_TRANSPORT_BY_P_TYPE_ATPASES</TD><TD>33</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>2.377e-03</TD><TD>-6.04</TD><TD>DOANE_BREAST_CANCER_CLASSES_DN</TD><TD>MSigDB lists</TD><TD>DOANE_BREAST_CANCER_CLASSES_DN</TD><TD>33</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,PLOD2</TD></TR>
<TR><TD>2.401e-03</TD><TD>-6.03</TD><TD>V$IK2_01</TD><TD>MSigDB lists</TD><TD>V$IK2_01</TD><TD>258</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,IGF1R,COL12A1,SYTL2</TD></TR>
<TR><TD>2.423e-03</TD><TD>-6.02</TD><TD>oesophagus-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-carcinoma</TD><TD>4462</TD><TD>18</TD><TD>17775</TD><TD>38</TD>
<TD>MFI2,LONRF3,HSPG2,ATP9A,NR4A1,CNTNAP2,FGF19,COL12A1,MECOM,MAP2,FRAS1,AIM1,TOX2,TRPC1,SUN3,PDE4D,SOX8,MYRIP</TD></TR>
<TR><TD>2.468e-03</TD><TD>-6.00</TD><TD>TTGTTT_V$FOXO4_01</TD><TD>MSigDB lists</TD><TD>TTGTTT_V$FOXO4_01</TD><TD>1950</TD><TD>11</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,LONRF3,HSPG2,PDLIM3,NR4A1,TSC22D3,COL4A5,IL18,PDE4D,SYTL2,MECOM</TD></TR>
<TR><TD>2.470e-03</TD><TD>-6.00</TD><TD>positive regulation of heart contraction</TD><TD>biological process</TD><TD>GO:0045823</TD><TD>32</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,CTGF</TD></TR>
<TR><TD>2.488e-03</TD><TD>-6.00</TD><TD>Growth_fac_rcpt_N_dom</TD><TD>interpro domains</TD><TD>IPR009030</TD><TD>127</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>CTGF,IGF1R,FRAS1</TD></TR>
<TR><TD>2.521e-03</TD><TD>-5.98</TD><TD>ATPase_P-typ_cyto_domN</TD><TD>interpro domains</TD><TD>IPR023299</TD><TD>35</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>2.609e-03</TD><TD>-5.95</TD><TD>KOYAMA_SEMA3B_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>KOYAMA_SEMA3B_TARGETS_UP</TD><TD>264</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,FRAS1,TOX2,AIM1</TD></TR>
<TR><TD>2.665e-03</TD><TD>-5.93</TD><TD>P_typ_ATPase</TD><TD>interpro domains</TD><TD>IPR001757</TD><TD>36</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>2.665e-03</TD><TD>-5.93</TD><TD>ATPase_P-typ_transduc_dom_A</TD><TD>interpro domains</TD><TD>IPR008250</TD><TD>36</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>2.665e-03</TD><TD>-5.93</TD><TD>ATPase_P-typ_P_site</TD><TD>interpro domains</TD><TD>IPR018303</TD><TD>36</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>2.684e-03</TD><TD>-5.92</TD><TD>mouth</TD><TD>COSMIC cancer mutations</TD><TD>mouth</TD><TD>9422</TD><TD>29</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ALDH2,CD55,MFI2,LONRF3,HSPG2,ATP9A,NR4A1,TSC22D3,ATP2C2,COL4A5,CNTNAP2,SLC1A3,FAM198B,COL12A1,MECOM,GALNT3,ZNF432,IGF1R,PLOD2,MAP2,FRAS1,AIM1,NETO2,TRPC1,TAGLN2,SOX8,MYRIP,SULT2B1</TD></TR>
<TR><TD>2.756e-03</TD><TD>-5.89</TD><TD>RODWELL_AGING_KIDNEY_UP</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_UP</TD><TD>445</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,SLC1A3,TIMP2,FAM198B,SYTL2</TD></TR>
<TR><TD>2.762e-03</TD><TD>-5.89</TD><TD>tissue development</TD><TD>biological process</TD><TD>GO:0009888</TD><TD>1601</TD><TD>10</TD><TD>16441</TD><TD>38</TD>
<TD>HSPG2,IGF1R,CTGF,FRAS1,TAGLN2,PDE4D,SOX8,FGF19,COL12A1,MECOM</TD></TR>
<TR><TD>2.774e-03</TD><TD>-5.89</TD><TD>PSAT1 (phosphoserine aminotransferase 1)</TD><TD>protein interactions</TD><TD>29968</TD><TD>37</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2,HSPG2</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>GNF2_PTX3</TD><TD>MSigDB lists</TD><TD>GNF2_PTX3</TD><TD>36</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,PLOD2</TD></TR>
<TR><TD>2.905e-03</TD><TD>-5.84</TD><TD>V$E4F1_Q6</TD><TD>MSigDB lists</TD><TD>V$E4F1_Q6</TD><TD>272</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,PDLIM3,NR4A1,TSC22D3</TD></TR>
<TR><TD>2.939e-03</TD><TD>-5.83</TD><TD>plasma membrane region</TD><TD>cellular component</TD><TD>GO:0098590</TD><TD>906</TD><TD>7</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,TRPC1,CNTNAP2,SLC1A3,PDE4D,IGF1R,MYRIP</TD></TR>
<TR><TD>2.942e-03</TD><TD>-5.83</TD><TD>HMRNUCRECPTR</TD><TD>prints domains</TD><TD>PR01285</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.942e-03</TD><TD>-5.83</TD><TD>TRPCHANNEL1</TD><TD>prints domains</TD><TD>PR01642</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>TRPC1</TD></TR>
<TR><TD>2.942e-03</TD><TD>-5.83</TD><TD>INTRLEUKIN18</TD><TD>prints domains</TD><TD>PR01933</TD><TD>1</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>IL18</TD></TR>
<TR><TD>2.977e-03</TD><TD>-5.82</TD><TD>VHL (von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase)</TD><TD>protein interactions</TD><TD>7428</TD><TD>285</TD><TD>4</TD><TD>16036</TD><TD>34</TD>
<TD>COL4A5,TAGLN2,PLOD2,NR4A1</TD></TR>
<TR><TD>3.027e-03</TD><TD>-5.80</TD><TD>Golgi apparatus</TD><TD>cellular component</TD><TD>GO:0005794</TD><TD>1442</TD><TD>9</TD><TD>17570</TD><TD>38</TD>
<TD>GALNT3,CTGF,HSPG2,ATP9A,ATP2C2,PDE4D,CNTNAP2,FAM198B,MECOM</TD></TR>
<TR><TD>3.036e-03</TD><TD>-5.80</TD><TD>RICIN</TD><TD>smart domains</TD><TD>SM00458</TD><TD>27</TD><TD>2</TD><TD>9131</TD><TD>28</TD>
<TD>GALNT3,AIM1</TD></TR>
<TR><TD>3.045e-03</TD><TD>-5.79</TD><TD>human chr3q21-q22</TD><TD>chromosome location</TD><TD>human chr3q21-q22</TD><TD>2</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>3.050e-03</TD><TD>-5.79</TD><TD>E1-E2_ATPase</TD><TD>pfam domains</TD><TD>PF00122</TD><TD>36</TD><TD>2</TD><TD>16629</TD><TD>38</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>3.067e-03</TD><TD>-5.79</TD><TD>Cilostazol Action Pathway</TD><TD>SMPDB pathways</TD><TD>SMP00263</TD><TD>1</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.067e-03</TD><TD>-5.79</TD><TD>Dipyridamole (Antiplatelet) Action Pathway</TD><TD>SMPDB pathways</TD><TD>SMP00264</TD><TD>1</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.082e-03</TD><TD>-5.78</TD><TD>RICIN_B_LECTIN</TD><TD>prosite domains</TD><TD>PS50231</TD><TD>29</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>GALNT3,AIM1</TD></TR>
<TR><TD>3.082e-03</TD><TD>-5.78</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN</TD><TD>MSigDB lists</TD><TD>LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN</TD><TD>133</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,TSC22D3,TOX2</TD></TR>
<TR><TD>3.122e-03</TD><TD>-5.77</TD><TD>VWF_dom</TD><TD>interpro domains</TD><TD>IPR001007</TD><TD>39</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>CTGF,FRAS1</TD></TR>
<TR><TD>3.148e-03</TD><TD>-5.76</TD><TD>WWTAAGGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>WWTAAGGC_UNKNOWN</TD><TD>134</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,MAP2,FGF19</TD></TR>
<TR><TD>3.161e-03</TD><TD>-5.76</TD><TD>central nervous system development</TD><TD>biological process</TD><TD>GO:0007417</TD><TD>859</TD><TD>7</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2,TIMP2,IGF1R,SOX8,HSPG2,MAP2,MECOM</TD></TR>
<TR><TD>3.166e-03</TD><TD>-5.76</TD><TD>cellular component disassembly</TD><TD>biological process</TD><TD>GO:0022411</TD><TD>637</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>COL4A5,TIMP2,SLC1A3,HSPG2,PLOD2,COL12A1</TD></TR>
<TR><TD>3.209e-03</TD><TD>-5.74</TD><TD>multicellular organismal development</TD><TD>biological process</TD><TD>GO:0007275</TD><TD>4594</TD><TD>19</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,HSPG2,NR4A1,IL18,COL4A5,SLC1A3,CNTNAP2,FGF19,COL12A1,MECOM,CTGF,IGF1R,PDLIM3,MAP2,FRAS1,TOX2,TRPC1,PDE4D,SOX8</TD></TR>
<TR><TD>3.215e-03</TD><TD>-5.74</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP</TD><TD>MSigDB lists</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP</TD><TD>135</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,SYTL2,MECOM</TD></TR>
<TR><TD>3.224e-03</TD><TD>-5.74</TD><TD>DURAND_STROMA_S_UP</TD><TD>MSigDB lists</TD><TD>DURAND_STROMA_S_UP</TD><TD>280</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,PDE4D,LONRF3,TSC22D3</TD></TR>
<TR><TD>3.282e-03</TD><TD>-5.72</TD><TD>LDLR_class-A_CS</TD><TD>interpro domains</TD><TD>IPR023415</TD><TD>40</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>HSPG2,NETO2</TD></TR>
<TR><TD>3.285e-03</TD><TD>-5.72</TD><TD>cellular developmental process</TD><TD>biological process</TD><TD>GO:0048869</TD><TD>3526</TD><TD>16</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,HSPG2,NR4A1,COL4A5,CNTNAP2,SLC1A3,FGF19,COL12A1,MECOM,CTGF,IGF1R,MAP2,TRPC1,PDE4D,TAGLN2,SOX8</TD></TR>
<TR><TD>3.478e-03</TD><TD>-5.66</TD><TD>NABA_BASEMENT_MEMBRANES</TD><TD>MSigDB lists</TD><TD>NABA_BASEMENT_MEMBRANES</TD><TD>40</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,HSPG2</TD></TR>
<TR><TD>3.490e-03</TD><TD>-5.66</TD><TD>CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN</TD><TD>MSigDB lists</TD><TD>CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN</TD><TD>139</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,COL4A5,CTGF</TD></TR>
<TR><TD>3.651e-03</TD><TD>-5.61</TD><TD>KEGG_LYSINE_DEGRADATION</TD><TD>MSigDB lists</TD><TD>KEGG_LYSINE_DEGRADATION</TD><TD>41</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>3.745e-03</TD><TD>-5.59</TD><TD>VWFC_1</TD><TD>prosite domains</TD><TD>PS01208</TD><TD>32</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>CTGF,FRAS1</TD></TR>
<TR><TD>3.780e-03</TD><TD>-5.58</TD><TD>LANDIS_ERBB2_BREAST_TUMORS_324_UP</TD><TD>MSigDB lists</TD><TD>LANDIS_ERBB2_BREAST_TUMORS_324_UP</TD><TD>143</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,NR4A1,AIM1</TD></TR>
<TR><TD>3.783e-03</TD><TD>-5.58</TD><TD>WONG_ADULT_TISSUE_STEM_MODULE</TD><TD>MSigDB lists</TD><TD>WONG_ADULT_TISSUE_STEM_MODULE</TD><TD>694</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,CTGF,PDLIM3,MAP2,NR4A1,AIM1</TD></TR>
<TR><TD>3.838e-03</TD><TD>-5.56</TD><TD>LI_INDUCED_T_TO_NATURAL_KILLER_UP</TD><TD>MSigDB lists</TD><TD>LI_INDUCED_T_TO_NATURAL_KILLER_UP</TD><TD>294</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,SULT2B1,SYTL2,AIM1</TD></TR>
<TR><TD>3.980e-03</TD><TD>-5.53</TD><TD>VWFC_2</TD><TD>prosite domains</TD><TD>PS50184</TD><TD>33</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>CTGF,FRAS1</TD></TR>
<TR><TD>4.009e-03</TD><TD>-5.52</TD><TD>LANDIS_BREAST_CANCER_PROGRESSION_UP</TD><TD>MSigDB lists</TD><TD>LANDIS_BREAST_CANCER_PROGRESSION_UP</TD><TD>43</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,AIM1</TD></TR>
<TR><TD>4.009e-03</TD><TD>-5.52</TD><TD>HALMOS_CEBPA_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>HALMOS_CEBPA_TARGETS_DN</TD><TD>43</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,TSC22D3</TD></TR>
<TR><TD>4.018e-03</TD><TD>-5.52</TD><TD>phosphatidylinositol-mediated signaling</TD><TD>biological process</TD><TD>GO:0048015</TD><TD>139</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,NR4A1,FGF19</TD></TR>
<TR><TD>4.019e-03</TD><TD>-5.52</TD><TD>CELL_FRACTION</TD><TD>MSigDB lists</TD><TD>CELL_FRACTION</TD><TD>486</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,SLC1A3,CD55,PDE4D,SYTL2</TD></TR>
<TR><TD>4.090e-03</TD><TD>-5.50</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1</TD><TD>MSigDB lists</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1</TD><TD>488</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,IGF1R,SULT2B1,SYTL2,COL12A1</TD></TR>
<TR><TD>4.195e-03</TD><TD>-5.47</TD><TD>MODULE_284</TD><TD>MSigDB lists</TD><TD>MODULE_284</TD><TD>44</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,IGF1R</TD></TR>
<TR><TD>4.195e-03</TD><TD>-5.47</TD><TD>BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN</TD><TD>MSigDB lists</TD><TD>BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN</TD><TD>44</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,IGF1R</TD></TR>
<TR><TD>4.195e-03</TD><TD>-5.47</TD><TD>CHANDRAN_METASTASIS_TOP50_DN</TD><TD>MSigDB lists</TD><TD>CHANDRAN_METASTASIS_TOP50_DN</TD><TD>44</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1,AIM1</TD></TR>
<TR><TD>4.195e-03</TD><TD>-5.47</TD><TD>NABA_COLLAGENS</TD><TD>MSigDB lists</TD><TD>NABA_COLLAGENS</TD><TD>44</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>4.209e-03</TD><TD>-5.47</TD><TD>TGGAAA_V$NFAT_Q4_01</TD><TD>MSigDB lists</TD><TD>TGGAAA_V$NFAT_Q4_01</TD><TD>1781</TD><TD>10</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,HSPG2,PDLIM3,PLOD2,NR4A1,TSC22D3,PDE4D,CNTNAP2,COL12A1,MECOM</TD></TR>
<TR><TD>4.236e-03</TD><TD>-5.46</TD><TD>ACYP2 (acylphosphatase 2, muscle type)</TD><TD>protein interactions</TD><TD>98</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>4.236e-03</TD><TD>-5.46</TD><TD>Arrb1 (arrestin, beta 1)</TD><TD>protein interactions</TD><TD>25387</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.236e-03</TD><TD>-5.46</TD><TD>IL18BP (interleukin 18 binding protein)</TD><TD>protein interactions</TD><TD>10068</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IL18</TD></TR>
<TR><TD>4.236e-03</TD><TD>-5.46</TD><TD>IGHG4 (immunoglobulin heavy constant gamma 4 (G4m marker))</TD><TD>protein interactions</TD><TD>3503</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.236e-03</TD><TD>-5.46</TD><TD>ABCA5 (ATP binding cassette subfamily A member 5)</TD><TD>protein interactions</TD><TD>23461</TD><TD>2</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.259e-03</TD><TD>-5.46</TD><TD>P-type_ATPase_IIA_PMR1</TD><TD>interpro domains</TD><TD>IPR006413</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>4.259e-03</TD><TD>-5.46</TD><TD>FAM198</TD><TD>interpro domains</TD><TD>IPR029207</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>FAM198B</TD></TR>
<TR><TD>4.259e-03</TD><TD>-5.46</TD><TD>Myrip/Melanophilin</TD><TD>interpro domains</TD><TD>IPR006788</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MYRIP</TD></TR>
<TR><TD>4.259e-03</TD><TD>-5.46</TD><TD>Evi1/Prdm16</TD><TD>interpro domains</TD><TD>IPR030413</TD><TD>2</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.266e-03</TD><TD>-5.46</TD><TD>inositol lipid-mediated signaling</TD><TD>biological process</TD><TD>GO:0048017</TD><TD>142</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,NR4A1,FGF19</TD></TR>
<TR><TD>4.321e-03</TD><TD>-5.44</TD><TD>CA3 pyramidal cell dendrite</TD><TD>cellular component</TD><TD>GO:0097442</TD><TD>2</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>MAP2</TD></TR>
<TR><TD>4.328e-03</TD><TD>-5.44</TD><TD>Ldl_recept_a</TD><TD>pfam domains</TD><TD>PF00057</TD><TD>43</TD><TD>2</TD><TD>16629</TD><TD>38</TD>
<TD>HSPG2,NETO2</TD></TR>
<TR><TD>4.469e-03</TD><TD>-5.41</TD><TD>LAM_G_DOMAIN</TD><TD>prosite domains</TD><TD>PS50025</TD><TD>35</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>CNTNAP2,HSPG2</TD></TR>
<TR><TD>4.475e-03</TD><TD>-5.41</TD><TD>DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP</TD><TD>MSigDB lists</TD><TD>DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP</TD><TD>307</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,CD55,PDE4D,CTGF</TD></TR>
<TR><TD>4.495e-03</TD><TD>-5.40</TD><TD>LIAO_METASTASIS</TD><TD>MSigDB lists</TD><TD>LIAO_METASTASIS</TD><TD>499</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,ZNF432,MAP2,MECOM,NETO2</TD></TR>
<TR><TD>4.497e-03</TD><TD>-5.40</TD><TD>NUYTTEN_NIPP1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>NUYTTEN_NIPP1_TARGETS_UP</TD><TD>719</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,CTGF,PLOD2,NR4A1,MECOM,NETO2</TD></TR>
<TR><TD>4.524e-03</TD><TD>-5.40</TD><TD>CATATPASE</TD><TD>prints domains</TD><TD>PR00119</TD><TD>35</TD><TD>2</TD><TD>4759</TD><TD>14</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>4.565e-03</TD><TD>-5.39</TD><TD>human chr2q34-q35</TD><TD>chromosome location</TD><TD>human chr2q34-q35</TD><TD>3</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>MAP2</TD></TR>
<TR><TD>4.565e-03</TD><TD>-5.39</TD><TD>human chr3q28-q29</TD><TD>chromosome location</TD><TD>human chr3q28-q29</TD><TD>3</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>MFI2</TD></TR>
<TR><TD>4.565e-03</TD><TD>-5.39</TD><TD>human chr6q12-q13</TD><TD>chromosome location</TD><TD>human chr6q12-q13</TD><TD>3</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>COL12A1</TD></TR>
<TR><TD>4.565e-03</TD><TD>-5.39</TD><TD>Rab_eff_C</TD><TD>pfam domains</TD><TD>PF04698</TD><TD>2</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>MYRIP</TD></TR>
<TR><TD>4.565e-03</TD><TD>-5.39</TD><TD>FAM198</TD><TD>pfam domains</TD><TD>PF15051</TD><TD>2</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>FAM198B</TD></TR>
<TR><TD>4.577e-03</TD><TD>-5.39</TD><TD>PID_SYNDECAN_1_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_SYNDECAN_1_PATHWAY</TD><TD>46</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>4.603e-03</TD><TD>-5.38</TD><TD>manganese-transporting ATPase activity</TD><TD>molecular function</TD><TD>GO:0015410</TD><TD>2</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>4.603e-03</TD><TD>-5.38</TD><TD>alcohol sulfotransferase activity</TD><TD>molecular function</TD><TD>GO:0004027</TD><TD>2</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>negative regulation of relaxation of muscle</TD><TD>biological process</TD><TD>GO:1901078</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>adrenergic receptor signaling pathway involved in heart process</TD><TD>biological process</TD><TD>GO:0086023</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>negative regulation of relaxation of cardiac muscle</TD><TD>biological process</TD><TD>GO:1901898</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>extracellular matrix constituent secretion</TD><TD>biological process</TD><TD>GO:0070278</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>regulation of kainate selective glutamate receptor activity</TD><TD>biological process</TD><TD>GO:2000312</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>gamma-aminobutyric acid biosynthetic process</TD><TD>biological process</TD><TD>GO:0009449</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>superior temporal gyrus development</TD><TD>biological process</TD><TD>GO:0071109</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>organ senescence</TD><TD>biological process</TD><TD>GO:0010260</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>interferon-gamma biosynthetic process</TD><TD>biological process</TD><TD>GO:0042095</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>CD4-positive, alpha-beta T cell cytokine production</TD><TD>biological process</TD><TD>GO:0035743</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CD55</TD></TR>
<TR><TD>4.617e-03</TD><TD>-5.38</TD><TD>chemokine metabolic process</TD><TD>biological process</TD><TD>GO:0050755</TD><TD>2</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>4.638e-03</TD><TD>-5.37</TD><TD>angiogenesis</TD><TD>biological process</TD><TD>GO:0001525</TD><TD>295</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CTGF,HSPG2,NR4A1</TD></TR>
<TR><TD>4.696e-03</TD><TD>-5.36</TD><TD>LDrepeatLR_classA_rpt</TD><TD>interpro domains</TD><TD>IPR002172</TD><TD>48</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>HSPG2,NETO2</TD></TR>
<TR><TD>4.697e-03</TD><TD>-5.36</TD><TD>follicular_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>follicular_lymphoma</TD><TD>1269</TD><TD>8</TD><TD>17775</TD><TD>38</TD>
<TD>IGF1R,PDLIM3,PLOD2,MAP2,FRAS1,ATP9A,CNTNAP2,MYRIP</TD></TR>
<TR><TD>4.712e-03</TD><TD>-5.36</TD><TD>alveolar</TD><TD>COSMIC cancer mutations</TD><TD>alveolar</TD><TD>2511</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>CD55,MFI2,IGF1R,PLOD2,MAP2,FRAS1,NR4A1,TOX2,AIM1,COL4A5,SLC1A3,CNTNAP2</TD></TR>
<TR><TD>4.712e-03</TD><TD>-5.36</TD><TD>soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar</TD><TD>2511</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>CD55,MFI2,IGF1R,PLOD2,MAP2,FRAS1,NR4A1,TOX2,AIM1,COL4A5,SLC1A3,CNTNAP2</TD></TR>
<TR><TD>4.718e-03</TD><TD>-5.36</TD><TD>haematopoietic_and_lymphoid_tissue-breast-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-breast-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>48</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>PLOD2,MAP2</TD></TR>
<TR><TD>4.723e-03</TD><TD>-5.36</TD><TD>ATPASE_E1_E2</TD><TD>prosite domains</TD><TD>PS00154</TD><TD>36</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>4.821e-03</TD><TD>-5.33</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN</TD><TD>MSigDB lists</TD><TD>PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN</TD><TD>156</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,PLOD2,MECOM</TD></TR>
<TR><TD>4.821e-03</TD><TD>-5.33</TD><TD>FBLN1 (fibulin 1)</TD><TD>protein interactions</TD><TD>2192</TD><TD>49</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>CTGF,HSPG2</TD></TR>
<TR><TD>4.876e-03</TD><TD>-5.32</TD><TD>upper_aerodigestive_tract</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract</TD><TD>13823</TD><TD>36</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,ATP9A,TSC22D3,ATP2C2,COL4A5,CNTNAP2,SLC1A3,FAM198B,FGF19,SYTL2,MECOM,ZNF432,CTGF,IGF1R,FRAS1,TOX2,AIM1,TRPC1,SUN3,TAGLN2,PDE4D,MYRIP,SULT2B1,AMOTL2,CD55,ALDH2,LONRF3,MFI2,NR4A1,COL12A1,GALNT3,PDLIM3,PLOD2,MAP2,NETO2,SOX8</TD></TR>
<TR><TD>4.974e-03</TD><TD>-5.30</TD><TD>ZHU_CMV_8_HR_UP</TD><TD>MSigDB lists</TD><TD>ZHU_CMV_8_HR_UP</TD><TD>48</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,NR4A1</TD></TR>
<TR><TD>4.974e-03</TD><TD>-5.30</TD><TD>BCAT_GDS748_UP</TD><TD>MSigDB lists</TD><TD>BCAT_GDS748_UP</TD><TD>48</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,AIM1</TD></TR>
<TR><TD>4.974e-03</TD><TD>-5.30</TD><TD>GYORFFY_DOXORUBICIN_RESISTANCE</TD><TD>MSigDB lists</TD><TD>GYORFFY_DOXORUBICIN_RESISTANCE</TD><TD>48</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,NETO2</TD></TR>
<TR><TD>5.009e-03</TD><TD>-5.30</TD><TD>WGTTNNNNNAAA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>WGTTNNNNNAAA_UNKNOWN</TD><TD>512</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,IGF1R,COL12A1,TOX2,MECOM</TD></TR>
<TR><TD>5.023e-03</TD><TD>-5.29</TD><TD>Asthma(PMID:19426955)</TD><TD>GWAS genes</TD><TD>Asthma(PMID:19426955)</TD><TD>1</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>PDE4D</TD></TR>
<TR><TD>5.023e-03</TD><TD>-5.29</TD><TD>Neuroticism(PMID:17667963)</TD><TD>GWAS genes</TD><TD>Neuroticism(PMID:17667963)</TD><TD>1</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>PDE4D</TD></TR>
<TR><TD>5.023e-03</TD><TD>-5.29</TD><TD>Sleep duration(PMID:17903308)</TD><TD>GWAS genes</TD><TD>Sleep duration(PMID:17903308)</TD><TD>1</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>MYRIP</TD></TR>
<TR><TD>5.083e-03</TD><TD>-5.28</TD><TD>MULLIGHAN_NPM1_SIGNATURE_3_DN</TD><TD>MSigDB lists</TD><TD>MULLIGHAN_NPM1_SIGNATURE_3_DN</TD><TD>159</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,HSPG2,ATP9A</TD></TR>
<TR><TD>5.152e-03</TD><TD>-5.27</TD><TD>HMG_box</TD><TD>pfam domains</TD><TD>PF00505</TD><TD>47</TD><TD>2</TD><TD>16629</TD><TD>38</TD>
<TD>SOX8,TOX2</TD></TR>
<TR><TD>5.178e-03</TD><TD>-5.26</TD><TD>BECKER_TAMOXIFEN_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>BECKER_TAMOXIFEN_RESISTANCE_DN</TD><TD>49</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,AIM1</TD></TR>
<TR><TD>5.199e-03</TD><TD>-5.26</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_T_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_T_cell_leukaemia</TD><TD>762</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>SUN3,IGF1R,HSPG2,FRAS1,ATP9A,COL12A1</TD></TR>
<TR><TD>5.199e-03</TD><TD>-5.26</TD><TD>acute_lymphoblastic_T_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>acute_lymphoblastic_T_cell_leukaemia</TD><TD>762</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>SUN3,IGF1R,HSPG2,FRAS1,ATP9A,COL12A1</TD></TR>
<TR><TD>5.217e-03</TD><TD>-5.26</TD><TD>urogenital system development</TD><TD>biological process</TD><TD>GO:0001655</TD><TD>305</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,SOX8,FRAS1,MECOM</TD></TR>
<TR><TD>5.256e-03</TD><TD>-5.25</TD><TD>neuron differentiation</TD><TD>biological process</TD><TD>GO:0030182</TD><TD>1196</TD><TD>8</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,MAP2,TRPC1,COL4A5,SLC1A3,CNTNAP2,SOX8,FGF19</TD></TR>
<TR><TD>5.348e-03</TD><TD>-5.23</TD><TD>ameboidal-type cell migration</TD><TD>biological process</TD><TD>GO:0001667</TD><TD>154</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,NR4A1,FGF19</TD></TR>
<TR><TD>5.387e-03</TD><TD>-5.22</TD><TD>BURTON_ADIPOGENESIS_7</TD><TD>MSigDB lists</TD><TD>BURTON_ADIPOGENESIS_7</TD><TD>50</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,TIMP2</TD></TR>
<TR><TD>5.387e-03</TD><TD>-5.22</TD><TD>BURTON_ADIPOGENESIS_PEAK_AT_2HR</TD><TD>MSigDB lists</TD><TD>BURTON_ADIPOGENESIS_PEAK_AT_2HR</TD><TD>50</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,NR4A1</TD></TR>
<TR><TD>5.446e-03</TD><TD>-5.21</TD><TD>TAAYNRNNTCC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TAAYNRNNTCC_UNKNOWN</TD><TD>163</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LONRF3,MAP2,SYTL2</TD></TR>
<TR><TD>5.476e-03</TD><TD>-5.21</TD><TD>MODULE_100</TD><TD>MSigDB lists</TD><TD>MODULE_100</TD><TD>523</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,CNTNAP2,MAP2,NR4A1,ATP9A</TD></TR>
<TR><TD>5.487e-03</TD><TD>-5.21</TD><TD>regulation of myoblast differentiation</TD><TD>biological process</TD><TD>GO:0045661</TD><TD>48</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,SOX8</TD></TR>
<TR><TD>5.521e-03</TD><TD>-5.20</TD><TD>skin-ankle-malignant_melanoma-acral_lentiginous</TD><TD>COSMIC cancer mutations</TD><TD>skin-ankle-malignant_melanoma-acral_lentiginous</TD><TD>335</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>ALDH2,CNTNAP2,HSPG2,MAP2</TD></TR>
<TR><TD>5.529e-03</TD><TD>-5.20</TD><TD>PEREZ_TP63_TARGETS</TD><TD>MSigDB lists</TD><TD>PEREZ_TP63_TARGETS</TD><TD>326</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>SOX8,IGF1R,LONRF3,TSC22D3</TD></TR>
<TR><TD>5.530e-03</TD><TD>-5.20</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma</TD><TD>1028</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,IGF1R,PDLIM3,PLOD2,MYRIP,MAP2,FRAS1</TD></TR>
<TR><TD>5.582e-03</TD><TD>-5.19</TD><TD>GGGAGGRR_V$MAZ_Q6</TD><TD>MSigDB lists</TD><TD>GGGAGGRR_V$MAZ_Q6</TD><TD>2165</TD><TD>11</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,CTGF,HSPG2,PDLIM3,TSC22D3,IL18,COL4A5,CNTNAP2,SULT2B1,COL12A1,MECOM</TD></TR>
<TR><TD>5.599e-03</TD><TD>-5.19</TD><TD>CHIBA_RESPONSE_TO_TSA_UP</TD><TD>MSigDB lists</TD><TD>CHIBA_RESPONSE_TO_TSA_UP</TD><TD>51</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,CTGF</TD></TR>
<TR><TD>5.601e-03</TD><TD>-5.18</TD><TD>Metabolism of serotonin</TD><TD>REACTOME pathways</TD><TD>R-HSA-380612</TD><TD>2</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>ALDH2</TD></TR>
<TR><TD>5.601e-03</TD><TD>-5.18</TD><TD>Serotonin clearance from the synaptic cleft</TD><TD>REACTOME pathways</TD><TD>R-HSA-380615</TD><TD>2</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>ALDH2</TD></TR>
<TR><TD>5.609e-03</TD><TD>-5.18</TD><TD>MODULE_137</TD><TD>MSigDB lists</TD><TD>MODULE_137</TD><TD>526</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,CNTNAP2,MAP2,NR4A1,ATP9A</TD></TR>
<TR><TD>5.633e-03</TD><TD>-5.18</TD><TD>GSE26495_NAIVE_VS_PD1HIGH_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE26495_NAIVE_VS_PD1HIGH_CD8_TCELL_UP</TD><TD>165</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,SOX8,IGF1R</TD></TR>
<TR><TD>5.709e-03</TD><TD>-5.17</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>MSigDB lists</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>329</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,ZNF432,AIM1,NETO2</TD></TR>
<TR><TD>5.713e-03</TD><TD>-5.17</TD><TD>regulation of steroid biosynthetic process</TD><TD>biological process</TD><TD>GO:0050810</TD><TD>49</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,FGF19</TD></TR>
<TR><TD>5.718e-03</TD><TD>-5.16</TD><TD>cell morphogenesis involved in neuron differentiation</TD><TD>biological process</TD><TD>GO:0048667</TD><TD>719</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,COL4A5,SLC1A3,IGF1R,MAP2,FGF19</TD></TR>
<TR><TD>5.824e-03</TD><TD>-5.15</TD><TD>GSE11057_NAIVE_VS_MEMORY_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE11057_NAIVE_VS_MEMORY_CD4_TCELL_UP</TD><TD>167</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,CD55,IGF1R</TD></TR>
<TR><TD>5.824e-03</TD><TD>-5.15</TD><TD>GSE11864_UNTREATED_VS_CSF1_IFNG_PAM3CYS_IN_MAC_UP</TD><TD>MSigDB lists</TD><TD>GSE11864_UNTREATED_VS_CSF1_IFNG_PAM3CYS_IN_MAC_UP</TD><TD>167</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FAM198B,PDE4D,SYTL2</TD></TR>
<TR><TD>5.835e-03</TD><TD>-5.14</TD><TD>MODULE_66</TD><TD>MSigDB lists</TD><TD>MODULE_66</TD><TD>531</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>CNTNAP2,SLC1A3,MAP2,NR4A1,ATP9A</TD></TR>
<TR><TD>5.910e-03</TD><TD>-5.13</TD><TD>HMG_box_dom</TD><TD>interpro domains</TD><TD>IPR009071</TD><TD>54</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>SOX8,TOX2</TD></TR>
<TR><TD>6.019e-03</TD><TD>-5.11</TD><TD>GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_12H_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_12H_CD4_TCELL_UP</TD><TD>169</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,TSC22D3,SYTL2</TD></TR>
<TR><TD>6.019e-03</TD><TD>-5.11</TD><TD>ESC_V6.5_UP_EARLY.V1_DN</TD><TD>MSigDB lists</TD><TD>ESC_V6.5_UP_EARLY.V1_DN</TD><TD>169</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,FAM198B,CTGF</TD></TR>
<TR><TD>6.019e-03</TD><TD>-5.11</TD><TD>GSE26928_EFF_MEMORY_VS_CXCR5_POS_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE26928_EFF_MEMORY_VS_CXCR5_POS_CD4_TCELL_DN</TD><TD>169</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,IGF1R,FRAS1</TD></TR>
<TR><TD>6.035e-03</TD><TD>-5.11</TD><TD>WATTEL_AUTONOMOUS_THYROID_ADENOMA_DN</TD><TD>MSigDB lists</TD><TD>WATTEL_AUTONOMOUS_THYROID_ADENOMA_DN</TD><TD>53</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,NR4A1</TD></TR>
<TR><TD>6.035e-03</TD><TD>-5.11</TD><TD>BOYLAN_MULTIPLE_MYELOMA_C_DN</TD><TD>MSigDB lists</TD><TD>BOYLAN_MULTIPLE_MYELOMA_C_DN</TD><TD>53</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,PLOD2</TD></TR>
<TR><TD>6.069e-03</TD><TD>-5.10</TD><TD>single-organism developmental process</TD><TD>biological process</TD><TD>GO:0044767</TD><TD>5226</TD><TD>20</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,HSPG2,NR4A1,IL18,COL4A5,SLC1A3,CNTNAP2,FGF19,COL12A1,MECOM,CTGF,IGF1R,PDLIM3,MAP2,FRAS1,TOX2,TRPC1,TAGLN2,PDE4D,SOX8</TD></TR>
<TR><TD>6.153e-03</TD><TD>-5.09</TD><TD>regulation of neurotransmitter levels</TD><TD>biological process</TD><TD>GO:0001505</TD><TD>162</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>ALDH2,SLC1A3,SYTL2</TD></TR>
<TR><TD>6.185e-03</TD><TD>-5.09</TD><TD>plasma membrane part</TD><TD>cellular component</TD><TD>GO:0044459</TD><TD>2566</TD><TD>12</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,CD55,MFI2,IGF1R,ATP2C2,NETO2,TRPC1,CNTNAP2,PDE4D,SLC1A3,MYRIP,SYTL2</TD></TR>
<TR><TD>6.210e-03</TD><TD>-5.08</TD><TD>SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP</TD><TD>MSigDB lists</TD><TD>SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP</TD><TD>337</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,IL18,CD55,CTGF</TD></TR>
<TR><TD>6.258e-03</TD><TD>-5.07</TD><TD>MODULE_175</TD><TD>MSigDB lists</TD><TD>MODULE_175</TD><TD>54</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,PLOD2</TD></TR>
<TR><TD>6.258e-03</TD><TD>-5.07</TD><TD>REACTOME_PI_3K_CASCADE</TD><TD>MSigDB lists</TD><TD>REACTOME_PI_3K_CASCADE</TD><TD>54</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>6.258e-03</TD><TD>-5.07</TD><TD>REACTOME_ION_CHANNEL_TRANSPORT</TD><TD>MSigDB lists</TD><TD>REACTOME_ION_CHANNEL_TRANSPORT</TD><TD>54</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>6.265e-03</TD><TD>-5.07</TD><TD>VWC</TD><TD>smart domains</TD><TD>SM00214</TD><TD>39</TD><TD>2</TD><TD>9131</TD><TD>28</TD>
<TD>CTGF,FRAS1</TD></TR>
<TR><TD>6.348e-03</TD><TD>-5.06</TD><TD>UTF1 (undifferentiated embryonic cell transcription factor 1)</TD><TD>protein interactions</TD><TD>8433</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SOX8</TD></TR>
<TR><TD>6.348e-03</TD><TD>-5.06</TD><TD>ALDH1A2 (aldehyde dehydrogenase 1 family, member A2)</TD><TD>protein interactions</TD><TD>8854</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>6.348e-03</TD><TD>-5.06</TD><TD>IL18RAP (interleukin 18 receptor accessory protein)</TD><TD>protein interactions</TD><TD>8807</TD><TD>3</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IL18</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>MAP2/MAP4/Tau</TD><TD>interpro domains</TD><TD>IPR027324</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Angiomotin</TD><TD>interpro domains</TD><TD>IPR009114</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Transferrin</TD><TD>interpro domains</TD><TD>IPR016357</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MFI2</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Sox_N</TD><TD>interpro domains</TD><TD>IPR022151</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SOX8</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>MAP_tubulin-bd_rpt</TD><TD>interpro domains</TD><TD>IPR001084</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Procol_lys_dOase</TD><TD>interpro domains</TD><TD>IPR001006</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PLOD2</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Tyr_kinase_insulin-like_rcpt</TD><TD>interpro domains</TD><TD>IPR016246</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Transferrin_Fe_BS</TD><TD>interpro domains</TD><TD>IPR018195</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MFI2</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>ZASP</TD><TD>interpro domains</TD><TD>IPR006643</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PDLIM3</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Transferrin-like_dom</TD><TD>interpro domains</TD><TD>IPR001156</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MFI2</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Nuc_orph_rcpt</TD><TD>interpro domains</TD><TD>IPR003070</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>NR4A1</TD></TR>
<TR><TD>6.383e-03</TD><TD>-5.05</TD><TD>Angiomotin_C</TD><TD>interpro domains</TD><TD>IPR024646</TD><TD>3</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>6.405e-03</TD><TD>-5.05</TD><TD>WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_UP</TD><TD>MSigDB lists</TD><TD>WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_UP</TD><TD>340</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,TIMP2,ALDH2,AIM1</TD></TR>
<TR><TD>6.409e-03</TD><TD>-5.05</TD><TD>ZWANG_TRANSIENTLY_UP_BY_1ST_EGF_PULSE_ONLY</TD><TD>MSigDB lists</TD><TD>ZWANG_TRANSIENTLY_UP_BY_1ST_EGF_PULSE_ONLY</TD><TD>1587</TD><TD>9</TD><TD>17758</TD><TD>39</TD>
<TD>ZNF432,IGF1R,MAP2,COL4A5,PDE4D,CNTNAP2,SLC1A3,SULT2B1,SYTL2</TD></TR>
<TR><TD>6.413e-03</TD><TD>-5.05</TD><TD>neural crest cell migration</TD><TD>biological process</TD><TD>GO:0001755</TD><TD>52</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,FGF19</TD></TR>
<TR><TD>6.413e-03</TD><TD>-5.05</TD><TD>positive regulation of alpha-beta T cell activation</TD><TD>biological process</TD><TD>GO:0046635</TD><TD>52</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>6.420e-03</TD><TD>-5.05</TD><TD>GSE12366_GC_BCELL_VS_PLASMA_CELL_DN</TD><TD>MSigDB lists</TD><TD>GSE12366_GC_BCELL_VS_PLASMA_CELL_DN</TD><TD>173</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,HSPG2,NETO2</TD></TR>
<TR><TD>6.468e-03</TD><TD>-5.04</TD><TD>epithelium development</TD><TD>biological process</TD><TD>GO:0060429</TD><TD>979</TD><TD>7</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,TAGLN2,IGF1R,SOX8,CTGF,FRAS1,MECOM</TD></TR>
<TR><TD>6.474e-03</TD><TD>-5.04</TD><TD>MAD1L1 (MAD1 mitotic arrest deficient-like 1 (yeast))</TD><TD>protein interactions</TD><TD>8379</TD><TD>57</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2,TSC22D3</TD></TR>
<TR><TD>6.475e-03</TD><TD>-5.04</TD><TD>anchoring collagen complex</TD><TD>cellular component</TD><TD>GO:0030934</TD><TD>3</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>COL12A1</TD></TR>
<TR><TD>6.485e-03</TD><TD>-5.04</TD><TD>GRADE_COLON_VS_RECTAL_CANCER_DN</TD><TD>MSigDB lists</TD><TD>GRADE_COLON_VS_RECTAL_CANCER_DN</TD><TD>55</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,FRAS1</TD></TR>
<TR><TD>6.603e-03</TD><TD>-5.02</TD><TD>acute_lymphoblastic_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>acute_lymphoblastic_leukaemia</TD><TD>2279</TD><TD>11</TD><TD>17775</TD><TD>38</TD>
<TD>CD55,CTGF,IGF1R,HSPG2,MAP2,FRAS1,TSC22D3,NETO2,COL4A5,FAM198B,COL12A1</TD></TR>
<TR><TD>6.608e-03</TD><TD>-5.02</TD><TD>putrescine degradation III</TD><TD>BIOCYC pathways</TD><TD>META_PWY-0</TD><TD>3</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>6.655e-03</TD><TD>-5.01</TD><TD>skin-arm-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-arm-malignant_melanoma</TD><TD>1345</TD><TD>8</TD><TD>17775</TD><TD>38</TD>
<TD>PLOD2,MAP2,ATP2C2,NETO2,COL4A5,SULT2B1,COL12A1,MECOM</TD></TR>
<TR><TD>6.686e-03</TD><TD>-5.01</TD><TD>LDLRA_1</TD><TD>prosite domains</TD><TD>PS01209</TD><TD>43</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>HSPG2,NETO2</TD></TR>
<TR><TD>6.716e-03</TD><TD>-5.00</TD><TD>MORI_LARGE_PRE_BII_LYMPHOCYTE_DN</TD><TD>MSigDB lists</TD><TD>MORI_LARGE_PRE_BII_LYMPHOCYTE_DN</TD><TD>56</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,AIM1</TD></TR>
<TR><TD>6.716e-03</TD><TD>-5.00</TD><TD>NAGASHIMA_EGF_SIGNALING_UP</TD><TD>MSigDB lists</TD><TD>NAGASHIMA_EGF_SIGNALING_UP</TD><TD>56</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,NR4A1</TD></TR>
<TR><TD>6.769e-03</TD><TD>-5.00</TD><TD>-</TD><TD>gene3d domains</TD><TD>4.10.400.10</TD><TD>46</TD><TD>2</TD><TD>9988</TD><TD>27</TD>
<TD>HSPG2,NETO2</TD></TR>
<TR><TD>6.838e-03</TD><TD>-4.99</TD><TD>GSE9988_ANTI_TREM1_VS_CTRL_TREATED_MONOCYTES_UP</TD><TD>MSigDB lists</TD><TD>GSE9988_ANTI_TREM1_VS_CTRL_TREATED_MONOCYTES_UP</TD><TD>177</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MFI2,LONRF3,NR4A1</TD></TR>
<TR><TD>6.839e-03</TD><TD>-4.99</TD><TD>response to external stimulus</TD><TD>biological process</TD><TD>GO:0009605</TD><TD>2118</TD><TD>11</TD><TD>16441</TD><TD>38</TD>
<TD>HSPG2,IGF1R,NR4A1,TRPC1,COL4A5,IL18,PDE4D,SLC1A3,CNTNAP2,FGF19,MECOM</TD></TR>
<TR><TD>6.840e-03</TD><TD>-4.98</TD><TD>Tubulin-binding</TD><TD>pfam domains</TD><TD>PF00418</TD><TD>3</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>MAP2</TD></TR>
<TR><TD>6.840e-03</TD><TD>-4.98</TD><TD>Sox_N</TD><TD>pfam domains</TD><TD>PF12444</TD><TD>3</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>6.840e-03</TD><TD>-4.98</TD><TD>Angiomotin_C</TD><TD>pfam domains</TD><TD>PF12240</TD><TD>3</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>6.840e-03</TD><TD>-4.98</TD><TD>Transferrin</TD><TD>pfam domains</TD><TD>PF00405</TD><TD>3</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>MFI2</TD></TR>
<TR><TD>6.897e-03</TD><TD>-4.98</TD><TD>procollagen-lysine 5-dioxygenase activity</TD><TD>molecular function</TD><TD>GO:0008475</TD><TD>3</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>PLOD2</TD></TR>
<TR><TD>6.897e-03</TD><TD>-4.98</TD><TD>steroid sulfotransferase activity</TD><TD>molecular function</TD><TD>GO:0050294</TD><TD>3</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>6.897e-03</TD><TD>-4.98</TD><TD>insulin-like growth factor-activated receptor activity</TD><TD>molecular function</TD><TD>GO:0005010</TD><TD>3</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>6.918e-03</TD><TD>-4.97</TD><TD>clustering of voltage-gated potassium channels</TD><TD>biological process</TD><TD>GO:0045163</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>6.918e-03</TD><TD>-4.97</TD><TD>protein O-linked glycosylation via serine</TD><TD>biological process</TD><TD>GO:0018242</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>GALNT3</TD></TR>
<TR><TD>6.918e-03</TD><TD>-4.97</TD><TD>malate-aspartate shuttle</TD><TD>biological process</TD><TD>GO:0043490</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>6.918e-03</TD><TD>-4.97</TD><TD>ureter morphogenesis</TD><TD>biological process</TD><TD>GO:0072197</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>6.918e-03</TD><TD>-4.97</TD><TD>response to anoxia</TD><TD>biological process</TD><TD>GO:0034059</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>6.918e-03</TD><TD>-4.97</TD><TD>renal vesicle induction</TD><TD>biological process</TD><TD>GO:0072034</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>6.918e-03</TD><TD>-4.97</TD><TD>interleukin-2 biosynthetic process</TD><TD>biological process</TD><TD>GO:0042094</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>6.918e-03</TD><TD>-4.97</TD><TD>negative regulation of activation-induced cell death of T cells</TD><TD>biological process</TD><TD>GO:0070236</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>6.918e-03</TD><TD>-4.97</TD><TD>regulation of Rap protein signal transduction</TD><TD>biological process</TD><TD>GO:0032487</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2</TD></TR>
<TR><TD>6.918e-03</TD><TD>-4.97</TD><TD>positive regulation of CD4-positive, alpha-beta T cell proliferation</TD><TD>biological process</TD><TD>GO:2000563</TD><TD>3</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CD55</TD></TR>
<TR><TD>6.944e-03</TD><TD>-4.97</TD><TD>ATF2_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>ATF2_UP.V1_DN</TD><TD>178</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ZNF432,FAM198B,PDLIM3</TD></TR>
<TR><TD>6.944e-03</TD><TD>-4.97</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_6H_ACT_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_6H_ACT_CD4_TCELL_DN</TD><TD>178</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,TOX2,SYTL2</TD></TR>
<TR><TD>6.944e-03</TD><TD>-4.97</TD><TD>GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_4H_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_4H_CD4_TCELL_UP</TD><TD>178</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,PDE4D,TSC22D3</TD></TR>
<TR><TD>6.944e-03</TD><TD>-4.97</TD><TD>AAAYRNCTG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AAAYRNCTG_UNKNOWN</TD><TD>348</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,MAP2,TSC22D3,COL12A1</TD></TR>
<TR><TD>6.951e-03</TD><TD>-4.97</TD><TD>CORDENONSI_YAP_CONSERVED_SIGNATURE</TD><TD>MSigDB lists</TD><TD>CORDENONSI_YAP_CONSERVED_SIGNATURE</TD><TD>57</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,CTGF</TD></TR>
<TR><TD>6.992e-03</TD><TD>-4.96</TD><TD>LDLRA_2</TD><TD>prosite domains</TD><TD>PS50068</TD><TD>44</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>HSPG2,NETO2</TD></TR>
<TR><TD>7.052e-03</TD><TD>-4.95</TD><TD>GSE3982_CENT_MEMORY_CD4_TCELL_VS_TH1_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_CENT_MEMORY_CD4_TCELL_VS_TH1_UP</TD><TD>179</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ZNF432,IL18,ATP2C2</TD></TR>
<TR><TD>7.052e-03</TD><TD>-4.95</TD><TD>WU_CELL_MIGRATION</TD><TD>MSigDB lists</TD><TD>WU_CELL_MIGRATION</TD><TD>179</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,CD55,AIM1</TD></TR>
<TR><TD>7.090e-03</TD><TD>-4.95</TD><TD>skin-scalp-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-scalp-carcinoma-squamous_cell_carcinoma</TD><TD>1659</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>ZNF432,MAP2,ATP9A,ATP2C2,AIM1,FAM198B,SULT2B1,SYTL2,MECOM</TD></TR>
<TR><TD>7.154e-03</TD><TD>-4.94</TD><TD>WGGAATGY_V$TEF1_Q6</TD><TD>MSigDB lists</TD><TD>WGGAATGY_V$TEF1_Q6</TD><TD>351</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,CTGF,NR4A1,SYTL2</TD></TR>
<TR><TD>7.161e-03</TD><TD>-4.94</TD><TD>GSE12845_IGD_POS_BLOOD_VS_NAIVE_TONSIL_BCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE12845_IGD_POS_BLOOD_VS_NAIVE_TONSIL_BCELL_UP</TD><TD>180</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,TIMP2,AIM1</TD></TR>
<TR><TD>7.161e-03</TD><TD>-4.94</TD><TD>LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP</TD><TD>MSigDB lists</TD><TD>LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP</TD><TD>180</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,COL4A5,MECOM</TD></TR>
<TR><TD>7.189e-03</TD><TD>-4.94</TD><TD>NAKAMURA_ADIPOGENESIS_EARLY_UP</TD><TD>MSigDB lists</TD><TD>NAKAMURA_ADIPOGENESIS_EARLY_UP</TD><TD>58</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FAM198B,PDE4D</TD></TR>
<TR><TD>7.189e-03</TD><TD>-4.94</TD><TD>LEE_LIVER_CANCER_DENA_UP</TD><TD>MSigDB lists</TD><TD>LEE_LIVER_CANCER_DENA_UP</TD><TD>58</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TAGLN2</TD></TR>
<TR><TD>7.189e-03</TD><TD>-4.94</TD><TD>CROONQUIST_STROMAL_STIMULATION_UP</TD><TD>MSigDB lists</TD><TD>CROONQUIST_STROMAL_STIMULATION_UP</TD><TD>58</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,TSC22D3</TD></TR>
<TR><TD>7.189e-03</TD><TD>-4.94</TD><TD>ISSAEVA_MLL2_TARGETS</TD><TD>MSigDB lists</TD><TD>ISSAEVA_MLL2_TARGETS</TD><TD>58</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,TAGLN2</TD></TR>
<TR><TD>7.271e-03</TD><TD>-4.92</TD><TD>GSE22886_NEUTROPHIL_VS_MONOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE22886_NEUTROPHIL_VS_MONOCYTE_UP</TD><TD>181</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2,PLOD2,FRAS1</TD></TR>
<TR><TD>7.297e-03</TD><TD>-4.92</TD><TD>MODULE_12</TD><TD>MSigDB lists</TD><TD>MODULE_12</TD><TD>353</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,HSPG2,NR4A1,ATP9A</TD></TR>
<TR><TD>7.342e-03</TD><TD>-4.91</TD><TD>developmental process</TD><TD>biological process</TD><TD>GO:0032502</TD><TD>5307</TD><TD>20</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,HSPG2,NR4A1,IL18,COL4A5,SLC1A3,CNTNAP2,FGF19,COL12A1,MECOM,CTGF,IGF1R,PDLIM3,MAP2,FRAS1,TOX2,TRPC1,TAGLN2,PDE4D,SOX8</TD></TR>
<TR><TD>7.356e-03</TD><TD>-4.91</TD><TD>arm</TD><TD>COSMIC cancer mutations</TD><TD>arm</TD><TD>1368</TD><TD>8</TD><TD>17775</TD><TD>38</TD>
<TD>PLOD2,MAP2,ATP2C2,NETO2,COL4A5,SULT2B1,COL12A1,MECOM</TD></TR>
<TR><TD>7.381e-03</TD><TD>-4.91</TD><TD>GSE22886_NAIVE_BCELL_VS_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE22886_NAIVE_BCELL_VS_DC_UP</TD><TD>182</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,TSC22D3,FRAS1</TD></TR>
<TR><TD>7.403e-03</TD><TD>-4.91</TD><TD>response to endogenous stimulus</TD><TD>biological process</TD><TD>GO:0009719</TD><TD>1545</TD><TD>9</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,CTGF,IGF1R,PLOD2,MAP2,NR4A1,TOX2,PDE4D,FGF19</TD></TR>
<TR><TD>7.431e-03</TD><TD>-4.90</TD><TD>MASSARWEH_RESPONSE_TO_ESTRADIOL</TD><TD>MSigDB lists</TD><TD>MASSARWEH_RESPONSE_TO_ESTRADIOL</TD><TD>59</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,MAP2</TD></TR>
<TR><TD>7.431e-03</TD><TD>-4.90</TD><TD>BROWNE_HCMV_INFECTION_1HR_UP</TD><TD>MSigDB lists</TD><TD>BROWNE_HCMV_INFECTION_1HR_UP</TD><TD>59</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,NR4A1</TD></TR>
<TR><TD>7.476e-03</TD><TD>-4.90</TD><TD>tat (p14)</TD><TD>protein interactions</TD><TD>155871</TD><TD>1701</TD><TD>9</TD><TD>16036</TD><TD>34</TD>
<TD>TIMP2,LONRF3,HSPG2,MAP2,NR4A1,TRPC1,COL4A5,IL18,PDE4D</TD></TR>
<TR><TD>7.493e-03</TD><TD>-4.89</TD><TD>GSE3982_MEMORY_CD4_TCELL_VS_TH1_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_MEMORY_CD4_TCELL_VS_TH1_UP</TD><TD>183</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,TSC22D3,ATP2C2</TD></TR>
<TR><TD>7.520e-03</TD><TD>-4.89</TD><TD>neuron development</TD><TD>biological process</TD><TD>GO:0048666</TD><TD>1007</TD><TD>7</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,COL4A5,CNTNAP2,SLC1A3,IGF1R,MAP2,FGF19</TD></TR>
<TR><TD>7.596e-03</TD><TD>-4.88</TD><TD>human chr6q23.1</TD><TD>chromosome location</TD><TD>human chr6q23.1</TD><TD>5</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>CTGF</TD></TR>
<TR><TD>7.596e-03</TD><TD>-4.88</TD><TD>human chr5q12</TD><TD>chromosome location</TD><TD>human chr5q12</TD><TD>5</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>PDE4D</TD></TR>
<TR><TD>7.606e-03</TD><TD>-4.88</TD><TD>GSE360_T_GONDII_VS_B_MALAYI_HIGH_DOSE_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE360_T_GONDII_VS_B_MALAYI_HIGH_DOSE_DC_UP</TD><TD>184</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TAGLN2,TSC22D3</TD></TR>
<TR><TD>7.606e-03</TD><TD>-4.88</TD><TD>ESC_V6.5_UP_LATE.V1_UP</TD><TD>MSigDB lists</TD><TD>ESC_V6.5_UP_LATE.V1_UP</TD><TD>184</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,PDLIM3,PLOD2</TD></TR>
<TR><TD>7.620e-03</TD><TD>-4.88</TD><TD>PAFAH1B1 (platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 (45kDa))</TD><TD>protein interactions</TD><TD>5048</TD><TD>62</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>PDE4D,MAP2</TD></TR>
<TR><TD>7.663e-03</TD><TD>-4.87</TD><TD>negative regulation of muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0051148</TD><TD>57</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,SOX8</TD></TR>
<TR><TD>7.720e-03</TD><TD>-4.86</TD><TD>GSE9988_ANTI_TREM1_VS_LPS_MONOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE9988_ANTI_TREM1_VS_LPS_MONOCYTE_UP</TD><TD>185</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MFI2,LONRF3,TSC22D3</TD></TR>
<TR><TD>7.720e-03</TD><TD>-4.86</TD><TD>GSE1460_INTRATHYMIC_T_PROGENITOR_VS_DP_THYMOCYTE_DN</TD><TD>MSigDB lists</TD><TD>GSE1460_INTRATHYMIC_T_PROGENITOR_VS_DP_THYMOCYTE_DN</TD><TD>185</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,CTGF,TSC22D3</TD></TR>
<TR><TD>7.720e-03</TD><TD>-4.86</TD><TD>V$HEN1_01</TD><TD>MSigDB lists</TD><TD>V$HEN1_01</TD><TD>185</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2,SULT2B1,SYTL2</TD></TR>
<TR><TD>7.720e-03</TD><TD>-4.86</TD><TD>STARK_PREFRONTAL_CORTEX_22Q11_DELETION_UP</TD><TD>MSigDB lists</TD><TD>STARK_PREFRONTAL_CORTEX_22Q11_DELETION_UP</TD><TD>185</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,TIMP2,IGF1R</TD></TR>
<TR><TD>7.720e-03</TD><TD>-4.86</TD><TD>YAGI_AML_FAB_MARKERS</TD><TD>MSigDB lists</TD><TD>YAGI_AML_FAB_MARKERS</TD><TD>185</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,TIMP2,PLOD2</TD></TR>
<TR><TD>7.834e-03</TD><TD>-4.85</TD><TD>GSE360_L_MAJOR_VS_T_GONDII_MAC_UP</TD><TD>MSigDB lists</TD><TD>GSE360_L_MAJOR_VS_T_GONDII_MAC_UP</TD><TD>186</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,IL18,CTGF</TD></TR>
<TR><TD>7.834e-03</TD><TD>-4.85</TD><TD>GSE24634_IL4_VS_CTRL_TREATED_NAIVE_CD4_TCELL_DAY7_DN</TD><TD>MSigDB lists</TD><TD>GSE24634_IL4_VS_CTRL_TREATED_NAIVE_CD4_TCELL_DAY7_DN</TD><TD>186</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,TIMP2,ALDH2</TD></TR>
<TR><TD>7.873e-03</TD><TD>-4.84</TD><TD>Lysine degradation</TD><TD>KEGG pathways</TD><TD>hsa00310</TD><TD>52</TD><TD>2</TD><TD>6908</TD><TD>18</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>7.873e-03</TD><TD>-4.84</TD><TD>Lysine degradation</TD><TD>KEGG pathways</TD><TD>ko00310</TD><TD>52</TD><TD>2</TD><TD>6908</TD><TD>18</TD>
<TD>ALDH2,PLOD2</TD></TR>
<TR><TD>7.923e-03</TD><TD>-4.84</TD><TD>LamG</TD><TD>smart domains</TD><TD>SM00282</TD><TD>44</TD><TD>2</TD><TD>9131</TD><TD>28</TD>
<TD>CNTNAP2,HSPG2</TD></TR>
<TR><TD>7.950e-03</TD><TD>-4.83</TD><TD>GSE13484_12H_UNSTIM_VS_YF17D_VACCINE_STIM_PBMC_UP</TD><TD>MSigDB lists</TD><TD>GSE13484_12H_UNSTIM_VS_YF17D_VACCINE_STIM_PBMC_UP</TD><TD>187</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,FAM198B,TSC22D3</TD></TR>
<TR><TD>7.957e-03</TD><TD>-4.83</TD><TD>organelle</TD><TD>cellular component</TD><TD>GO:0043226</TD><TD>12606</TD><TD>34</TD><TD>17570</TD><TD>38</TD>
<TD>HSPG2,TSC22D3,ATP9A,ATP2C2,IL18,COL4A5,FAM198B,SLC1A3,CNTNAP2,SYTL2,MECOM,ZNF432,CTGF,IGF1R,TOX2,TRPC1,SUN3,PDE4D,TAGLN2,MYRIP,SULT2B1,AMOTL2,CD55,ALDH2,TIMP2,MFI2,ASCL5,NR4A1,COL12A1,GALNT3,PDLIM3,MAP2,PLOD2,SOX8</TD></TR>
<TR><TD>8.067e-03</TD><TD>-4.82</TD><TD>GSE9650_EFFECTOR_VS_EXHAUSTED_CD8_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE9650_EFFECTOR_VS_EXHAUSTED_CD8_TCELL_DN</TD><TD>188</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,IGF1R,MAP2</TD></TR>
<TR><TD>8.067e-03</TD><TD>-4.82</TD><TD>GSE12845_NAIVE_VS_DARKZONE_GC_TONSIL_BCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE12845_NAIVE_VS_DARKZONE_GC_TONSIL_BCELL_UP</TD><TD>188</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,CTGF,SULT2B1</TD></TR>
<TR><TD>8.166e-03</TD><TD>-4.81</TD><TD>Ion transport by P-type ATPases</TD><TD>REACTOME pathways</TD><TD>R-HSA-936837</TD><TD>49</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>8.185e-03</TD><TD>-4.81</TD><TD>GSE22886_DC_VS_MONOCYTE_DN</TD><TD>MSigDB lists</TD><TD>GSE22886_DC_VS_MONOCYTE_DN</TD><TD>189</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,IGF1R,TSC22D3</TD></TR>
<TR><TD>8.185e-03</TD><TD>-4.81</TD><TD>GSE3982_DC_VS_BASOPHIL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_DC_VS_BASOPHIL_DN</TD><TD>189</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,PDE4D,MYRIP</TD></TR>
<TR><TD>8.185e-03</TD><TD>-4.81</TD><TD>EGFR_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>EGFR_UP.V1_DN</TD><TD>189</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,PDLIM3,TSC22D3</TD></TR>
<TR><TD>8.185e-03</TD><TD>-4.81</TD><TD>GSE24634_TREG_VS_TCONV_POST_DAY5_IL4_CONVERSION_DN</TD><TD>MSigDB lists</TD><TD>GSE24634_TREG_VS_TCONV_POST_DAY5_IL4_CONVERSION_DN</TD><TD>189</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,TIMP2,TSC22D3</TD></TR>
<TR><TD>8.185e-03</TD><TD>-4.81</TD><TD>GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN2_THYMOCYTE_FETAL_DN</TD><TD>MSigDB lists</TD><TD>GSE24142_EARLY_THYMIC_PROGENITOR_VS_DN2_THYMOCYTE_FETAL_DN</TD><TD>189</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,TIMP2,COL12A1</TD></TR>
<TR><TD>8.185e-03</TD><TD>-4.81</TD><TD>GSE1460_NAIVE_CD4_TCELL_ADULT_BLOOD_VS_THYMIC_STROMAL_CELL_DN</TD><TD>MSigDB lists</TD><TD>GSE1460_NAIVE_CD4_TCELL_ADULT_BLOOD_VS_THYMIC_STROMAL_CELL_DN</TD><TD>189</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TAGLN2,ALDH2</TD></TR>
<TR><TD>8.192e-03</TD><TD>-4.80</TD><TD>positive regulation of interferon-gamma production</TD><TD>biological process</TD><TD>GO:0032729</TD><TD>59</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,PDE4D</TD></TR>
<TR><TD>8.303e-03</TD><TD>-4.79</TD><TD>GSE1460_DP_VS_CD4_THYMOCYTE_DN</TD><TD>MSigDB lists</TD><TD>GSE1460_DP_VS_CD4_THYMOCYTE_DN</TD><TD>190</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,PDE4D,AIM1</TD></TR>
<TR><TD>8.303e-03</TD><TD>-4.79</TD><TD>LTE2_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>LTE2_UP.V1_DN</TD><TD>190</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,PDLIM3,SYTL2</TD></TR>
<TR><TD>8.348e-03</TD><TD>-4.79</TD><TD>SGK1 (serum/glucocorticoid regulated kinase 1)</TD><TD>protein interactions</TD><TD>6446</TD><TD>65</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>SLC1A3,TSC22D3</TD></TR>
<TR><TD>8.390e-03</TD><TD>-4.78</TD><TD>betaKlotho-mediated ligand binding</TD><TD>REACTOME pathways</TD><TD>R-HSA-1307965</TD><TD>3</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF19</TD></TR>
<TR><TD>8.423e-03</TD><TD>-4.78</TD><TD>GSE360_HIGH_DOSE_B_MALAYI_VS_M_TUBERCULOSIS_MAC_DN</TD><TD>MSigDB lists</TD><TD>GSE360_HIGH_DOSE_B_MALAYI_VS_M_TUBERCULOSIS_MAC_DN</TD><TD>191</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,PLOD2,TSC22D3</TD></TR>
<TR><TD>8.423e-03</TD><TD>-4.78</TD><TD>GSE3982_MEMORY_CD4_TCELL_VS_TH1_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_MEMORY_CD4_TCELL_VS_TH1_DN</TD><TD>191</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,PDE4D,ATP9A</TD></TR>
<TR><TD>8.423e-03</TD><TD>-4.78</TD><TD>KAECH_DAY15_EFF_VS_MEMORY_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>KAECH_DAY15_EFF_VS_MEMORY_CD8_TCELL_UP</TD><TD>191</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,ALDH2,IGF1R</TD></TR>
<TR><TD>8.423e-03</TD><TD>-4.78</TD><TD>GSE3982_DC_VS_TH2_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_DC_VS_TH2_DN</TD><TD>191</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,TAGLN2,PDE4D</TD></TR>
<TR><TD>8.435e-03</TD><TD>-4.78</TD><TD>RIZKI_TUMOR_INVASIVENESS_2D_DN</TD><TD>MSigDB lists</TD><TD>RIZKI_TUMOR_INVASIVENESS_2D_DN</TD><TD>63</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,SULT2B1</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>FFAR2 (free fatty acid receptor 2)</TD><TD>protein interactions</TD><TD>2867</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>ANKIB1 (ankyrin repeat and IBR domain containing 1)</TD><TD>protein interactions</TD><TD>54467</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>DCLK2 (doublecortin-like kinase 2)</TD><TD>protein interactions</TD><TD>166614</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>LSS (lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase))</TD><TD>protein interactions</TD><TD>4047</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>IL18R1 (interleukin 18 receptor 1)</TD><TD>protein interactions</TD><TD>8809</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IL18</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>ABCB11 (ATP binding cassette subfamily B member 11)</TD><TD>protein interactions</TD><TD>8647</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>CHI3L1 (chitinase 3-like 1 (cartilage glycoprotein-39))</TD><TD>protein interactions</TD><TD>1116</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>ALS2CR12 (amyotrophic lateral sclerosis 2 chromosome region candidate 12)</TD><TD>protein interactions</TD><TD>130540</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>SULT1B1 (sulfotransferase family 1B member 1)</TD><TD>protein interactions</TD><TD>27284</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>KRT27 (keratin 27, type I)</TD><TD>protein interactions</TD><TD>342574</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>ARHGEF10L (Rho guanine nucleotide exchange factor 10 like)</TD><TD>protein interactions</TD><TD>55160</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>8.455e-03</TD><TD>-4.77</TD><TD>ZNF461 (zinc finger protein 461)</TD><TD>protein interactions</TD><TD>92283</TD><TD>4</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TOX2</TD></TR>
<TR><TD>8.501e-03</TD><TD>-4.77</TD><TD>TIMP</TD><TD>interpro domains</TD><TD>IPR001820</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>8.501e-03</TD><TD>-4.77</TD><TD>TIMP_C</TD><TD>interpro domains</TD><TD>IPR027465</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>8.501e-03</TD><TD>-4.77</TD><TD>TIMP_CS</TD><TD>interpro domains</TD><TD>IPR030490</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>8.501e-03</TD><TD>-4.77</TD><TD>TSC-22_Dip_Bun</TD><TD>interpro domains</TD><TD>IPR000580</TD><TD>4</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>8.572e-03</TD><TD>-4.76</TD><TD>TRANSFERRIN_LIKE_4</TD><TD>prosite domains</TD><TD>PS51408</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>MFI2</TD></TR>
<TR><TD>8.572e-03</TD><TD>-4.76</TD><TD>TAU_MAP_2</TD><TD>prosite domains</TD><TD>PS51491</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>MAP2</TD></TR>
<TR><TD>8.572e-03</TD><TD>-4.76</TD><TD>TRANSFERRIN_LIKE_3</TD><TD>prosite domains</TD><TD>PS00207</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>MFI2</TD></TR>
<TR><TD>8.572e-03</TD><TD>-4.76</TD><TD>TAU_MAP_1</TD><TD>prosite domains</TD><TD>PS00229</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>MAP2</TD></TR>
<TR><TD>8.572e-03</TD><TD>-4.76</TD><TD>TRANSFERRIN_LIKE_2</TD><TD>prosite domains</TD><TD>PS00206</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>MFI2</TD></TR>
<TR><TD>8.572e-03</TD><TD>-4.76</TD><TD>TRANSFERRIN_LIKE_1</TD><TD>prosite domains</TD><TD>PS00205</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>MFI2</TD></TR>
<TR><TD>8.572e-03</TD><TD>-4.76</TD><TD>LYS_HYDROXYLASE</TD><TD>prosite domains</TD><TD>PS01325</TD><TD>3</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>PLOD2</TD></TR>
<TR><TD>8.586e-03</TD><TD>-4.76</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.10.30.10</TD><TD>52</TD><TD>2</TD><TD>9988</TD><TD>27</TD>
<TD>SOX8,TOX2</TD></TR>
<TR><TD>8.615e-03</TD><TD>-4.75</TD><TD>HMG_BOX_2</TD><TD>prosite domains</TD><TD>PS50118</TD><TD>49</TD><TD>2</TD><TD>11866</TD><TD>34</TD>
<TD>SOX8,TOX2</TD></TR>
<TR><TD>8.666e-03</TD><TD>-4.75</TD><TD>GSE30962_ACUTE_VS_CHRONIC_LCMV_PRIMARY_INF_CD8_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE30962_ACUTE_VS_CHRONIC_LCMV_PRIMARY_INF_CD8_TCELL_DN</TD><TD>193</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2,PLOD2,TOX2</TD></TR>
<TR><TD>8.673e-03</TD><TD>-4.75</TD><TD>embryonic morphogenesis</TD><TD>biological process</TD><TD>GO:0048598</TD><TD>556</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,HSPG2,FRAS1,COL12A1,MECOM</TD></TR>
<TR><TD>8.684e-03</TD><TD>-4.75</TD><TD>generation of neurons</TD><TD>biological process</TD><TD>GO:0048699</TD><TD>1584</TD><TD>9</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,IGF1R,MAP2,TRPC1,COL4A5,SLC1A3,CNTNAP2,SOX8,FGF19</TD></TR>
<TR><TD>8.696e-03</TD><TD>-4.74</TD><TD>YWATTWNNRGCT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YWATTWNNRGCT_UNKNOWN</TD><TD>64</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2,NR4A1</TD></TR>
<TR><TD>8.757e-03</TD><TD>-4.74</TD><TD>chr6q</TD><TD>MSigDB lists</TD><TD>chr6q</TD><TD>4</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>AIM1</TD></TR>
<TR><TD>8.767e-03</TD><TD>-4.74</TD><TD>extracellular region part</TD><TD>cellular component</TD><TD>GO:0044421</TD><TD>3764</TD><TD>15</TD><TD>17570</TD><TD>38</TD>
<TD>GALNT3,CD55,TIMP2,ALDH2,CTGF,MFI2,HSPG2,PLOD2,FRAS1,COL4A5,IL18,SLC1A3,TAGLN2,SULT2B1,COL12A1</TD></TR>
<TR><TD>8.789e-03</TD><TD>-4.73</TD><TD>GSE3982_BASOPHIL_VS_TH1_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_BASOPHIL_VS_TH1_DN</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,SYTL2,NETO2</TD></TR>
<TR><TD>8.789e-03</TD><TD>-4.73</TD><TD>GSE20715_WT_VS_TLR4_KO_48H_OZONE_LUNG_UP</TD><TD>MSigDB lists</TD><TD>GSE20715_WT_VS_TLR4_KO_48H_OZONE_LUNG_UP</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,TSC22D3,MECOM</TD></TR>
<TR><TD>8.789e-03</TD><TD>-4.73</TD><TD>GSE29618_BCELL_VS_MONOCYTE_DAY7_FLU_VACCINE_DN</TD><TD>MSigDB lists</TD><TD>GSE29618_BCELL_VS_MONOCYTE_DAY7_FLU_VACCINE_DN</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,FAM198B,ALDH2</TD></TR>
<TR><TD>8.789e-03</TD><TD>-4.73</TD><TD>GSE22886_IGG_IGA_MEMORY_BCELL_VS_BLOOD_PLASMA_CELL_UP</TD><TD>MSigDB lists</TD><TD>GSE22886_IGG_IGA_MEMORY_BCELL_VS_BLOOD_PLASMA_CELL_UP</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,TSC22D3,AIM1</TD></TR>
<TR><TD>8.789e-03</TD><TD>-4.73</TD><TD>GSE20366_TREG_VS_NAIVE_CD4_TCELL_DEC205_CONVERSION_UP</TD><TD>MSigDB lists</TD><TD>GSE20366_TREG_VS_NAIVE_CD4_TCELL_DEC205_CONVERSION_UP</TD><TD>194</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SULT2B1,SYTL2,NETO2</TD></TR>
<TR><TD>8.801e-03</TD><TD>-4.73</TD><TD>NUCLEARECPTR</TD><TD>prints domains</TD><TD>PR01284</TD><TD>3</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>NR4A1</TD></TR>
<TR><TD>8.801e-03</TD><TD>-4.73</TD><TD>TRANSFERRIN</TD><TD>prints domains</TD><TD>PR00422</TD><TD>3</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>MFI2</TD></TR>
<TR><TD>8.801e-03</TD><TD>-4.73</TD><TD>ANGIOMOTIN</TD><TD>prints domains</TD><TD>PR01807</TD><TD>3</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>8.806e-03</TD><TD>-4.73</TD><TD>phenylethylamine degradation I</TD><TD>BIOCYC pathways</TD><TD>HUMAN_2PHENDEG-PWY</TD><TD>4</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>8.806e-03</TD><TD>-4.73</TD><TD>ethanol degradation II</TD><TD>BIOCYC pathways</TD><TD>META_PWY66-21</TD><TD>4</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>8.806e-03</TD><TD>-4.73</TD><TD>oxidative ethanol degradation III</TD><TD>BIOCYC pathways</TD><TD>META_PWY66-161</TD><TD>4</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>8.806e-03</TD><TD>-4.73</TD><TD>L-phenylalanine degradation IV (mammalian, via side chain)</TD><TD>BIOCYC pathways</TD><TD>META_PWY-6318</TD><TD>4</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>8.806e-03</TD><TD>-4.73</TD><TD>ethanol degradation IV</TD><TD>BIOCYC pathways</TD><TD>META_PWY66-162</TD><TD>4</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>8.913e-03</TD><TD>-4.72</TD><TD>GSE17721_POLYIC_VS_PAM3CSK4_1H_BMDM_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_POLYIC_VS_PAM3CSK4_1H_BMDM_DN</TD><TD>195</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,CNTNAP2,MECOM</TD></TR>
<TR><TD>8.913e-03</TD><TD>-4.72</TD><TD>HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</TD><TD>MSigDB lists</TD><TD>HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</TD><TD>195</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,PLOD2,COL12A1</TD></TR>
<TR><TD>8.913e-03</TD><TD>-4.72</TD><TD>GSE36392_EOSINOPHIL_VS_NEUTROPHIL_IL25_TREATED_LUNG_UP</TD><TD>MSigDB lists</TD><TD>GSE36392_EOSINOPHIL_VS_NEUTROPHIL_IL25_TREATED_LUNG_UP</TD><TD>195</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,IGF1R,TSC22D3</TD></TR>
<TR><TD>8.913e-03</TD><TD>-4.72</TD><TD>GSE7852_LN_VS_FAT_TCONV_DN</TD><TD>MSigDB lists</TD><TD>GSE7852_LN_VS_FAT_TCONV_DN</TD><TD>195</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,NR4A1,MECOM</TD></TR>
<TR><TD>8.955e-03</TD><TD>-4.72</TD><TD>rough endoplasmic reticulum</TD><TD>cellular component</TD><TD>GO:0005791</TD><TD>66</TD><TD>2</TD><TD>17570</TD><TD>38</TD>
<TD>PLOD2,MAP2</TD></TR>
<TR><TD>9.110e-03</TD><TD>-4.70</TD><TD>TSC22</TD><TD>pfam domains</TD><TD>PF01166</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>9.110e-03</TD><TD>-4.70</TD><TD>2OG-FeII_Oxy</TD><TD>pfam domains</TD><TD>PF03171</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>PLOD2</TD></TR>
<TR><TD>9.110e-03</TD><TD>-4.70</TD><TD>TIMP</TD><TD>pfam domains</TD><TD>PF00965</TD><TD>4</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>TIMP2</TD></TR>
<TR><TD>9.172e-03</TD><TD>-4.69</TD><TD>ZM</TD><TD>smart domains</TD><TD>SM00735</TD><TD>3</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>PDLIM3</TD></TR>
<TR><TD>9.172e-03</TD><TD>-4.69</TD><TD>TR_FER</TD><TD>smart domains</TD><TD>SM00094</TD><TD>3</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>MFI2</TD></TR>
<TR><TD>9.186e-03</TD><TD>-4.69</TD><TD>peptidyl-lysine 5-dioxygenase activity</TD><TD>molecular function</TD><TD>GO:0070815</TD><TD>4</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>PLOD2</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>negative regulation of bile acid biosynthetic process</TD><TD>biological process</TD><TD>GO:0070858</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>FGF19</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>protein O-linked glycosylation via threonine</TD><TD>biological process</TD><TD>GO:0018243</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>GALNT3</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>astrocyte fate commitment</TD><TD>biological process</TD><TD>GO:0060018</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>T cell cytokine production</TD><TD>biological process</TD><TD>GO:0002369</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CD55</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>positive regulation of NK T cell proliferation</TD><TD>biological process</TD><TD>GO:0051142</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>positive regulation of steroid hormone biosynthetic process</TD><TD>biological process</TD><TD>GO:0090031</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>protein localization to juxtaparanode region of axon</TD><TD>biological process</TD><TD>GO:0071205</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>metanephric nephron tubule formation</TD><TD>biological process</TD><TD>GO:0072289</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>negative regulation of bile acid metabolic process</TD><TD>biological process</TD><TD>GO:1904252</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>FGF19</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>D-aspartate import</TD><TD>biological process</TD><TD>GO:0070779</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>positive regulation of heart rate by epinephrine-norepinephrine</TD><TD>biological process</TD><TD>GO:0001996</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>regulation of NK T cell proliferation</TD><TD>biological process</TD><TD>GO:0051140</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>gamma-aminobutyric acid metabolic process</TD><TD>biological process</TD><TD>GO:0009448</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>D-aspartate transport</TD><TD>biological process</TD><TD>GO:0070777</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>retinal rod cell differentiation</TD><TD>biological process</TD><TD>GO:0060221</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>9.214e-03</TD><TD>-4.69</TD><TD>regulation of CD4-positive, alpha-beta T cell proliferation</TD><TD>biological process</TD><TD>GO:2000561</TD><TD>4</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CD55</TD></TR>
<TR><TD>9.226e-03</TD><TD>-4.69</TD><TD>SHAFFER_IRF4_TARGETS_IN_PLASMA_CELL_VS_MATURE_B_LYMPHOCYTE</TD><TD>MSigDB lists</TD><TD>SHAFFER_IRF4_TARGETS_IN_PLASMA_CELL_VS_MATURE_B_LYMPHOCYTE</TD><TD>66</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,NR4A1</TD></TR>
<TR><TD>9.226e-03</TD><TD>-4.69</TD><TD>JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN</TD><TD>MSigDB lists</TD><TD>JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN</TD><TD>66</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,NR4A1</TD></TR>
<TR><TD>9.226e-03</TD><TD>-4.69</TD><TD>YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_1</TD><TD>MSigDB lists</TD><TD>YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_1</TD><TD>66</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,NR4A1</TD></TR>
<TR><TD>9.291e-03</TD><TD>-4.68</TD><TD>GOLDRATH_EFF_VS_MEMORY_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GOLDRATH_EFF_VS_MEMORY_CD8_TCELL_UP</TD><TD>198</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,TAGLN2,NR4A1</TD></TR>
<TR><TD>9.376e-03</TD><TD>-4.67</TD><TD>response to organic cyclic compound</TD><TD>biological process</TD><TD>GO:0014070</TD><TD>798</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,PDE4D,CTGF,IGF1R,MAP2,NR4A1</TD></TR>
<TR><TD>9.376e-03</TD><TD>-4.67</TD><TD>LDLa</TD><TD>smart domains</TD><TD>SM00192</TD><TD>48</TD><TD>2</TD><TD>9131</TD><TD>28</TD>
<TD>HSPG2,NETO2</TD></TR>
<TR><TD>9.497e-03</TD><TD>-4.66</TD><TD>GEORGANTAS_HSC_MARKERS</TD><TD>MSigDB lists</TD><TD>GEORGANTAS_HSC_MARKERS</TD><TD>67</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FAM198B,MECOM</TD></TR>
<TR><TD>9.497e-03</TD><TD>-4.66</TD><TD>LINDSTEDT_DENDRITIC_CELL_MATURATION_C</TD><TD>MSigDB lists</TD><TD>LINDSTEDT_DENDRITIC_CELL_MATURATION_C</TD><TD>67</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,IGF1R</TD></TR>
<TR><TD>9.548e-03</TD><TD>-4.65</TD><TD>V$STAT5A_04</TD><TD>MSigDB lists</TD><TD>V$STAT5A_04</TD><TD>200</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1,SYTL2,MECOM</TD></TR>
<TR><TD>9.548e-03</TD><TD>-4.65</TD><TD>HALLMARK_ESTROGEN_RESPONSE_EARLY</TD><TD>MSigDB lists</TD><TD>HALLMARK_ESTROGEN_RESPONSE_EARLY</TD><TD>200</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,PDLIM3,SULT2B1</TD></TR>
<TR><TD>9.582e-03</TD><TD>-4.65</TD><TD>regulation of release of sequestered calcium ion into cytosol</TD><TD>biological process</TD><TD>GO:0051279</TD><TD>64</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,PDE4D</TD></TR>
<TR><TD>9.701e-03</TD><TD>-4.64</TD><TD>FYN (FYN proto-oncogene, Src family tyrosine kinase)</TD><TD>protein interactions</TD><TD>2534</TD><TD>209</TD><TD>3</TD><TD>16036</TD><TD>34</TD>
<TD>CD55,PDE4D,MAP2</TD></TR>
<TR><TD>9.780e-03</TD><TD>-4.63</TD><TD>myofibril</TD><TD>cellular component</TD><TD>GO:0030016</TD><TD>205</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>TRPC1,PDE4D,PDLIM3</TD></TR>
<TR><TD>9.941e-03</TD><TD>-4.61</TD><TD>KIM_WT1_TARGETS_12HR_DN</TD><TD>MSigDB lists</TD><TD>KIM_WT1_TARGETS_12HR_DN</TD><TD>203</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,CTGF,PLOD2</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>Esophageal cancer(PMID:19698717)</TD><TD>GWAS genes</TD><TD>Esophageal cancer(PMID:19698717)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>Stroke(PMID:17434096)</TD><TD>GWAS genes</TD><TD>Stroke(PMID:17434096)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>AIM1</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>Coronary heart disease(PMID:21971053)</TD><TD>GWAS genes</TD><TD>Coronary heart disease(PMID:21971053)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>Interleukin-18 levels(PMID:20150558)</TD><TD>GWAS genes</TD><TD>Interleukin-18 levels(PMID:20150558)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>IL18</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>Drinking behavior(PMID:21372407)</TD><TD>GWAS genes</TD><TD>Drinking behavior(PMID:21372407)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.002e-02</TD><TD>-4.60</TD><TD>Sleepiness(PMID:17903308)</TD><TD>GWAS genes</TD><TD>Sleepiness(PMID:17903308)</TD><TD>2</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>PDE4D</TD></TR>
<TR><TD>1.005e-02</TD><TD>-4.60</TD><TD>LIN_MELANOMA_COPY_NUMBER_UP</TD><TD>MSigDB lists</TD><TD>LIN_MELANOMA_COPY_NUMBER_UP</TD><TD>69</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ATP9A,FGF19</TD></TR>
<TR><TD>1.009e-02</TD><TD>-4.60</TD><TD>urinary_tract-bladder-carcinoma-transitional_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract-bladder-carcinoma-transitional_cell_carcinoma</TD><TD>6320</TD><TD>21</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ALDH2,LONRF3,HSPG2,NR4A1,ATP2C2,COL4A5,CNTNAP2,SLC1A3,COL12A1,SYTL2,MECOM,GALNT3,ZNF432,CTGF,PDLIM3,IGF1R,MAP2,TOX2,AIM1,MYRIP</TD></TR>
<TR><TD>1.014e-02</TD><TD>-4.59</TD><TD>transitional_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>transitional_cell_carcinoma</TD><TD>6322</TD><TD>21</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ALDH2,LONRF3,HSPG2,NR4A1,ATP2C2,COL4A5,CNTNAP2,SLC1A3,COL12A1,SYTL2,MECOM,GALNT3,ZNF432,CTGF,PDLIM3,IGF1R,MAP2,TOX2,AIM1,MYRIP</TD></TR>
<TR><TD>1.021e-02</TD><TD>-4.58</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_UP</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_UP</TD><TD>205</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,TIMP2,SYTL2</TD></TR>
<TR><TD>1.021e-02</TD><TD>-4.58</TD><TD>BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP</TD><TD>MSigDB lists</TD><TD>BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP</TD><TD>205</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SOX8,PDLIM3,SULT2B1</TD></TR>
<TR><TD>1.028e-02</TD><TD>-4.58</TD><TD>carboxylic acid binding</TD><TD>molecular function</TD><TD>GO:0031406</TD><TD>196</TD><TD>3</TD><TD>16491</TD><TD>38</TD>
<TD>SLC1A3,PLOD2,SYTL2</TD></TR>
<TR><TD>1.038e-02</TD><TD>-4.57</TD><TD>blood vessel morphogenesis</TD><TD>biological process</TD><TD>GO:0048514</TD><TD>372</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CTGF,HSPG2,NR4A1</TD></TR>
<TR><TD>1.040e-02</TD><TD>-4.57</TD><TD>extracellular matrix structural constituent</TD><TD>molecular function</TD><TD>GO:0005201</TD><TD>67</TD><TD>2</TD><TD>16491</TD><TD>38</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>1.042e-02</TD><TD>-4.56</TD><TD>organic acid binding</TD><TD>molecular function</TD><TD>GO:0043177</TD><TD>197</TD><TD>3</TD><TD>16491</TD><TD>38</TD>
<TD>SLC1A3,PLOD2,SYTL2</TD></TR>
<TR><TD>1.042e-02</TD><TD>-4.56</TD><TD>CAGGTG_V$E12_Q6</TD><TD>MSigDB lists</TD><TD>CAGGTG_V$E12_Q6</TD><TD>2354</TD><TD>11</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,LONRF3,PDLIM3,PLOD2,NR4A1,TSC22D3,TOX2,NETO2,TAGLN2,SULT2B1,COL12A1</TD></TR>
<TR><TD>1.046e-02</TD><TD>-4.56</TD><TD>RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_UP</TD><TD>MSigDB lists</TD><TD>RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_UP</TD><TD>392</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,SLC1A3,TIMP2,CD55</TD></TR>
<TR><TD>1.046e-02</TD><TD>-4.56</TD><TD>ankle</TD><TD>COSMIC cancer mutations</TD><TD>ankle</TD><TD>403</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>ALDH2,CNTNAP2,HSPG2,MAP2</TD></TR>
<TR><TD>1.046e-02</TD><TD>-4.56</TD><TD>neural crest cell development</TD><TD>biological process</TD><TD>GO:0014032</TD><TD>67</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,FGF19</TD></TR>
<TR><TD>1.054e-02</TD><TD>-4.55</TD><TD>HMG</TD><TD>smart domains</TD><TD>SM00398</TD><TD>51</TD><TD>2</TD><TD>9131</TD><TD>28</TD>
<TD>SOX8,TOX2</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>IGHG3 (immunoglobulin heavy constant gamma 3 (G3m marker))</TD><TD>protein interactions</TD><TD>3502</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>ADGRE5 (adhesion G protein-coupled receptor E5)</TD><TD>protein interactions</TD><TD>976</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>AMY2A (amylase, alpha 2A (pancreatic))</TD><TD>protein interactions</TD><TD>279</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>FXYD3 (FXYD domain containing ion transport regulator 3)</TD><TD>protein interactions</TD><TD>5349</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>Fam107b (family with sequence similarity 107, member B)</TD><TD>protein interactions</TD><TD>66540</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>HPGDS (hematopoietic prostaglandin D synthase)</TD><TD>protein interactions</TD><TD>27306</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>VWA1 (von Willebrand factor A domain containing 1)</TD><TD>protein interactions</TD><TD>64856</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>C7orf43 (chromosome 7 open reading frame 43)</TD><TD>protein interactions</TD><TD>55262</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>ABCC6 (ATP binding cassette subfamily C member 6)</TD><TD>protein interactions</TD><TD>368</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>GPLD1 (glycosylphosphatidylinositol specific phospholipase D1)</TD><TD>protein interactions</TD><TD>2822</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>PRICKLE3 (prickle homolog 3)</TD><TD>protein interactions</TD><TD>4007</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>DERL3 (derlin 3)</TD><TD>protein interactions</TD><TD>91319</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.056e-02</TD><TD>-4.55</TD><TD>ALDH1A1 (aldehyde dehydrogenase 1 family, member A1)</TD><TD>protein interactions</TD><TD>216</TD><TD>5</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6</TD><TD>MSigDB lists</TD><TD>YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6</TD><TD>71</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,CTGF</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>GU_PDEF_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>GU_PDEF_TARGETS_UP</TD><TD>71</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,CTGF</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>KEGG_MELANOMA</TD><TD>MSigDB lists</TD><TD>KEGG_MELANOMA</TD><TD>71</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,FGF19</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>Achaete-scute-rel</TD><TD>interpro domains</TD><TD>IPR015660</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ASCL5</TD></TR>
<TR><TD>1.062e-02</TD><TD>-4.55</TD><TD>IGFBP_CNN</TD><TD>interpro domains</TD><TD>IPR012395</TD><TD>5</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>1.065e-02</TD><TD>-4.54</TD><TD>connective tissue development</TD><TD>biological process</TD><TD>GO:0061448</TD><TD>198</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>HSPG2,SOX8,CTGF</TD></TR>
<TR><TD>1.071e-02</TD><TD>-4.54</TD><TD>GCANCTGNY_V$MYOD_Q6</TD><TD>MSigDB lists</TD><TD>GCANCTGNY_V$MYOD_Q6</TD><TD>863</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,LONRF3,SULT2B1,TSC22D3,COL12A1,SYTL2</TD></TR>
<TR><TD>1.074e-02</TD><TD>-4.53</TD><TD>oesophagus-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-carcinoma-squamous_cell_carcinoma</TD><TD>6791</TD><TD>22</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ALDH2,HSPG2,ATP9A,ATP2C2,COL4A5,CNTNAP2,FAM198B,COL12A1,SYTL2,MECOM,GALNT3,ZNF432,IGF1R,PLOD2,MAP2,FRAS1,TOX2,AIM1,SUN3,PDE4D,MYRIP</TD></TR>
<TR><TD>1.076e-02</TD><TD>-4.53</TD><TD>AFFAR_YY1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>AFFAR_YY1_TARGETS_UP</TD><TD>209</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,PDLIM3,PLOD2</TD></TR>
<TR><TD>1.077e-02</TD><TD>-4.53</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.90.370.10</TD><TD>4</TD><TD>1</TD><TD>9988</TD><TD>27</TD>
<TD>TIMP2</TD></TR>
<TR><TD>1.082e-02</TD><TD>-4.53</TD><TD>PI3K-Akt signaling pathway</TD><TD>KEGG pathways</TD><TD>hsa04151</TD><TD>346</TD><TD>4</TD><TD>6908</TD><TD>18</TD>
<TD>COL4A5,IGF1R,NR4A1,FGF19</TD></TR>
<TR><TD>1.082e-02</TD><TD>-4.53</TD><TD>PI3K-Akt signaling pathway</TD><TD>KEGG pathways</TD><TD>ko04151</TD><TD>346</TD><TD>4</TD><TD>6908</TD><TD>18</TD>
<TD>COL4A5,IGF1R,NR4A1,FGF19</TD></TR>
<TR><TD>1.090e-02</TD><TD>-4.52</TD><TD>ZWANG_CLASS_3_TRANSIENTLY_INDUCED_BY_EGF</TD><TD>MSigDB lists</TD><TD>ZWANG_CLASS_3_TRANSIENTLY_INDUCED_BY_EGF</TD><TD>210</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,IGF1R,NR4A1</TD></TR>
<TR><TD>1.090e-02</TD><TD>-4.52</TD><TD>MODULE_120</TD><TD>MSigDB lists</TD><TD>MODULE_120</TD><TD>72</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,PLOD2</TD></TR>
<TR><TD>1.090e-02</TD><TD>-4.52</TD><TD>RODRIGUES_THYROID_CARCINOMA_DN</TD><TD>MSigDB lists</TD><TD>RODRIGUES_THYROID_CARCINOMA_DN</TD><TD>72</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2,SYTL2</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>chr16q11</TD><TD>MSigDB lists</TD><TD>chr16q11</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NETO2</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX3</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX3</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>WANG_RESPONSE_TO_PACLITAXEL_VIA_MAPK8_DN</TD><TD>MSigDB lists</TD><TD>WANG_RESPONSE_TO_PACLITAXEL_VIA_MAPK8_DN</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>RODRIGUES_DCC_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>RODRIGUES_DCC_TARGETS_UP</TD><TD>5</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD55</TD></TR>
<TR><TD>1.100e-02</TD><TD>-4.51</TD><TD>serotonin degradation</TD><TD>BIOCYC pathways</TD><TD>META_PWY-6313</TD><TD>5</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.100e-02</TD><TD>-4.51</TD><TD>ethanol degradation IV</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY66-162</TD><TD>5</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.100e-02</TD><TD>-4.51</TD><TD>ethanol degradation II</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY66-21</TD><TD>5</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.111e-02</TD><TD>-4.50</TD><TD>MODULE_6</TD><TD>MSigDB lists</TD><TD>MODULE_6</TD><TD>399</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,HSPG2,NR4A1,ATP9A</TD></TR>
<TR><TD>1.112e-02</TD><TD>-4.50</TD><TD>contractile fiber</TD><TD>cellular component</TD><TD>GO:0043292</TD><TD>215</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>TRPC1,PDE4D,PDLIM3</TD></TR>
<TR><TD>1.113e-02</TD><TD>-4.50</TD><TD>lymph_node</TD><TD>COSMIC cancer mutations</TD><TD>lymph_node</TD><TD>1781</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>ZNF432,CTGF,IGF1R,PDLIM3,PLOD2,ATP9A,SLC1A3,CNTNAP2,MYRIP</TD></TR>
<TR><TD>1.117e-02</TD><TD>-4.49</TD><TD>Astrocytic Glutamate-Glutamine Uptake And Metabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-210455</TD><TD>4</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.117e-02</TD><TD>-4.49</TD><TD>Neurotransmitter uptake and Metabolism In Glial Cells</TD><TD>REACTOME pathways</TD><TD>R-HSA-112313</TD><TD>4</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.120e-02</TD><TD>-4.49</TD><TD>MODULE_139</TD><TD>MSigDB lists</TD><TD>MODULE_139</TD><TD>73</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SULT2B1,SYTL2</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>GTGACGY_V$E4F1_Q6</TD><TD>MSigDB lists</TD><TD>GTGACGY_V$E4F1_Q6</TD><TD>623</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TAGLN2,PDLIM3,NR4A1,TSC22D3</TD></TR>
<TR><TD>1.130e-02</TD><TD>-4.48</TD><TD>RUTELLA_RESPONSE_TO_HGF_UP</TD><TD>MSigDB lists</TD><TD>RUTELLA_RESPONSE_TO_HGF_UP</TD><TD>401</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,SLC1A3,TIMP2,NETO2</TD></TR>
<TR><TD>1.138e-02</TD><TD>-4.48</TD><TD>regulation of alpha-beta T cell activation</TD><TD>biological process</TD><TD>GO:0046634</TD><TD>70</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>1.140e-02</TD><TD>-4.47</TD><TD>ConA-like_dom</TD><TD>interpro domains</TD><TD>IPR013320</TD><TD>220</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>CNTNAP2,HSPG2,COL12A1</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>TSC22</TD><TD>prosite domains</TD><TD>PS01289</TD><TD>4</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>TIMP</TD><TD>prosite domains</TD><TD>PS00288</TD><TD>4</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>TIMP2</TD></TR>
<TR><TD>1.143e-02</TD><TD>-4.47</TD><TD>Collagen</TD><TD>interpro domains</TD><TD>IPR008160</TD><TD>76</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>1.147e-02</TD><TD>-4.47</TD><TD>beta-2 adrenergic receptor binding</TD><TD>molecular function</TD><TD>GO:0031698</TD><TD>5</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>1.147e-02</TD><TD>-4.47</TD><TD>MRF binding</TD><TD>molecular function</TD><TD>GO:0043426</TD><TD>5</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>1.149e-02</TD><TD>-4.47</TD><TD>RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP</TD><TD>MSigDB lists</TD><TD>RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP</TD><TD>74</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,AIM1</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>positive regulation of G0 to G1 transition</TD><TD>biological process</TD><TD>GO:0070318</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>regulation of activation-induced cell death of T cells</TD><TD>biological process</TD><TD>GO:0070235</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>positive regulation of natural killer cell proliferation</TD><TD>biological process</TD><TD>GO:0032819</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>positive regulation of plasminogen activation</TD><TD>biological process</TD><TD>GO:0010756</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>response to corticotropin-releasing hormone</TD><TD>biological process</TD><TD>GO:0043435</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>ethanol catabolic process</TD><TD>biological process</TD><TD>GO:0006068</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>regulation of type B pancreatic cell proliferation</TD><TD>biological process</TD><TD>GO:0061469</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>vocal learning</TD><TD>biological process</TD><TD>GO:0042297</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>learned vocalization behavior or vocal learning</TD><TD>biological process</TD><TD>GO:0098598</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>cellular response to corticotropin-releasing hormone stimulus</TD><TD>biological process</TD><TD>GO:0071376</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>positive regulation of extracellular matrix disassembly</TD><TD>biological process</TD><TD>GO:0090091</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MFI2</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>imitative learning</TD><TD>biological process</TD><TD>GO:0098596</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>G-protein coupled receptor signaling pathway involved in heart process</TD><TD>biological process</TD><TD>GO:0086103</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>1.150e-02</TD><TD>-4.47</TD><TD>negative regulation of photoreceptor cell differentiation</TD><TD>biological process</TD><TD>GO:0046533</TD><TD>5</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>1.156e-02</TD><TD>-4.46</TD><TD>CASK (calcium/calmodulin-dependent serine protein kinase (MAGUK family))</TD><TD>protein interactions</TD><TD>8573</TD><TD>77</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>IL18,CNTNAP2</TD></TR>
<TR><TD>1.161e-02</TD><TD>-4.46</TD><TD>V$MEF2_02</TD><TD>MSigDB lists</TD><TD>V$MEF2_02</TD><TD>215</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,CTGF,NR4A1</TD></TR>
<TR><TD>1.165e-02</TD><TD>-4.45</TD><TD>large_intestine-caecum-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-caecum-carcinoma-adenocarcinoma</TD><TD>14963</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,ATP9A,TSC22D3,ATP2C2,COL4A5,IL18,CNTNAP2,SLC1A3,FAM198B,FGF19,SYTL2,MECOM,ZNF432,CTGF,IGF1R,FRAS1,TOX2,AIM1,TRPC1,SUN3,TAGLN2,PDE4D,MYRIP,SULT2B1,AMOTL2,CD55,ALDH2,LONRF3,MFI2,NR4A1,COL12A1,GALNT3,PDLIM3,PLOD2,MAP2,NETO2,SOX8</TD></TR>
<TR><TD>1.179e-02</TD><TD>-4.44</TD><TD>HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_UP</TD><TD>MSigDB lists</TD><TD>HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_UP</TD><TD>75</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PLOD2,MECOM</TD></TR>
<TR><TD>1.179e-02</TD><TD>-4.44</TD><TD>chrxq22</TD><TD>MSigDB lists</TD><TD>chrxq22</TD><TD>75</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TSC22D3</TD></TR>
<TR><TD>1.179e-02</TD><TD>-4.44</TD><TD>MAHAJAN_RESPONSE_TO_IL1A_DN</TD><TD>MSigDB lists</TD><TD>MAHAJAN_RESPONSE_TO_IL1A_DN</TD><TD>75</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,CTGF</TD></TR>
<TR><TD>1.183e-02</TD><TD>-4.44</TD><TD>TGACATY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TGACATY_UNKNOWN</TD><TD>631</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,PDE4D,MAP2,PLOD2,FGF19</TD></TR>
<TR><TD>1.184e-02</TD><TD>-4.44</TD><TD>neurogenesis</TD><TD>biological process</TD><TD>GO:0022008</TD><TD>1664</TD><TD>9</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,IGF1R,MAP2,TRPC1,COL4A5,SLC1A3,CNTNAP2,SOX8,FGF19</TD></TR>
<TR><TD>1.190e-02</TD><TD>-4.43</TD><TD>MILI_PSEUDOPODIA_HAPTOTAXIS_DN</TD><TD>MSigDB lists</TD><TD>MILI_PSEUDOPODIA_HAPTOTAXIS_DN</TD><TD>632</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,COL4A5,TIMP2,IGF1R,HSPG2</TD></TR>
<TR><TD>1.190e-02</TD><TD>-4.43</TD><TD>COLDREN_GEFITINIB_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>COLDREN_GEFITINIB_RESISTANCE_DN</TD><TD>217</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,ATP2C2,AIM1</TD></TR>
<TR><TD>1.191e-02</TD><TD>-4.43</TD><TD>metal ion binding</TD><TD>molecular function</TD><TD>GO:0046872</TD><TD>4013</TD><TD>16</TD><TD>16491</TD><TD>38</TD>
<TD>TIMP2,LONRF3,MFI2,HSPG2,ATP9A,NR4A1,ATP2C2,SYTL2,MECOM,GALNT3,ZNF432,PDLIM3,PLOD2,FRAS1,PDE4D,MYRIP</TD></TR>
<TR><TD>1.196e-02</TD><TD>-4.43</TD><TD>caecum</TD><TD>COSMIC cancer mutations</TD><TD>caecum</TD><TD>14975</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,ATP9A,TSC22D3,ATP2C2,COL4A5,IL18,CNTNAP2,SLC1A3,FAM198B,FGF19,SYTL2,MECOM,ZNF432,CTGF,IGF1R,FRAS1,TOX2,AIM1,TRPC1,SUN3,TAGLN2,PDE4D,MYRIP,SULT2B1,AMOTL2,CD55,ALDH2,LONRF3,MFI2,NR4A1,COL12A1,GALNT3,PDLIM3,PLOD2,MAP2,NETO2,SOX8</TD></TR>
<TR><TD>1.197e-02</TD><TD>-4.43</TD><TD>EGF-like_dom</TD><TD>interpro domains</TD><TD>IPR000742</TD><TD>224</TD><TD>3</TD><TD>18293</TD><TD>39</TD>
<TD>CNTNAP2,HSPG2,FRAS1</TD></TR>
<TR><TD>1.209e-02</TD><TD>-4.42</TD><TD>SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE</TD><TD>MSigDB lists</TD><TD>SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,TIMP2</TD></TR>
<TR><TD>1.209e-02</TD><TD>-4.42</TD><TD>LINDVALL_IMMORTALIZED_BY_TERT_DN</TD><TD>MSigDB lists</TD><TD>LINDVALL_IMMORTALIZED_BY_TERT_DN</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2,PLOD2</TD></TR>
<TR><TD>1.209e-02</TD><TD>-4.42</TD><TD>MCBRYAN_PUBERTAL_BREAST_6_7WK_DN</TD><TD>MSigDB lists</TD><TD>MCBRYAN_PUBERTAL_BREAST_6_7WK_DN</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,PLOD2</TD></TR>
<TR><TD>1.209e-02</TD><TD>-4.42</TD><TD>MARIADASON_REGULATED_BY_HISTONE_ACETYLATION_UP</TD><TD>MSigDB lists</TD><TD>MARIADASON_REGULATED_BY_HISTONE_ACETYLATION_UP</TD><TD>76</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,HSPG2</TD></TR>
<TR><TD>1.221e-02</TD><TD>-4.41</TD><TD>NTR</TD><TD>smart domains</TD><TD>SM00206</TD><TD>4</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>TIMP2</TD></TR>
<TR><TD>1.224e-02</TD><TD>-4.40</TD><TD>nervous system development</TD><TD>biological process</TD><TD>GO:0007399</TD><TD>2292</TD><TD>11</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,IGF1R,HSPG2,MAP2,TRPC1,COL4A5,CNTNAP2,SLC1A3,SOX8,FGF19,MECOM</TD></TR>
<TR><TD>1.240e-02</TD><TD>-4.39</TD><TD>HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_UP</TD><TD>MSigDB lists</TD><TD>HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_UP</TD><TD>77</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,IGF1R</TD></TR>
<TR><TD>1.247e-02</TD><TD>-4.38</TD><TD>TTANTCA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TTANTCA_UNKNOWN</TD><TD>892</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TAGLN2,PDE4D,IGF1R,MAP2,SYTL2</TD></TR>
<TR><TD>1.260e-02</TD><TD>-4.37</TD><TD>HAD-like_dom</TD><TD>interpro domains</TD><TD>IPR023214</TD><TD>80</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>1.265e-02</TD><TD>-4.37</TD><TD>SENESE_HDAC1_AND_HDAC2_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SENESE_HDAC1_AND_HDAC2_TARGETS_UP</TD><TD>222</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,PDE4D,MFI2</TD></TR>
<TR><TD>1.265e-02</TD><TD>-4.37</TD><TD>collagen catabolic process</TD><TD>biological process</TD><TD>GO:0030574</TD><TD>74</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>1.265e-02</TD><TD>-4.37</TD><TD>regulation of steroid metabolic process</TD><TD>biological process</TD><TD>GO:0019218</TD><TD>74</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,FGF19</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>CR1 (complement component (3b/4b) receptor 1 (Knops blood group))</TD><TD>protein interactions</TD><TD>1378</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>MMP8 (matrix metallopeptidase 8)</TD><TD>protein interactions</TD><TD>4317</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TIMP2</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>POU3F3 (POU class 3 homeobox 3)</TD><TD>protein interactions</TD><TD>5455</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SOX8</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>ZNF829 (zinc finger protein 829)</TD><TD>protein interactions</TD><TD>374899</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AIM1</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>C6orf120 (chromosome 6 open reading frame 120)</TD><TD>protein interactions</TD><TD>387263</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>FGFBP1 (fibroblast growth factor binding protein 1)</TD><TD>protein interactions</TD><TD>9982</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>CPEB1 (cytoplasmic polyadenylation element binding protein 1)</TD><TD>protein interactions</TD><TD>64506</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>MAP2</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>OLIG2 (oligodendrocyte lineage transcription factor 2)</TD><TD>protein interactions</TD><TD>10215</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SOX8</TD></TR>
<TR><TD>1.266e-02</TD><TD>-4.37</TD><TD>EIF5AL1 (eukaryotic translation initiation factor 5A-like 1)</TD><TD>protein interactions</TD><TD>143244</TD><TD>6</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.268e-02</TD><TD>-4.37</TD><TD>diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_large_B_cell_lymphoma</TD><TD>4353</TD><TD>16</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,HSPG2,ATP9A,ATP2C2,SLC1A3,CNTNAP2,COL12A1,ZNF432,IGF1R,MAP2,PLOD2,FRAS1,TOX2,TRPC1,SUN3,MYRIP</TD></TR>
<TR><TD>1.271e-02</TD><TD>-4.37</TD><TD>ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP</TD><TD>MSigDB lists</TD><TD>ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP</TD><TD>78</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,TSC22D3</TD></TR>
<TR><TD>1.273e-02</TD><TD>-4.36</TD><TD>DUF4749</TD><TD>interpro domains</TD><TD>IPR031847</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PDLIM3</TD></TR>
<TR><TD>1.273e-02</TD><TD>-4.36</TD><TD>Collagen_VI_NC</TD><TD>interpro domains</TD><TD>IPR001442</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.273e-02</TD><TD>-4.36</TD><TD>TRP_dom</TD><TD>interpro domains</TD><TD>IPR013555</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TRPC1</TD></TR>
<TR><TD>1.273e-02</TD><TD>-4.36</TD><TD>TRPC_channel</TD><TD>interpro domains</TD><TD>IPR002153</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TRPC1</TD></TR>
<TR><TD>1.273e-02</TD><TD>-4.36</TD><TD>Calponin_repeat</TD><TD>interpro domains</TD><TD>IPR000557</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.273e-02</TD><TD>-4.36</TD><TD>LON_substr-bd_dom</TD><TD>interpro domains</TD><TD>IPR003111</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>LONRF3</TD></TR>
<TR><TD>1.273e-02</TD><TD>-4.36</TD><TD>RII_binding_1</TD><TD>interpro domains</TD><TD>IPR018459</TD><TD>6</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>1.281e-02</TD><TD>-4.36</TD><TD>TCCATTKW_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TCCATTKW_UNKNOWN</TD><TD>223</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2,MAP2,NR4A1</TD></TR>
<TR><TD>1.291e-02</TD><TD>-4.35</TD><TD>FACIT collagen trimer</TD><TD>cellular component</TD><TD>GO:0005593</TD><TD>6</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>COL12A1</TD></TR>
<TR><TD>1.291e-02</TD><TD>-4.35</TD><TD>collagen type IV trimer</TD><TD>cellular component</TD><TD>GO:0005587</TD><TD>6</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.297e-02</TD><TD>-4.35</TD><TD>locomotion</TD><TD>biological process</TD><TD>GO:0040011</TD><TD>1396</TD><TD>8</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,CTGF,NR4A1,TRPC1,COL4A5,PDE4D,SOX8,FGF19</TD></TR>
<TR><TD>1.298e-02</TD><TD>-4.34</TD><TD>neural crest cell differentiation</TD><TD>biological process</TD><TD>GO:0014033</TD><TD>75</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,FGF19</TD></TR>
<TR><TD>1.299e-02</TD><TD>-4.34</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia</TD><TD>2156</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>CD55,IGF1R,HSPG2,MAP2,FRAS1,TSC22D3,NETO2,COL4A5,FAM198B,COL12A1</TD></TR>
<TR><TD>1.303e-02</TD><TD>-4.34</TD><TD>Collagen</TD><TD>pfam domains</TD><TD>PF01391</TD><TD>76</TD><TD>2</TD><TD>16629</TD><TD>38</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>1.304e-02</TD><TD>-4.34</TD><TD>cell morphogenesis involved in differentiation</TD><TD>biological process</TD><TD>GO:0000904</TD><TD>857</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,COL4A5,SLC1A3,IGF1R,MAP2,FGF19</TD></TR>
<TR><TD>1.311e-02</TD><TD>-4.33</TD><TD>PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_DN</TD><TD>MSigDB lists</TD><TD>PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_DN</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PLOD2</TD></TR>
<TR><TD>1.311e-02</TD><TD>-4.33</TD><TD>TERAO_AOX4_TARGETS_HG_DN</TD><TD>MSigDB lists</TD><TD>TERAO_AOX4_TARGETS_HG_DN</TD><TD>6</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>1.319e-02</TD><TD>-4.33</TD><TD>noradrenaline and adrenaline degradation</TD><TD>BIOCYC pathways</TD><TD>META_PWY-6342</TD><TD>6</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.319e-02</TD><TD>-4.33</TD><TD>oxidative ethanol degradation III</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY66-161</TD><TD>6</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.321e-02</TD><TD>-4.33</TD><TD>HAN_SATB1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>HAN_SATB1_TARGETS_DN</TD><TD>420</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,COL4A5,PDE4D,PLOD2</TD></TR>
<TR><TD>1.333e-02</TD><TD>-4.32</TD><TD>BASSO_HAIRY_CELL_LEUKEMIA_DN</TD><TD>MSigDB lists</TD><TD>BASSO_HAIRY_CELL_LEUKEMIA_DN</TD><TD>80</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,PLOD2</TD></TR>
<TR><TD>1.342e-02</TD><TD>-4.31</TD><TD>MARTENS_BOUND_BY_PML_RARA_FUSION</TD><TD>MSigDB lists</TD><TD>MARTENS_BOUND_BY_PML_RARA_FUSION</TD><TD>422</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,TIMP2,ALDH2,TOX2</TD></TR>
<TR><TD>1.349e-02</TD><TD>-4.31</TD><TD>membrane-bounded organelle</TD><TD>cellular component</TD><TD>GO:0043227</TD><TD>11730</TD><TD>32</TD><TD>17570</TD><TD>38</TD>
<TD>HSPG2,TSC22D3,ATP9A,ATP2C2,IL18,COL4A5,FAM198B,SLC1A3,CNTNAP2,SYTL2,MECOM,ZNF432,CTGF,IGF1R,TOX2,SUN3,PDE4D,TAGLN2,MYRIP,SULT2B1,AMOTL2,ALDH2,TIMP2,CD55,MFI2,ASCL5,NR4A1,COL12A1,GALNT3,MAP2,PLOD2,SOX8</TD></TR>
<TR><TD>1.356e-02</TD><TD>-4.30</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>653</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,FAM198B,CNTNAP2,IGF1R,SYTL2</TD></TR>
<TR><TD>1.362e-02</TD><TD>-4.30</TD><TD>GGGCGGR_V$SP1_Q6</TD><TD>MSigDB lists</TD><TD>GGGCGGR_V$SP1_Q6</TD><TD>2787</TD><TD>12</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,ALDH2,IGF1R,LONRF3,NR4A1,TSC22D3,TOX2,TRPC1,COL4A5,TAGLN2,FGF19,COL12A1</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP</TD><TD>MSigDB lists</TD><TD>ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP</TD><TD>424</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,CD55,NR4A1,COL12A1</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>human chr12q24.2</TD><TD>chromosome location</TD><TD>human chr12q24.2</TD><TD>9</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>human chr4q35</TD><TD>chromosome location</TD><TD>human chr4q35</TD><TD>9</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>PDLIM3</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>human chr11q14</TD><TD>chromosome location</TD><TD>human chr11q14</TD><TD>9</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>SYTL2</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>DUF4749</TD><TD>pfam domains</TD><TD>PF15936</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>PDLIM3</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>TRP_2</TD><TD>pfam domains</TD><TD>PF08344</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>TRPC1</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>C4</TD><TD>pfam domains</TD><TD>PF01413</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>Calponin</TD><TD>pfam domains</TD><TD>PF00402</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>LON_substr_bdg</TD><TD>pfam domains</TD><TD>PF02190</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>LONRF3</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>RII_binding_1</TD><TD>pfam domains</TD><TD>PF10522</TD><TD>6</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>MAP2</TD></TR>
<TR><TD>1.365e-02</TD><TD>-4.29</TD><TD>HSPH1 (heat shock 105kDa/110kDa protein 1)</TD><TD>protein interactions</TD><TD>10808</TD><TD>84</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2,PLOD2</TD></TR>
<TR><TD>1.368e-02</TD><TD>-4.29</TD><TD>neuron projection development</TD><TD>biological process</TD><TD>GO:0031175</TD><TD>866</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,COL4A5,CNTNAP2,IGF1R,MAP2,FGF19</TD></TR>
<TR><TD>1.374e-02</TD><TD>-4.29</TD><TD>MODULE_5</TD><TD>MSigDB lists</TD><TD>MODULE_5</TD><TD>425</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,TIMP2,HSPG2,NR4A1</TD></TR>
<TR><TD>1.375e-02</TD><TD>-4.29</TD><TD>insulin binding</TD><TD>molecular function</TD><TD>GO:0043559</TD><TD>6</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.375e-02</TD><TD>-4.29</TD><TD>manganese ion transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0005384</TD><TD>6</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>1.375e-02</TD><TD>-4.29</TD><TD>extracellular matrix structural constituent conferring tensile strength</TD><TD>molecular function</TD><TD>GO:0030020</TD><TD>6</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>COL12A1</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>D-amino acid transport</TD><TD>biological process</TD><TD>GO:0042940</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>negative regulation of membrane protein ectodomain proteolysis</TD><TD>biological process</TD><TD>GO:0051045</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>glutamate biosynthetic process</TD><TD>biological process</TD><TD>GO:0006537</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>metanephric tubule formation</TD><TD>biological process</TD><TD>GO:0072174</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>positive regulation of brown fat cell differentiation</TD><TD>biological process</TD><TD>GO:0090336</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>manganese ion transmembrane transport</TD><TD>biological process</TD><TD>GO:0071421</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>regulation of photoreceptor cell differentiation</TD><TD>biological process</TD><TD>GO:0046532</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>regulation of heart rate by chemical signal</TD><TD>biological process</TD><TD>GO:0003062</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>regulation of relaxation of cardiac muscle</TD><TD>biological process</TD><TD>GO:1901897</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>negative regulation of metalloenzyme activity</TD><TD>biological process</TD><TD>GO:0048553</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2</TD></TR>
<TR><TD>1.379e-02</TD><TD>-4.28</TD><TD>regulation of natural killer cell proliferation</TD><TD>biological process</TD><TD>GO:0032817</TD><TD>6</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>1.399e-02</TD><TD>-4.27</TD><TD>regulation of cardiac muscle contraction</TD><TD>biological process</TD><TD>GO:0055117</TD><TD>78</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,CTGF</TD></TR>
<TR><TD>1.401e-02</TD><TD>-4.27</TD><TD>bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>677</TD><TD>5</TD><TD>17775</TD><TD>38</TD>
<TD>MFI2,FRAS1,NR4A1,COL12A1,SYTL2</TD></TR>
<TR><TD>1.407e-02</TD><TD>-4.26</TD><TD>WINTER_HYPOXIA_METAGENE</TD><TD>MSigDB lists</TD><TD>WINTER_HYPOXIA_METAGENE</TD><TD>231</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,PLOD2,NR4A1</TD></TR>
<TR><TD>1.407e-02</TD><TD>-4.26</TD><TD>V$CEBPA_01</TD><TD>MSigDB lists</TD><TD>V$CEBPA_01</TD><TD>231</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,PDE4D,LONRF3</TD></TR>
<TR><TD>1.413e-02</TD><TD>-4.26</TD><TD>calcium ion transport</TD><TD>biological process</TD><TD>GO:0006816</TD><TD>220</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CTGF,ATP2C2</TD></TR>
<TR><TD>1.423e-02</TD><TD>-4.25</TD><TD>V$COUP_DR1_Q6</TD><TD>MSigDB lists</TD><TD>V$COUP_DR1_Q6</TD><TD>232</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LONRF3,NR4A1,SYTL2</TD></TR>
<TR><TD>1.429e-02</TD><TD>-4.25</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN</TD><TD>MSigDB lists</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN</TD><TD>430</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,SLC1A3,TOX2,AIM1</TD></TR>
<TR><TD>1.431e-02</TD><TD>-4.25</TD><TD>TSH signaling pathway</TD><TD>WikiPathways</TD><TD>WP2032</TD><TD>64</TD><TD>2</TD><TD>4455</TD><TD>13</TD>
<TD>PDE4D,IGF1R</TD></TR>
<TR><TD>1.433e-02</TD><TD>-4.25</TD><TD>Melanoma</TD><TD>KEGG pathways</TD><TD>hsa05218</TD><TD>71</TD><TD>2</TD><TD>6908</TD><TD>18</TD>
<TD>IGF1R,FGF19</TD></TR>
<TR><TD>1.433e-02</TD><TD>-4.25</TD><TD>Melanoma</TD><TD>KEGG pathways</TD><TD>ko05218</TD><TD>71</TD><TD>2</TD><TD>6908</TD><TD>18</TD>
<TD>IGF1R,FGF19</TD></TR>
<TR><TD>1.433e-02</TD><TD>-4.25</TD><TD>regulation of protein processing</TD><TD>biological process</TD><TD>GO:0070613</TD><TD>79</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,MFI2</TD></TR>
<TR><TD>1.437e-02</TD><TD>-4.24</TD><TD>cell development</TD><TD>biological process</TD><TD>GO:0048468</TD><TD>1717</TD><TD>9</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,MAP2,TRPC1,COL4A5,PDE4D,SLC1A3,CNTNAP2,SOX8,FGF19</TD></TR>
<TR><TD>1.455e-02</TD><TD>-4.23</TD><TD>receptor binding</TD><TD>molecular function</TD><TD>GO:0005102</TD><TD>1429</TD><TD>8</TD><TD>16491</TD><TD>38</TD>
<TD>TIMP2,IGF1R,CTGF,NETO2,IL18,PDE4D,FGF19,SYTL2</TD></TR>
<TR><TD>1.456e-02</TD><TD>-4.23</TD><TD>V$MYB_Q3</TD><TD>MSigDB lists</TD><TD>V$MYB_Q3</TD><TD>234</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FRAS1,COL12A1,TOX2</TD></TR>
<TR><TD>1.458e-02</TD><TD>-4.23</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3</TD><TD>MSigDB lists</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3</TD><TD>665</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,CD55,LONRF3,CTGF,ATP2C2</TD></TR>
<TR><TD>1.463e-02</TD><TD>-4.22</TD><TD>HATPASE</TD><TD>prints domains</TD><TD>PR00120</TD><TD>5</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>1.468e-02</TD><TD>-4.22</TD><TD>regulation of protein maturation</TD><TD>biological process</TD><TD>GO:1903317</TD><TD>80</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,MFI2</TD></TR>
<TR><TD>1.475e-02</TD><TD>-4.22</TD><TD>INF2 (inverted formin, FH2 and WH2 domain containing)</TD><TD>protein interactions</TD><TD>64423</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>1.475e-02</TD><TD>-4.22</TD><TD>HABP2 (hyaluronan binding protein 2)</TD><TD>protein interactions</TD><TD>3026</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.475e-02</TD><TD>-4.22</TD><TD>MTERF1 (mitochondrial transcription termination factor 1)</TD><TD>protein interactions</TD><TD>7978</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SYTL2</TD></TR>
<TR><TD>1.475e-02</TD><TD>-4.22</TD><TD>COL13A1 (collagen, type XIII, alpha 1)</TD><TD>protein interactions</TD><TD>1305</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>1.475e-02</TD><TD>-4.22</TD><TD>PMP2 (peripheral myelin protein 2)</TD><TD>protein interactions</TD><TD>5375</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.475e-02</TD><TD>-4.22</TD><TD>CAMP (cathelicidin antimicrobial peptide)</TD><TD>protein interactions</TD><TD>820</TD><TD>7</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.483e-02</TD><TD>-4.21</TD><TD>Na-dicarboxylate_symporter_CS</TD><TD>interpro domains</TD><TD>IPR018107</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.483e-02</TD><TD>-4.21</TD><TD>Furin-like_Cys-rich_dom</TD><TD>interpro domains</TD><TD>IPR006211</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.483e-02</TD><TD>-4.21</TD><TD>Na-dicarboxylate_symporter</TD><TD>interpro domains</TD><TD>IPR001991</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.483e-02</TD><TD>-4.21</TD><TD>Rcpt_L-dom</TD><TD>interpro domains</TD><TD>IPR000494</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.483e-02</TD><TD>-4.21</TD><TD>SUN_dom</TD><TD>interpro domains</TD><TD>IPR012919</TD><TD>7</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>SUN3</TD></TR>
<TR><TD>1.484e-02</TD><TD>-4.21</TD><TD>synapse</TD><TD>cellular component</TD><TD>GO:0045202</TD><TD>679</TD><TD>5</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5,SLC1A3,MYRIP,MAP2,NETO2</TD></TR>
<TR><TD>1.486e-02</TD><TD>-4.21</TD><TD>cation binding</TD><TD>molecular function</TD><TD>GO:0043169</TD><TD>4106</TD><TD>16</TD><TD>16491</TD><TD>38</TD>
<TD>TIMP2,LONRF3,MFI2,HSPG2,ATP9A,NR4A1,ATP2C2,SYTL2,MECOM,GALNT3,ZNF432,PDLIM3,PLOD2,FRAS1,PDE4D,MYRIP</TD></TR>
<TR><TD>1.490e-02</TD><TD>-4.21</TD><TD>V$MYB_Q6</TD><TD>MSigDB lists</TD><TD>V$MYB_Q6</TD><TD>236</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,FRAS1,TOX2</TD></TR>
<TR><TD>1.496e-02</TD><TD>-4.20</TD><TD>LIU_VAV3_PROSTATE_CARCINOGENESIS_UP</TD><TD>MSigDB lists</TD><TD>LIU_VAV3_PROSTATE_CARCINOGENESIS_UP</TD><TD>85</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,PLOD2</TD></TR>
<TR><TD>1.500e-02</TD><TD>-4.20</TD><TD>Nasopharyngeal carcinoma(PMID:20512145)</TD><TD>GWAS genes</TD><TD>Nasopharyngeal carcinoma(PMID:20512145)</TD><TD>3</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.500e-02</TD><TD>-4.20</TD><TD>Triglycerides(PMID:22171074)</TD><TD>GWAS genes</TD><TD>Triglycerides(PMID:22171074)</TD><TD>3</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.500e-02</TD><TD>-4.20</TD><TD>Bone mineral density(PMID:17903296)</TD><TD>GWAS genes</TD><TD>Bone mineral density(PMID:17903296)</TD><TD>3</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.503e-02</TD><TD>-4.20</TD><TD>multicellular organismal catabolic process</TD><TD>biological process</TD><TD>GO:0044243</TD><TD>81</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>1.504e-02</TD><TD>-4.20</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>2204</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>IGF1R,PLOD2,MAP2,FRAS1,ATP9A,NETO2,TRPC1,SLC1A3,CNTNAP2,MYRIP</TD></TR>
<TR><TD>1.504e-02</TD><TD>-4.20</TD><TD>Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>Burkitt_lymphoma</TD><TD>2204</TD><TD>10</TD><TD>17775</TD><TD>38</TD>
<TD>IGF1R,PLOD2,MAP2,FRAS1,ATP9A,NETO2,TRPC1,SLC1A3,CNTNAP2,MYRIP</TD></TR>
<TR><TD>1.504e-02</TD><TD>-4.20</TD><TD>collagen network</TD><TD>cellular component</TD><TD>GO:0098645</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.504e-02</TD><TD>-4.20</TD><TD>network-forming collagen trimer</TD><TD>cellular component</TD><TD>GO:0098642</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.504e-02</TD><TD>-4.20</TD><TD>kainate selective glutamate receptor complex</TD><TD>cellular component</TD><TD>GO:0032983</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>NETO2</TD></TR>
<TR><TD>1.504e-02</TD><TD>-4.20</TD><TD>microtubule organizing center attachment site</TD><TD>cellular component</TD><TD>GO:0034992</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>SUN3</TD></TR>
<TR><TD>1.504e-02</TD><TD>-4.20</TD><TD>LINC complex</TD><TD>cellular component</TD><TD>GO:0034993</TD><TD>7</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>SUN3</TD></TR>
<TR><TD>1.514e-02</TD><TD>-4.19</TD><TD>human chr4q21.21</TD><TD>chromosome location</TD><TD>human chr4q21.21</TD><TD>10</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>FRAS1</TD></TR>
<TR><TD>1.514e-02</TD><TD>-4.19</TD><TD>human chr5p13</TD><TD>chromosome location</TD><TD>human chr5p13</TD><TD>10</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.519e-02</TD><TD>-4.19</TD><TD>MODULE_37</TD><TD>MSigDB lists</TD><TD>MODULE_37</TD><TD>438</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,TIMP2,PDE4D,TSC22D3</TD></TR>
<TR><TD>1.523e-02</TD><TD>-4.18</TD><TD>V$NFAT_Q6</TD><TD>MSigDB lists</TD><TD>V$NFAT_Q6</TD><TD>238</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,HSPG2,PLOD2</TD></TR>
<TR><TD>1.527e-02</TD><TD>-4.18</TD><TD>LOPEZ_MESOTELIOMA_SURVIVAL_TIME_DN</TD><TD>MSigDB lists</TD><TD>LOPEZ_MESOTELIOMA_SURVIVAL_TIME_DN</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.527e-02</TD><TD>-4.18</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_7</TD><TD>MSigDB lists</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_7</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.527e-02</TD><TD>-4.18</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>7</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.538e-02</TD><TD>-4.17</TD><TD>regulation of calcium ion transport into cytosol</TD><TD>biological process</TD><TD>GO:0010522</TD><TD>82</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,PDE4D</TD></TR>
<TR><TD>1.538e-02</TD><TD>-4.17</TD><TD>serotonin degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-6313</TD><TD>7</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.540e-02</TD><TD>-4.17</TD><TD>V$HLF_01</TD><TD>MSigDB lists</TD><TD>V$HLF_01</TD><TD>239</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,LONRF3,TSC22D3</TD></TR>
<TR><TD>1.543e-02</TD><TD>-4.17</TD><TD>Nucleotide-diphossugar_trans</TD><TD>interpro domains</TD><TD>IPR029044</TD><TD>89</TD><TD>2</TD><TD>18293</TD><TD>39</TD>
<TD>GALNT3,PLOD2</TD></TR>
<TR><TD>1.552e-02</TD><TD>-4.17</TD><TD>vesicle</TD><TD>cellular component</TD><TD>GO:0031982</TD><TD>3622</TD><TD>14</TD><TD>17570</TD><TD>38</TD>
<TD>GALNT3,AMOTL2,CD55,TIMP2,ALDH2,MFI2,HSPG2,PLOD2,IL18,TAGLN2,MYRIP,SULT2B1,SYTL2,COL12A1</TD></TR>
<TR><TD>1.555e-02</TD><TD>-4.16</TD><TD>TAZ (tafazzin)</TD><TD>protein interactions</TD><TD>6901</TD><TD>90</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>MFI2,FRAS1</TD></TR>
<TR><TD>1.558e-02</TD><TD>-4.16</TD><TD>V$AREB6_04</TD><TD>MSigDB lists</TD><TD>V$AREB6_04</TD><TD>240</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,CTGF,IGF1R</TD></TR>
<TR><TD>1.563e-02</TD><TD>-4.16</TD><TD>SASSON_RESPONSE_TO_GONADOTROPHINS_DN</TD><TD>MSigDB lists</TD><TD>SASSON_RESPONSE_TO_GONADOTROPHINS_DN</TD><TD>87</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM3,ATP9A</TD></TR>
<TR><TD>1.574e-02</TD><TD>-4.15</TD><TD>collagen metabolic process</TD><TD>biological process</TD><TD>GO:0032963</TD><TD>83</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>1.578e-02</TD><TD>-4.15</TD><TD>cytoplasmic part</TD><TD>cellular component</TD><TD>GO:0044444</TD><TD>7817</TD><TD>24</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,CD55,ALDH2,HSPG2,TSC22D3,ATP9A,ATP2C2,COL4A5,IL18,FAM198B,SLC1A3,CNTNAP2,SYTL2,COL12A1,MECOM,GALNT3,PDLIM3,CTGF,PLOD2,MAP2,TRPC1,PDE4D,MYRIP,SULT2B1</TD></TR>
<TR><TD>1.585e-02</TD><TD>-4.14</TD><TD>collagen trimer</TD><TD>cellular component</TD><TD>GO:0005581</TD><TD>89</TD><TD>2</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>1.586e-02</TD><TD>-4.14</TD><TD>TATAAA_V$TATA_01</TD><TD>MSigDB lists</TD><TD>TATAAA_V$TATA_01</TD><TD>1222</TD><TD>7</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,CTGF,PDLIM3,PLOD2,NR4A1,TSC22D3,SYTL2</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>Furin-like</TD><TD>pfam domains</TD><TD>PF00757</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>Sad1_UNC</TD><TD>pfam domains</TD><TD>PF07738</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>SUN3</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>Recep_L_domain</TD><TD>pfam domains</TD><TD>PF01030</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.589e-02</TD><TD>-4.14</TD><TD>SDF</TD><TD>pfam domains</TD><TD>PF00375</TD><TD>7</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.597e-02</TD><TD>-4.14</TD><TD>SASSON_RESPONSE_TO_FORSKOLIN_DN</TD><TD>MSigDB lists</TD><TD>SASSON_RESPONSE_TO_FORSKOLIN_DN</TD><TD>88</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM3,ATP9A</TD></TR>
<TR><TD>1.597e-02</TD><TD>-4.14</TD><TD>SANA_TNF_SIGNALING_DN</TD><TD>MSigDB lists</TD><TD>SANA_TNF_SIGNALING_DN</TD><TD>88</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FAM198B,CTGF</TD></TR>
<TR><TD>1.602e-02</TD><TD>-4.13</TD><TD>aldehyde dehydrogenase [NAD(P)+] activity</TD><TD>molecular function</TD><TD>GO:0004030</TD><TD>7</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.607e-02</TD><TD>-4.13</TD><TD>positive regulation of cardiac muscle contraction</TD><TD>biological process</TD><TD>GO:0060452</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>1.607e-02</TD><TD>-4.13</TD><TD>interleukin-2 production</TD><TD>biological process</TD><TD>GO:0032623</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>1.607e-02</TD><TD>-4.13</TD><TD>regulation of brown fat cell differentiation</TD><TD>biological process</TD><TD>GO:0090335</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.607e-02</TD><TD>-4.13</TD><TD>saliva secretion</TD><TD>biological process</TD><TD>GO:0046541</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1</TD></TR>
<TR><TD>1.607e-02</TD><TD>-4.13</TD><TD>positive regulation of interleukin-5 production</TD><TD>biological process</TD><TD>GO:0032754</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>1.607e-02</TD><TD>-4.13</TD><TD>observational learning</TD><TD>biological process</TD><TD>GO:0098597</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.607e-02</TD><TD>-4.13</TD><TD>positive regulation of hormone biosynthetic process</TD><TD>biological process</TD><TD>GO:0046886</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.607e-02</TD><TD>-4.13</TD><TD>type 2 immune response</TD><TD>biological process</TD><TD>GO:0042092</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>1.607e-02</TD><TD>-4.13</TD><TD>positive regulation of mucus secretion</TD><TD>biological process</TD><TD>GO:0070257</TD><TD>7</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SYTL2</TD></TR>
<TR><TD>1.610e-02</TD><TD>-4.13</TD><TD>positive regulation of blood circulation</TD><TD>biological process</TD><TD>GO:1903524</TD><TD>84</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,CTGF</TD></TR>
<TR><TD>1.610e-02</TD><TD>-4.13</TD><TD>metanephros development</TD><TD>biological process</TD><TD>GO:0001656</TD><TD>84</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,FRAS1</TD></TR>
<TR><TD>1.610e-02</TD><TD>-4.13</TD><TD>GTTTGTT,MIR-495</TD><TD>MSigDB lists</TD><TD>GTTTGTT,MIR-495</TD><TD>243</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,PDE4D,TSC22D3</TD></TR>
<TR><TD>1.611e-02</TD><TD>-4.13</TD><TD>-</TD><TD>gene3d domains</TD><TD>2.170.240.10</TD><TD>6</TD><TD>1</TD><TD>9988</TD><TD>27</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.613e-02</TD><TD>-4.13</TD><TD>oesophagus-middle_third-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-middle_third-carcinoma-squamous_cell_carcinoma</TD><TD>3681</TD><TD>14</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,GALNT3,HSPG2,PLOD2,FRAS1,ATP2C2,TRPC1,FAM198B,PDE4D,CNTNAP2,MYRIP,SYTL2,COL12A1,MECOM</TD></TR>
<TR><TD>1.621e-02</TD><TD>-4.12</TD><TD>middle_third</TD><TD>COSMIC cancer mutations</TD><TD>middle_third</TD><TD>3683</TD><TD>14</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,GALNT3,HSPG2,PLOD2,FRAS1,ATP2C2,TRPC1,FAM198B,PDE4D,CNTNAP2,MYRIP,SYTL2,COL12A1,MECOM</TD></TR>
<TR><TD>1.621e-02</TD><TD>-4.12</TD><TD>APPBP2 (amyloid beta precursor protein (cytoplasmic tail) binding protein 2)</TD><TD>protein interactions</TD><TD>10513</TD><TD>92</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>GALNT3,LONRF3</TD></TR>
<TR><TD>1.627e-02</TD><TD>-4.12</TD><TD>V$TEF_Q6</TD><TD>MSigDB lists</TD><TD>V$TEF_Q6</TD><TD>244</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,PDLIM3,MAP2</TD></TR>
<TR><TD>1.646e-02</TD><TD>-4.11</TD><TD>aging</TD><TD>biological process</TD><TD>GO:0007568</TD><TD>233</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,PDE4D,CTGF</TD></TR>
<TR><TD>1.646e-02</TD><TD>-4.11</TD><TD>positive regulation of T cell proliferation</TD><TD>biological process</TD><TD>GO:0042102</TD><TD>85</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>1.646e-02</TD><TD>-4.11</TD><TD>kidney morphogenesis</TD><TD>biological process</TD><TD>GO:0060993</TD><TD>85</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,FRAS1</TD></TR>
<TR><TD>1.658e-02</TD><TD>-4.10</TD><TD>oesophagus-lower_third-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-lower_third-carcinoma-adenocarcinoma</TD><TD>6579</TD><TD>21</TD><TD>17775</TD><TD>38</TD>
<TD>MFI2,LONRF3,HSPG2,NR4A1,ATP2C2,COL4A5,CNTNAP2,COL12A1,SYTL2,ZNF432,CTGF,IGF1R,MAP2,FRAS1,TOX2,AIM1,TRPC1,SUN3,PDE4D,SOX8,MYRIP</TD></TR>
<TR><TD>1.663e-02</TD><TD>-4.10</TD><TD>ONDER_CDH1_TARGETS_2_UP</TD><TD>MSigDB lists</TD><TD>ONDER_CDH1_TARGETS_2_UP</TD><TD>246</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,PLOD2,TSC22D3</TD></TR>
<TR><TD>1.681e-02</TD><TD>-4.09</TD><TD>V$SREBP_Q3</TD><TD>MSigDB lists</TD><TD>V$SREBP_Q3</TD><TD>247</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LONRF3,HSPG2,SYTL2</TD></TR>
<TR><TD>1.681e-02</TD><TD>-4.09</TD><TD>V$TATA_01</TD><TD>MSigDB lists</TD><TD>V$TATA_01</TD><TD>247</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1,TSC22D3,FGF19</TD></TR>
<TR><TD>1.681e-02</TD><TD>-4.09</TD><TD>V$HNF4_Q6</TD><TD>MSigDB lists</TD><TD>V$HNF4_Q6</TD><TD>247</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,CTGF,SULT2B1</TD></TR>
<TR><TD>1.684e-02</TD><TD>-4.08</TD><TD>ABCG8 (ATP binding cassette subfamily G member 8)</TD><TD>protein interactions</TD><TD>64241</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.684e-02</TD><TD>-4.08</TD><TD>SOCS4 (suppressor of cytokine signaling 4)</TD><TD>protein interactions</TD><TD>122809</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.684e-02</TD><TD>-4.08</TD><TD>GSTM5 (glutathione S-transferase mu 5)</TD><TD>protein interactions</TD><TD>2949</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>1.684e-02</TD><TD>-4.08</TD><TD>ZNF331 (zinc finger protein 331)</TD><TD>protein interactions</TD><TD>55422</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.684e-02</TD><TD>-4.08</TD><TD>ARL8A (ADP-ribosylation factor like GTPase 8A)</TD><TD>protein interactions</TD><TD>127829</TD><TD>8</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.686e-02</TD><TD>-4.08</TD><TD>KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP</TD><TD>MSigDB lists</TD><TD>KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP</TD><TD>690</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,CD55,TIMP2,PDE4D,TSC22D3</TD></TR>
<TR><TD>1.689e-02</TD><TD>-4.08</TD><TD>PIAS4 (protein inhibitor of activated STAT 4)</TD><TD>protein interactions</TD><TD>51588</TD><TD>94</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>PDE4D,MECOM</TD></TR>
<TR><TD>1.693e-02</TD><TD>-4.08</TD><TD>Laminin_IV</TD><TD>interpro domains</TD><TD>IPR000034</TD><TD>8</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>HSPG2</TD></TR>
<TR><TD>1.699e-02</TD><TD>-4.08</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_UP</TD><TD>MSigDB lists</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_UP</TD><TD>248</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,TSC22D3,TOX2</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>CALPONIN_1</TD><TD>prosite domains</TD><TD>PS01052</TD><TD>6</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>SUN</TD><TD>prosite domains</TD><TD>PS51469</TD><TD>6</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>SUN3</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>NC1_IV</TD><TD>prosite domains</TD><TD>PS51403</TD><TD>6</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>CALPONIN_2</TD><TD>prosite domains</TD><TD>PS51122</TD><TD>6</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.718e-02</TD><TD>-4.06</TD><TD>basement membrane collagen trimer</TD><TD>cellular component</TD><TD>GO:0098651</TD><TD>8</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.719e-02</TD><TD>-4.06</TD><TD>Signaling by the B Cell Receptor (BCR)</TD><TD>REACTOME pathways</TD><TD>R-HSA-983705</TD><TD>198</TD><TD>3</TD><TD>8202</TD><TD>23</TD>
<TD>TRPC1,NR4A1,FGF19</TD></TR>
<TR><TD>1.728e-02</TD><TD>-4.06</TD><TD>Pathways in cancer</TD><TD>KEGG pathways</TD><TD>hsa05200</TD><TD>397</TD><TD>4</TD><TD>6908</TD><TD>18</TD>
<TD>COL4A5,IGF1R,FGF19,MECOM</TD></TR>
<TR><TD>1.730e-02</TD><TD>-4.06</TD><TD>extracellular region</TD><TD>cellular component</TD><TD>GO:0005576</TD><TD>4445</TD><TD>16</TD><TD>17570</TD><TD>38</TD>
<TD>CD55,TIMP2,ALDH2,MFI2,HSPG2,COL4A5,IL18,SLC1A3,FGF19,COL12A1,GALNT3,CTGF,PLOD2,FRAS1,TAGLN2,SULT2B1</TD></TR>
<TR><TD>1.735e-02</TD><TD>-4.05</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP</TD><TD>MSigDB lists</TD><TD>WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP</TD><TD>250</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,SYTL2,MECOM</TD></TR>
<TR><TD>1.737e-02</TD><TD>-4.05</TD><TD>ZHU_CMV_24_HR_UP</TD><TD>MSigDB lists</TD><TD>ZHU_CMV_24_HR_UP</TD><TD>92</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,NR4A1</TD></TR>
<TR><TD>1.742e-02</TD><TD>-4.05</TD><TD>CTTTGT_V$LEF1_Q2</TD><TD>MSigDB lists</TD><TD>CTTTGT_V$LEF1_Q2</TD><TD>1862</TD><TD>9</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,PLOD2,MAP2,TSC22D3,FRAS1,TOX2,FAM198B,PDE4D,COL12A1</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>OXFORD_RALB_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>OXFORD_RALB_TARGETS_UP</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>GALIE_TUMOR_ANGIOGENESIS</TD><TD>MSigDB lists</TD><TD>GALIE_TUMOR_ANGIOGENESIS</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>COLLER_MYC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>COLLER_MYC_TARGETS_DN</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>KONDO_HYPOXIA</TD><TD>MSigDB lists</TD><TD>KONDO_HYPOXIA</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>RAMJAUN_APOPTOSIS_BY_TGFB1_VIA_MAPK1_DN</TD><TD>MSigDB lists</TD><TD>RAMJAUN_APOPTOSIS_BY_TGFB1_VIA_MAPK1_DN</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.744e-02</TD><TD>-4.05</TD><TD>SAMOLS_TARGETS_OF_KHSV_MIRNAS_UP</TD><TD>MSigDB lists</TD><TD>SAMOLS_TARGETS_OF_KHSV_MIRNAS_UP</TD><TD>8</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3</TD></TR>
<TR><TD>1.745e-02</TD><TD>-4.05</TD><TD>cell-cell signaling</TD><TD>biological process</TD><TD>GO:0007267</TD><TD>914</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,SLC1A3,ALDH2,SOX8,CTGF,SYTL2</TD></TR>
<TR><TD>1.750e-02</TD><TD>-4.05</TD><TD>adenoma</TD><TD>COSMIC cancer mutations</TD><TD>adenoma</TD><TD>2966</TD><TD>12</TD><TD>17775</TD><TD>38</TD>
<TD>ALDH2,PDLIM3,HSPG2,MAP2,ATP9A,NR4A1,NETO2,TRPC1,PDE4D,CNTNAP2,SULT2B1,COL12A1</TD></TR>
<TR><TD>1.753e-02</TD><TD>-4.04</TD><TD>TRNSRECEPTRP</TD><TD>prints domains</TD><TD>PR01097</TD><TD>6</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>TRPC1</TD></TR>
<TR><TD>1.754e-02</TD><TD>-4.04</TD><TD>V$SOX5_01</TD><TD>MSigDB lists</TD><TD>V$SOX5_01</TD><TD>251</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,NR4A1,TSC22D3</TD></TR>
<TR><TD>1.754e-02</TD><TD>-4.04</TD><TD>CAGCTTT,MIR-320</TD><TD>MSigDB lists</TD><TD>CAGCTTT,MIR-320</TD><TD>251</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,TSC22D3,AIM1</TD></TR>
<TR><TD>1.754e-02</TD><TD>-4.04</TD><TD>V$STAT4_01</TD><TD>MSigDB lists</TD><TD>V$STAT4_01</TD><TD>251</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,NR4A1,MECOM</TD></TR>
<TR><TD>1.754e-02</TD><TD>-4.04</TD><TD>V$BACH1_01</TD><TD>MSigDB lists</TD><TD>V$BACH1_01</TD><TD>251</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,LONRF3,MAP2</TD></TR>
<TR><TD>1.754e-02</TD><TD>-4.04</TD><TD>MORF_BRCA1</TD><TD>MSigDB lists</TD><TD>MORF_BRCA1</TD><TD>251</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,MAP2,SULT2B1</TD></TR>
<TR><TD>1.757e-02</TD><TD>-4.04</TD><TD>multicellular organismal macromolecule metabolic process</TD><TD>biological process</TD><TD>GO:0044259</TD><TD>88</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>1.762e-02</TD><TD>-4.04</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP</TD><TD>458</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TSC22D3,ATP2C2,AIM1</TD></TR>
<TR><TD>1.772e-02</TD><TD>-4.03</TD><TD>V$OCT1_06</TD><TD>MSigDB lists</TD><TD>V$OCT1_06</TD><TD>252</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,FGF19,MECOM</TD></TR>
<TR><TD>1.773e-02</TD><TD>-4.03</TD><TD>AACTGAC,MIR-223</TD><TD>MSigDB lists</TD><TD>AACTGAC,MIR-223</TD><TD>93</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,IGF1R</TD></TR>
<TR><TD>1.773e-02</TD><TD>-4.03</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_A</TD><TD>MSigDB lists</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_A</TD><TD>93</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FGF19,FRAS1</TD></TR>
<TR><TD>1.785e-02</TD><TD>-4.03</TD><TD>Rab GTPase binding</TD><TD>molecular function</TD><TD>GO:0017137</TD><TD>89</TD><TD>2</TD><TD>16491</TD><TD>38</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>1.791e-02</TD><TD>-4.02</TD><TD>V$AML_Q6</TD><TD>MSigDB lists</TD><TD>V$AML_Q6</TD><TD>253</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM3,NR4A1,TSC22D3</TD></TR>
<TR><TD>1.795e-02</TD><TD>-4.02</TD><TD>blood vessel development</TD><TD>biological process</TD><TD>GO:0001568</TD><TD>438</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CTGF,HSPG2,NR4A1</TD></TR>
<TR><TD>1.814e-02</TD><TD>-4.01</TD><TD>Laminin_B</TD><TD>pfam domains</TD><TD>PF00052</TD><TD>8</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>HSPG2</TD></TR>
<TR><TD>1.822e-02</TD><TD>-4.01</TD><TD>heart development</TD><TD>biological process</TD><TD>GO:0007507</TD><TD>440</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>HSPG2,PDLIM3,FGF19,MECOM</TD></TR>
<TR><TD>1.826e-02</TD><TD>-4.00</TD><TD>C4</TD><TD>smart domains</TD><TD>SM00111</TD><TD>6</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.833e-02</TD><TD>-4.00</TD><TD>regulation of interferon-gamma production</TD><TD>biological process</TD><TD>GO:0032649</TD><TD>90</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,PDE4D</TD></TR>
<TR><TD>1.835e-02</TD><TD>-4.00</TD><TD>metanephric nephron tubule morphogenesis</TD><TD>biological process</TD><TD>GO:0072282</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>1.835e-02</TD><TD>-4.00</TD><TD>L-glutamate import</TD><TD>biological process</TD><TD>GO:0051938</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.835e-02</TD><TD>-4.00</TD><TD>positive regulation of blood pressure by epinephrine-norepinephrine</TD><TD>biological process</TD><TD>GO:0003321</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>1.835e-02</TD><TD>-4.00</TD><TD>sulfate assimilation</TD><TD>biological process</TD><TD>GO:0000103</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>1.835e-02</TD><TD>-4.00</TD><TD>neutrophil homeostasis</TD><TD>biological process</TD><TD>GO:0001780</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MECOM</TD></TR>
<TR><TD>1.835e-02</TD><TD>-4.00</TD><TD>regulation of bile acid biosynthetic process</TD><TD>biological process</TD><TD>GO:0070857</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>FGF19</TD></TR>
<TR><TD>1.835e-02</TD><TD>-4.00</TD><TD>cytoskeletal anchoring at nuclear membrane</TD><TD>biological process</TD><TD>GO:0090286</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SUN3</TD></TR>
<TR><TD>1.835e-02</TD><TD>-4.00</TD><TD>primary alcohol catabolic process</TD><TD>biological process</TD><TD>GO:0034310</TD><TD>8</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.839e-02</TD><TD>-4.00</TD><TD>cellular component organization</TD><TD>biological process</TD><TD>GO:0016043</TD><TD>5336</TD><TD>19</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,HSPG2,ATP9A,COL4A5,SLC1A3,CNTNAP2,FGF19,SYTL2,COL12A1,MECOM,IGF1R,CTGF,PDLIM3,PLOD2,MAP2,TOX2,TRPC1,SUN3,PDE4D</TD></TR>
<TR><TD>1.847e-02</TD><TD>-3.99</TD><TD>V$HAND1E47_01</TD><TD>MSigDB lists</TD><TD>V$HAND1E47_01</TD><TD>256</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>LONRF3,COL12A1,MECOM</TD></TR>
<TR><TD>1.858e-02</TD><TD>-3.99</TD><TD>cell surface</TD><TD>cellular component</TD><TD>GO:0009986</TD><TD>719</TD><TD>5</TD><TD>17570</TD><TD>38</TD>
<TD>CD55,TIMP2,CNTNAP2,SLC1A3,MFI2</TD></TR>
<TR><TD>1.863e-02</TD><TD>-3.98</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>7542</TD><TD>23</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ALDH2,CD55,HSPG2,ATP9A,TSC22D3,ATP2C2,CNTNAP2,SLC1A3,COL12A1,SYTL2,GALNT3,PDLIM3,IGF1R,MAP2,FRAS1,TOX2,NETO2,SUN3,PDE4D,SOX8,MYRIP,SULT2B1</TD></TR>
<TR><TD>1.866e-02</TD><TD>-3.98</TD><TD>V$AP1_Q4</TD><TD>MSigDB lists</TD><TD>V$AP1_Q4</TD><TD>257</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,PDE4D,MAP2</TD></TR>
<TR><TD>1.870e-02</TD><TD>-3.98</TD><TD>axonogenesis</TD><TD>biological process</TD><TD>GO:0007409</TD><TD>674</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,COL4A5,IGF1R,MAP2,FGF19</TD></TR>
<TR><TD>1.872e-02</TD><TD>-3.98</TD><TD>regulation of striated muscle contraction</TD><TD>biological process</TD><TD>GO:0006942</TD><TD>91</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,CTGF</TD></TR>
<TR><TD>1.872e-02</TD><TD>-3.98</TD><TD>regulation of receptor activity</TD><TD>biological process</TD><TD>GO:0010469</TD><TD>91</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,NETO2</TD></TR>
<TR><TD>1.878e-02</TD><TD>-3.98</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.10.3860.10</TD><TD>7</TD><TD>1</TD><TD>9988</TD><TD>27</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.878e-02</TD><TD>-3.98</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.80.20.20</TD><TD>7</TD><TD>1</TD><TD>9988</TD><TD>27</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.882e-02</TD><TD>-3.97</TD><TD>GRADE_COLON_AND_RECTAL_CANCER_DN</TD><TD>MSigDB lists</TD><TD>GRADE_COLON_AND_RECTAL_CANCER_DN</TD><TD>96</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TOX2</TD></TR>
<TR><TD>1.882e-02</TD><TD>-3.97</TD><TD>PROTEINACEOUS_EXTRACELLULAR_MATRIX</TD><TD>MSigDB lists</TD><TD>PROTEINACEOUS_EXTRACELLULAR_MATRIX</TD><TD>96</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,CTGF</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>FABP7 (fatty acid binding protein 7, brain)</TD><TD>protein interactions</TD><TD>2173</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>SULT2B1 (sulfotransferase family 2B member 1)</TD><TD>protein interactions</TD><TD>6820</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>CYTH4 (cytohesin 4)</TD><TD>protein interactions</TD><TD>27128</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>RAB27B (RAB27B, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>5874</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SYTL2</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>DOK5 (docking protein 5)</TD><TD>protein interactions</TD><TD>55816</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>BCL2L10 (BCL2-like 10 (apoptosis facilitator))</TD><TD>protein interactions</TD><TD>10017</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>CNTN2 (contactin 2 (axonal))</TD><TD>protein interactions</TD><TD>6900</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>CUTA (cutA divalent cation tolerance homolog (E. coli))</TD><TD>protein interactions</TD><TD>51596</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>TTBK1 (tau tubulin kinase 1)</TD><TD>protein interactions</TD><TD>84630</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>MAP2</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>ECI1 (enoyl-CoA delta isomerase 1)</TD><TD>protein interactions</TD><TD>1632</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>ABCC3 (ATP binding cassette subfamily C member 3)</TD><TD>protein interactions</TD><TD>8714</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>ATP9A</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>CLIC3 (chloride intracellular channel 3)</TD><TD>protein interactions</TD><TD>9022</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>WISP2 (WNT1 inducible signaling pathway protein 2)</TD><TD>protein interactions</TD><TD>8839</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>GSTO2 (glutathione S-transferase omega 2)</TD><TD>protein interactions</TD><TD>119391</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>ANTXR2 (anthrax toxin receptor 2)</TD><TD>protein interactions</TD><TD>118429</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>COL4A5</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>ZMIZ1 (zinc finger, MIZ-type containing 1)</TD><TD>protein interactions</TD><TD>57178</TD><TD>9</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>1.903e-02</TD><TD>-3.96</TD><TD>IL-1_fam</TD><TD>interpro domains</TD><TD>IPR000975</TD><TD>9</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>1.903e-02</TD><TD>-3.96</TD><TD>Calx_beta</TD><TD>interpro domains</TD><TD>IPR003644</TD><TD>9</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>FRAS1</TD></TR>
<TR><TD>1.919e-02</TD><TD>-3.95</TD><TD>REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR</TD><TD>MSigDB lists</TD><TD>REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR</TD><TD>97</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>1.919e-02</TD><TD>-3.95</TD><TD>EXTRACELLULAR_MATRIX</TD><TD>MSigDB lists</TD><TD>EXTRACELLULAR_MATRIX</TD><TD>97</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,CTGF</TD></TR>
<TR><TD>1.933e-02</TD><TD>-3.95</TD><TD>MTA2 (metastasis associated 1 family member 2)</TD><TD>protein interactions</TD><TD>9219</TD><TD>101</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1,TSC22D3</TD></TR>
<TR><TD>1.947e-02</TD><TD>-3.94</TD><TD>Interleukin-1 processing</TD><TD>REACTOME pathways</TD><TD>R-HSA-448706</TD><TD>7</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>IL18</TD></TR>
<TR><TD>1.950e-02</TD><TD>-3.94</TD><TD>NUYTTEN_EZH2_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>NUYTTEN_EZH2_TARGETS_UP</TD><TD>985</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,SLC1A3,CTGF,MAP2,PLOD2,NETO2</TD></TR>
<TR><TD>1.956e-02</TD><TD>-3.93</TD><TD>GAGCCTG,MIR-484</TD><TD>MSigDB lists</TD><TD>GAGCCTG,MIR-484</TD><TD>98</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2,COL12A1</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_5</TD><TD>MSigDB lists</TD><TD>PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_5</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>BYSTRYKH_HEMATOPOIESIS_STEM_CELL_RUNX1</TD><TD>MSigDB lists</TD><TD>BYSTRYKH_HEMATOPOIESIS_STEM_CELL_RUNX1</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD55</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>SASSON_FSH_RESPONSE</TD><TD>MSigDB lists</TD><TD>SASSON_FSH_RESPONSE</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD55</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>OXFORD_RALA_AND_RALB_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>OXFORD_RALA_AND_RALB_TARGETS_DN</TD><TD>9</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>ossification</TD><TD>biological process</TD><TD>GO:0001503</TD><TD>249</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>HSPG2,SOX8,CTGF</TD></TR>
<TR><TD>1.976e-02</TD><TD>-3.92</TD><TD>putrescine degradation III</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-0</TD><TD>9</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>1.982e-02</TD><TD>-3.92</TD><TD>ATTCTTT,MIR-186</TD><TD>MSigDB lists</TD><TD>ATTCTTT,MIR-186</TD><TD>263</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,CNTNAP2,MAP2</TD></TR>
<TR><TD>1.989e-02</TD><TD>-3.92</TD><TD>NA_DICARBOXYL_SYMP_2</TD><TD>prosite domains</TD><TD>PS00714</TD><TD>7</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.989e-02</TD><TD>-3.92</TD><TD>NA_DICARBOXYL_SYMP_1</TD><TD>prosite domains</TD><TD>PS00713</TD><TD>7</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>1.994e-02</TD><TD>-3.92</TD><TD>SHAFFER_IRF4_TARGETS_IN_MYELOMA_VS_MATURE_B_LYMPHOCYTE</TD><TD>MSigDB lists</TD><TD>SHAFFER_IRF4_TARGETS_IN_MYELOMA_VS_MATURE_B_LYMPHOCYTE</TD><TD>99</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,NR4A1</TD></TR>
<TR><TD>1.994e-02</TD><TD>-3.92</TD><TD>CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP</TD><TD>MSigDB lists</TD><TD>CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP</TD><TD>99</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,TSC22D3</TD></TR>
<TR><TD>1.995e-02</TD><TD>-3.91</TD><TD>Intracranial aneurysm(PMID:22286173)</TD><TD>GWAS genes</TD><TD>Intracranial aneurysm(PMID:22286173)</TD><TD>4</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.000e-02</TD><TD>-3.91</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.90.550.10</TD><TD>81</TD><TD>2</TD><TD>9988</TD><TD>27</TD>
<TD>GALNT3,PLOD2</TD></TR>
<TR><TD>2.019e-02</TD><TD>-3.90</TD><TD>cellular response to chemical stimulus</TD><TD>biological process</TD><TD>GO:0070887</TD><TD>2460</TD><TD>11</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,ALDH2,CTGF,IGF1R,PLOD2,MAP2,NR4A1,IL18,PDE4D,SULT2B1,FGF19</TD></TR>
<TR><TD>2.025e-02</TD><TD>-3.90</TD><TD>whole membrane</TD><TD>cellular component</TD><TD>GO:0098805</TD><TD>1942</TD><TD>9</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,CD55,IGF1R,ATP9A,TRPC1,SLC1A3,CNTNAP2,PDE4D,MYRIP</TD></TR>
<TR><TD>2.032e-02</TD><TD>-3.90</TD><TD>CROONQUIST_NRAS_VS_STROMAL_STIMULATION_DN</TD><TD>MSigDB lists</TD><TD>CROONQUIST_NRAS_VS_STROMAL_STIMULATION_DN</TD><TD>100</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,TSC22D3</TD></TR>
<TR><TD>2.038e-02</TD><TD>-3.89</TD><TD>Calx-beta</TD><TD>pfam domains</TD><TD>PF03160</TD><TD>9</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>FRAS1</TD></TR>
<TR><TD>2.038e-02</TD><TD>-3.89</TD><TD>IL1</TD><TD>pfam domains</TD><TD>PF00340</TD><TD>9</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>2.038e-02</TD><TD>-3.89</TD><TD>Hydrolase</TD><TD>pfam domains</TD><TD>PF00702</TD><TD>9</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>2.040e-02</TD><TD>-3.89</TD><TD>skin-extremity-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-extremity-malignant_melanoma</TD><TD>1967</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>PDLIM3,HSPG2,ATP2C2,COL4A5,FAM198B,CNTNAP2,FGF19,COL12A1,MECOM</TD></TR>
<TR><TD>2.041e-02</TD><TD>-3.89</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma</TD><TD>1322</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,IGF1R,FRAS1,ATP9A,COL12A1,SYTL2,MECOM</TD></TR>
<TR><TD>2.041e-02</TD><TD>-3.89</TD><TD>plasma_cell_myeloma</TD><TD>COSMIC cancer mutations</TD><TD>plasma_cell_myeloma</TD><TD>1322</TD><TD>7</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,IGF1R,FRAS1,ATP9A,COL12A1,SYTL2,MECOM</TD></TR>
<TR><TD>2.041e-02</TD><TD>-3.89</TD><TD>MEISSNER_NPC_HCP_WITH_H3K4ME2</TD><TD>MSigDB lists</TD><TD>MEISSNER_NPC_HCP_WITH_H3K4ME2</TD><TD>479</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,ATP9A,TSC22D3,COL12A1</TD></TR>
<TR><TD>2.042e-02</TD><TD>-3.89</TD><TD>FAF1 (Fas (TNFRSF6) associated factor 1)</TD><TD>protein interactions</TD><TD>11124</TD><TD>104</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>PLOD2,NR4A1</TD></TR>
<TR><TD>2.042e-02</TD><TD>-3.89</TD><TD>KEGG_MAPK_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>KEGG_MAPK_SIGNALING_PATHWAY</TD><TD>266</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1,FGF19,MECOM</TD></TR>
<TR><TD>2.042e-02</TD><TD>-3.89</TD><TD>EDTRNSPORT</TD><TD>prints domains</TD><TD>PR00173</TD><TD>7</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>2.046e-02</TD><TD>-3.89</TD><TD>extremity</TD><TD>COSMIC cancer mutations</TD><TD>extremity</TD><TD>1968</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>PDLIM3,HSPG2,ATP2C2,COL4A5,FAM198B,CNTNAP2,FGF19,COL12A1,MECOM</TD></TR>
<TR><TD>2.055e-02</TD><TD>-3.88</TD><TD>insulin-like growth factor I binding</TD><TD>molecular function</TD><TD>GO:0031994</TD><TD>9</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.055e-02</TD><TD>-3.88</TD><TD>calcium-transporting ATPase activity</TD><TD>molecular function</TD><TD>GO:0005388</TD><TD>9</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>2.057e-02</TD><TD>-3.88</TD><TD>membrane raft</TD><TD>cellular component</TD><TD>GO:0045121</TD><TD>271</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>TRPC1,CD55,IGF1R</TD></TR>
<TR><TD>2.062e-02</TD><TD>-3.88</TD><TD>regulation of bile acid metabolic process</TD><TD>biological process</TD><TD>GO:1904251</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>FGF19</TD></TR>
<TR><TD>2.062e-02</TD><TD>-3.88</TD><TD>chemokine production</TD><TD>biological process</TD><TD>GO:0032602</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>2.062e-02</TD><TD>-3.88</TD><TD>aspartate transport</TD><TD>biological process</TD><TD>GO:0015810</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>2.062e-02</TD><TD>-3.88</TD><TD>regulation of cell communication by electrical coupling involved in cardiac conduction</TD><TD>biological process</TD><TD>GO:1901844</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.062e-02</TD><TD>-3.88</TD><TD>regulation of G0 to G1 transition</TD><TD>biological process</TD><TD>GO:0070316</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>2.062e-02</TD><TD>-3.88</TD><TD>regulation of relaxation of muscle</TD><TD>biological process</TD><TD>GO:1901077</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.062e-02</TD><TD>-3.88</TD><TD>regulation of systemic arterial blood pressure by norepinephrine-epinephrine</TD><TD>biological process</TD><TD>GO:0001993</TD><TD>9</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.070e-02</TD><TD>-3.88</TD><TD>TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA</TD><TD>MSigDB lists</TD><TD>TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA</TD><TD>101</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FRAS1,NETO2</TD></TR>
<TR><TD>2.077e-02</TD><TD>-3.87</TD><TD>membrane microdomain</TD><TD>cellular component</TD><TD>GO:0098857</TD><TD>272</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>TRPC1,CD55,IGF1R</TD></TR>
<TR><TD>2.079e-02</TD><TD>-3.87</TD><TD>bone-tibia-other-chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-other-chondroblastoma</TD><TD>104</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>CTGF,IGF1R</TD></TR>
<TR><TD>2.079e-02</TD><TD>-3.87</TD><TD>PDIA3 (protein disulfide isomerase family A member 3)</TD><TD>protein interactions</TD><TD>2923</TD><TD>105</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2,MFI2</TD></TR>
<TR><TD>2.083e-02</TD><TD>-3.87</TD><TD>CACTGCC,MIR-34A,MIR-34C,MIR-449</TD><TD>MSigDB lists</TD><TD>CACTGCC,MIR-34A,MIR-34C,MIR-449</TD><TD>268</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CNTNAP2,MYRIP,COL12A1</TD></TR>
<TR><TD>2.083e-02</TD><TD>-3.87</TD><TD>MODULE_49</TD><TD>MSigDB lists</TD><TD>MODULE_49</TD><TD>268</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,CNTNAP2,FRAS1</TD></TR>
<TR><TD>2.086e-02</TD><TD>-3.87</TD><TD>pigment granule</TD><TD>cellular component</TD><TD>GO:0048770</TD><TD>103</TD><TD>2</TD><TD>17570</TD><TD>38</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>2.086e-02</TD><TD>-3.87</TD><TD>melanosome</TD><TD>cellular component</TD><TD>GO:0042470</TD><TD>103</TD><TD>2</TD><TD>17570</TD><TD>38</TD>
<TD>MYRIP,SYTL2</TD></TR>
<TR><TD>2.097e-02</TD><TD>-3.86</TD><TD>Transmembrane transport of small molecules</TD><TD>REACTOME pathways</TD><TD>R-HSA-382551</TD><TD>586</TD><TD>5</TD><TD>8202</TD><TD>23</TD>
<TD>TRPC1,SLC1A3,ATP9A,TSC22D3,ATP2C2</TD></TR>
<TR><TD>2.101e-02</TD><TD>-3.86</TD><TD>MAN2A1 (mannosidase, alpha, class 2A, member 1)</TD><TD>protein interactions</TD><TD>4124</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>2.101e-02</TD><TD>-3.86</TD><TD>FAM184A (family with sequence similarity 184, member A)</TD><TD>protein interactions</TD><TD>79632</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>2.101e-02</TD><TD>-3.86</TD><TD>HPCAL4 (hippocalcin like 4)</TD><TD>protein interactions</TD><TD>51440</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>2.101e-02</TD><TD>-3.86</TD><TD>NACAD (NAC alpha domain containing)</TD><TD>protein interactions</TD><TD>23148</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.101e-02</TD><TD>-3.86</TD><TD>AKAP6 (A kinase (PRKA) anchor protein 6)</TD><TD>protein interactions</TD><TD>9472</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.101e-02</TD><TD>-3.86</TD><TD>ZPBP2 (zona pellucida binding protein 2)</TD><TD>protein interactions</TD><TD>124626</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>FRAS1</TD></TR>
<TR><TD>2.101e-02</TD><TD>-3.86</TD><TD>HSDL2 (hydroxysteroid dehydrogenase like 2)</TD><TD>protein interactions</TD><TD>84263</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>2.101e-02</TD><TD>-3.86</TD><TD>GNG11 (guanine nucleotide binding protein (G protein), gamma 11)</TD><TD>protein interactions</TD><TD>2791</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>2.101e-02</TD><TD>-3.86</TD><TD>TKTL2 (transketolase-like 2)</TD><TD>protein interactions</TD><TD>84076</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>2.101e-02</TD><TD>-3.86</TD><TD>DLX5 (distal-less homeobox 5)</TD><TD>protein interactions</TD><TD>1749</TD><TD>10</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SOX8</TD></TR>
<TR><TD>2.105e-02</TD><TD>-3.86</TD><TD>ECM-receptor interaction</TD><TD>KEGG pathways</TD><TD>hsa04512</TD><TD>87</TD><TD>2</TD><TD>6908</TD><TD>18</TD>
<TD>COL4A5,HSPG2</TD></TR>
<TR><TD>2.105e-02</TD><TD>-3.86</TD><TD>ECM-receptor interaction</TD><TD>KEGG pathways</TD><TD>ko04512</TD><TD>87</TD><TD>2</TD><TD>6908</TD><TD>18</TD>
<TD>COL4A5,HSPG2</TD></TR>
<TR><TD>2.116e-02</TD><TD>-3.86</TD><TD>RAE1 (ribonucleic acid export 1)</TD><TD>protein interactions</TD><TD>8480</TD><TD>106</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2,MAP2</TD></TR>
<TR><TD>2.116e-02</TD><TD>-3.86</TD><TD>NCOA1 (nuclear receptor coactivator 1)</TD><TD>protein interactions</TD><TD>8648</TD><TD>106</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1,SYTL2</TD></TR>
<TR><TD>2.128e-02</TD><TD>-3.85</TD><TD>LamB</TD><TD>smart domains</TD><TD>SM00281</TD><TD>7</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>HSPG2</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>Sulfate/Sulfite Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00041</TD><TD>7</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>Ethanol Degradation</TD><TD>SMPDB pathways</TD><TD>SMP00449</TD><TD>7</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.134e-02</TD><TD>-3.85</TD><TD>Sulfite oxidase deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00532</TD><TD>7</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>2.138e-02</TD><TD>-3.85</TD><TD>vasculature development</TD><TD>biological process</TD><TD>GO:0001944</TD><TD>462</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CTGF,HSPG2,NR4A1</TD></TR>
<TR><TD>2.140e-02</TD><TD>-3.84</TD><TD>negative regulation of cellular protein metabolic process</TD><TD>biological process</TD><TD>GO:0032269</TD><TD>957</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,TIMP2,PDE4D,IGF1R,SYTL2,MECOM</TD></TR>
<TR><TD>2.142e-02</TD><TD>-3.84</TD><TD>exocytic vesicle</TD><TD>cellular component</TD><TD>GO:0070382</TD><TD>10</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>SYTL2</TD></TR>
<TR><TD>2.142e-02</TD><TD>-3.84</TD><TD>juxtaparanode region of axon</TD><TD>cellular component</TD><TD>GO:0044224</TD><TD>10</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.142e-02</TD><TD>-3.84</TD><TD>dense core granule</TD><TD>cellular component</TD><TD>GO:0031045</TD><TD>10</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>MYRIP</TD></TR>
<TR><TD>2.144e-02</TD><TD>-3.84</TD><TD>MORF_NOS2A</TD><TD>MSigDB lists</TD><TD>MORF_NOS2A</TD><TD>271</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,MAP2,SULT2B1</TD></TR>
<TR><TD>2.147e-02</TD><TD>-3.84</TD><TD>LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT</TD><TD>MSigDB lists</TD><TD>LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT</TD><TD>103</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,SYTL2</TD></TR>
<TR><TD>2.147e-02</TD><TD>-3.84</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN</TD><TD>MSigDB lists</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN</TD><TD>103</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PLOD2,SYTL2</TD></TR>
<TR><TD>2.147e-02</TD><TD>-3.84</TD><TD>AMBROSINI_FLAVOPIRIDOL_TREATMENT_TP53</TD><TD>MSigDB lists</TD><TD>AMBROSINI_FLAVOPIRIDOL_TREATMENT_TP53</TD><TD>103</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,CTGF</TD></TR>
<TR><TD>2.153e-02</TD><TD>-3.84</TD><TD>axon development</TD><TD>biological process</TD><TD>GO:0061564</TD><TD>699</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,COL4A5,IGF1R,MAP2,FGF19</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>OXIDOREDUCTASE_ACTIVITY_GO_0016706</TD><TD>MSigDB lists</TD><TD>OXIDOREDUCTASE_ACTIVITY_GO_0016706</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>REACTOME_ETHANOL_OXIDATION</TD><TD>MSigDB lists</TD><TD>REACTOME_ETHANOL_OXIDATION</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>MCCABE_HOXC6_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>MCCABE_HOXC6_TARGETS_UP</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>2.175e-02</TD><TD>-3.83</TD><TD>KEGG_LIMONENE_AND_PINENE_DEGRADATION</TD><TD>MSigDB lists</TD><TD>KEGG_LIMONENE_AND_PINENE_DEGRADATION</TD><TD>10</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.178e-02</TD><TD>-3.83</TD><TD>apical plasma membrane</TD><TD>cellular component</TD><TD>GO:0016324</TD><TD>277</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,PDE4D,MYRIP</TD></TR>
<TR><TD>2.183e-02</TD><TD>-3.82</TD><TD>MODULE_69</TD><TD>MSigDB lists</TD><TD>MODULE_69</TD><TD>489</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,AMOTL2,PDE4D,TSC22D3</TD></TR>
<TR><TD>2.188e-02</TD><TD>-3.82</TD><TD>ONKEN_UVEAL_MELANOMA_UP</TD><TD>MSigDB lists</TD><TD>ONKEN_UVEAL_MELANOMA_UP</TD><TD>738</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,TIMP2,CD55,ATP9A,NETO2</TD></TR>
<TR><TD>2.194e-02</TD><TD>-3.82</TD><TD>noradrenaline and adrenaline degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-6342</TD><TD>10</TD><TD>1</TD><TD>907</TD><TD>2</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.197e-02</TD><TD>-3.82</TD><TD>Protein digestion and absorption</TD><TD>KEGG pathways</TD><TD>hsa04974</TD><TD>89</TD><TD>2</TD><TD>6908</TD><TD>18</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>2.197e-02</TD><TD>-3.82</TD><TD>Protein digestion and absorption</TD><TD>KEGG pathways</TD><TD>ko04974</TD><TD>89</TD><TD>2</TD><TD>6908</TD><TD>18</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>2.221e-02</TD><TD>-3.81</TD><TD>amino acid binding</TD><TD>molecular function</TD><TD>GO:0016597</TD><TD>100</TD><TD>2</TD><TD>16491</TD><TD>38</TD>
<TD>SLC1A3,SYTL2</TD></TR>
<TR><TD>2.222e-02</TD><TD>-3.81</TD><TD>Neurotransmitter Clearance In The Synaptic Cleft</TD><TD>REACTOME pathways</TD><TD>R-HSA-112311</TD><TD>8</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.226e-02</TD><TD>-3.80</TD><TD>BRUECKNER_TARGETS_OF_MIRLET7A3_UP</TD><TD>MSigDB lists</TD><TD>BRUECKNER_TARGETS_OF_MIRLET7A3_UP</TD><TD>105</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,SULT2B1</TD></TR>
<TR><TD>2.229e-02</TD><TD>-3.80</TD><TD>KRTAP10-5 (keratin associated protein 10-5)</TD><TD>protein interactions</TD><TD>386680</TD><TD>109</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2,NR4A1</TD></TR>
<TR><TD>2.229e-02</TD><TD>-3.80</TD><TD>ion transport</TD><TD>biological process</TD><TD>GO:0006811</TD><TD>1245</TD><TD>7</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,SLC1A3,CTGF,MFI2,TSC22D3,ATP9A,ATP2C2</TD></TR>
<TR><TD>2.261e-02</TD><TD>-3.79</TD><TD>divalent metal ion transport</TD><TD>biological process</TD><TD>GO:0070838</TD><TD>263</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CTGF,ATP2C2</TD></TR>
<TR><TD>2.262e-02</TD><TD>-3.79</TD><TD>human chr7p12.3</TD><TD>chromosome location</TD><TD>human chr7p12.3</TD><TD>15</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>SUN3</TD></TR>
<TR><TD>2.266e-02</TD><TD>-3.79</TD><TD>GROSS_HYPOXIA_VIA_HIF1A_DN</TD><TD>MSigDB lists</TD><TD>GROSS_HYPOXIA_VIA_HIF1A_DN</TD><TD>106</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,CTGF</TD></TR>
<TR><TD>2.266e-02</TD><TD>-3.79</TD><TD>SERVITJA_ISLET_HNF1A_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>SERVITJA_ISLET_HNF1A_TARGETS_DN</TD><TD>106</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MFI2,IGF1R</TD></TR>
<TR><TD>2.270e-02</TD><TD>-3.79</TD><TD>LAMININ_IVA</TD><TD>prosite domains</TD><TD>PS51115</TD><TD>8</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>2.280e-02</TD><TD>-3.78</TD><TD>localization</TD><TD>biological process</TD><TD>GO:0051179</TD><TD>4664</TD><TD>17</TD><TD>16441</TD><TD>38</TD>
<TD>MFI2,HSPG2,TSC22D3,ATP9A,NR4A1,ATP2C2,SLC1A3,CNTNAP2,FGF19,SYTL2,CTGF,FRAS1,TRPC1,SUN3,PDE4D,SOX8,MYRIP</TD></TR>
<TR><TD>2.281e-02</TD><TD>-3.78</TD><TD>sodium:dicarboxylate symporter activity</TD><TD>molecular function</TD><TD>GO:0017153</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>2.281e-02</TD><TD>-3.78</TD><TD>inositol 1,4,5 trisphosphate binding</TD><TD>molecular function</TD><TD>GO:0070679</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>TRPC1</TD></TR>
<TR><TD>2.281e-02</TD><TD>-3.78</TD><TD>dystroglycan binding</TD><TD>molecular function</TD><TD>GO:0002162</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>MAP2</TD></TR>
<TR><TD>2.281e-02</TD><TD>-3.78</TD><TD>ATP-dependent peptidase activity</TD><TD>molecular function</TD><TD>GO:0004176</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>LONRF3</TD></TR>
<TR><TD>2.281e-02</TD><TD>-3.78</TD><TD>3',5'-cyclic-AMP phosphodiesterase activity</TD><TD>molecular function</TD><TD>GO:0004115</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.281e-02</TD><TD>-3.78</TD><TD>glutamate binding</TD><TD>molecular function</TD><TD>GO:0016595</TD><TD>10</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>regulation of mucus secretion</TD><TD>biological process</TD><TD>GO:0070255</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SYTL2</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>positive regulation of osteoblast proliferation</TD><TD>biological process</TD><TD>GO:0033690</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>regulation of plasminogen activation</TD><TD>biological process</TD><TD>GO:0010755</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MFI2</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>positive regulation of striated muscle contraction</TD><TD>biological process</TD><TD>GO:0045989</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>C4-dicarboxylate transport</TD><TD>biological process</TD><TD>GO:0015740</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>metanephric tubule morphogenesis</TD><TD>biological process</TD><TD>GO:0072173</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>endothelial cell chemotaxis</TD><TD>biological process</TD><TD>GO:0035767</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>regulation of steroid hormone biosynthetic process</TD><TD>biological process</TD><TD>GO:0090030</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>positive regulation of hormone metabolic process</TD><TD>biological process</TD><TD>GO:0032352</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>negative regulation of complement activation</TD><TD>biological process</TD><TD>GO:0045916</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CD55</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>exocrine pancreas development</TD><TD>biological process</TD><TD>GO:0031017</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.288e-02</TD><TD>-3.78</TD><TD>chondrocyte proliferation</TD><TD>biological process</TD><TD>GO:0035988</TD><TD>10</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>2.292e-02</TD><TD>-3.78</TD><TD>acral_lentiginous</TD><TD>COSMIC cancer mutations</TD><TD>acral_lentiginous</TD><TD>768</TD><TD>5</TD><TD>17775</TD><TD>38</TD>
<TD>ALDH2,CNTNAP2,HSPG2,MAP2,COL12A1</TD></TR>
<TR><TD>2.293e-02</TD><TD>-3.78</TD><TD>GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN</TD><TD>MSigDB lists</TD><TD>GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN</TD><TD>1022</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,COL4A5,SLC1A3,TIMP2,PDE4D,SOX8</TD></TR>
<TR><TD>2.298e-02</TD><TD>-3.77</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>2007</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>PDLIM3,MAP2,NR4A1,AIM1,NETO2,SUN3,COL4A5,CNTNAP2,SYTL2</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>JAM2 (junctional adhesion molecule 2)</TD><TD>protein interactions</TD><TD>58494</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SOX8</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>ENDOV (endonuclease V)</TD><TD>protein interactions</TD><TD>284131</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>MTMR6 (myotubularin related protein 6)</TD><TD>protein interactions</TD><TD>9107</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>ITGB1BP2 (integrin beta 1 binding protein (melusin) 2)</TD><TD>protein interactions</TD><TD>26548</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>FABP3 (fatty acid binding protein 3, muscle and heart)</TD><TD>protein interactions</TD><TD>2170</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>NFIL3 (nuclear factor, interleukin 3 regulated)</TD><TD>protein interactions</TD><TD>4783</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>2.308e-02</TD><TD>-3.77</TD><TD>CDKN2D (cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4))</TD><TD>protein interactions</TD><TD>1032</TD><TD>11</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.311e-02</TD><TD>-3.77</TD><TD>larynx</TD><TD>COSMIC cancer mutations</TD><TD>larynx</TD><TD>2009</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>PDLIM3,MAP2,NR4A1,AIM1,NETO2,SUN3,COL4A5,CNTNAP2,SYTL2</TD></TR>
<TR><TD>2.312e-02</TD><TD>-3.77</TD><TD>anatomical structure formation involved in morphogenesis</TD><TD>biological process</TD><TD>GO:0048646</TD><TD>974</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,SOX8,CTGF,HSPG2,NR4A1,COL12A1</TD></TR>
<TR><TD>2.318e-02</TD><TD>-3.76</TD><TD>multicellular organismal metabolic process</TD><TD>biological process</TD><TD>GO:0044236</TD><TD>102</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>COL4A5,COL12A1</TD></TR>
<TR><TD>2.318e-02</TD><TD>-3.76</TD><TD>fat cell differentiation</TD><TD>biological process</TD><TD>GO:0045444</TD><TD>102</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,NR4A1</TD></TR>
<TR><TD>2.321e-02</TD><TD>-3.76</TD><TD>TRP_channel</TD><TD>interpro domains</TD><TD>IPR004729</TD><TD>11</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TRPC1</TD></TR>
<TR><TD>2.321e-02</TD><TD>-3.76</TD><TD>Insulin_GF-bd_Cys-rich_CS</TD><TD>interpro domains</TD><TD>IPR017891</TD><TD>11</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>2.321e-02</TD><TD>-3.76</TD><TD>SM22_calponin</TD><TD>interpro domains</TD><TD>IPR003096</TD><TD>11</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>2.321e-02</TD><TD>-3.76</TD><TD>Tyr_kinase_rcpt_2_CS</TD><TD>interpro domains</TD><TD>IPR002011</TD><TD>11</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.321e-02</TD><TD>-3.76</TD><TD>prostate</TD><TD>COSMIC cancer mutations</TD><TD>prostate</TD><TD>14584</TD><TD>36</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,ATP9A,TSC22D3,ATP2C2,COL4A5,CNTNAP2,SLC1A3,FAM198B,FGF19,SYTL2,MECOM,ZNF432,CTGF,IGF1R,FRAS1,TOX2,AIM1,TRPC1,SUN3,TAGLN2,PDE4D,MYRIP,SULT2B1,AMOTL2,CD55,ALDH2,MFI2,ASCL5,NR4A1,COL12A1,GALNT3,PDLIM3,PLOD2,MAP2,NETO2,SOX8</TD></TR>
<TR><TD>2.329e-02</TD><TD>-3.76</TD><TD>divalent inorganic cation transport</TD><TD>biological process</TD><TD>GO:0072511</TD><TD>266</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CTGF,ATP2C2</TD></TR>
<TR><TD>2.330e-02</TD><TD>-3.76</TD><TD>BLALOCK_ALZHEIMERS_DISEASE_UP</TD><TD>MSigDB lists</TD><TD>BLALOCK_ALZHEIMERS_DISEASE_UP</TD><TD>1631</TD><TD>8</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,IGF1R,PDLIM3,PLOD2,AIM1,COL4A5,IL18,PDE4D</TD></TR>
<TR><TD>2.332e-02</TD><TD>-3.76</TD><TD>ENK_UV_RESPONSE_EPIDERMIS_DN</TD><TD>MSigDB lists</TD><TD>ENK_UV_RESPONSE_EPIDERMIS_DN</TD><TD>499</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,CD55,ALDH2,SULT2B1</TD></TR>
<TR><TD>2.332e-02</TD><TD>-3.76</TD><TD>PI3K/AKT Signaling in Cancer</TD><TD>REACTOME pathways</TD><TD>R-HSA-2219528</TD><TD>85</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>2.334e-02</TD><TD>-3.76</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4</TD><TD>MSigDB lists</TD><TD>CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4</TD><TD>280</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,IGF1R,PDLIM3</TD></TR>
<TR><TD>2.345e-02</TD><TD>-3.75</TD><TD>SMARCE1 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1)</TD><TD>protein interactions</TD><TD>6605</TD><TD>112</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2,NR4A1</TD></TR>
<TR><TD>2.345e-02</TD><TD>-3.75</TD><TD>PHB (prohibitin)</TD><TD>protein interactions</TD><TD>5245</TD><TD>112</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2,LONRF3</TD></TR>
<TR><TD>2.346e-02</TD><TD>-3.75</TD><TD>LABBE_WNT3A_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>LABBE_WNT3A_TARGETS_UP</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,CTGF</TD></TR>
<TR><TD>2.346e-02</TD><TD>-3.75</TD><TD>REACTOME_SIGNALING_BY_FGFR</TD><TD>MSigDB lists</TD><TD>REACTOME_SIGNALING_BY_FGFR</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>2.346e-02</TD><TD>-3.75</TD><TD>LAIHO_COLORECTAL_CANCER_SERRATED_UP</TD><TD>MSigDB lists</TD><TD>LAIHO_COLORECTAL_CANCER_SERRATED_UP</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,CTGF</TD></TR>
<TR><TD>2.346e-02</TD><TD>-3.75</TD><TD>LABBE_TARGETS_OF_TGFB1_AND_WNT3A_UP</TD><TD>MSigDB lists</TD><TD>LABBE_TARGETS_OF_TGFB1_AND_WNT3A_UP</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,MAP2</TD></TR>
<TR><TD>2.346e-02</TD><TD>-3.75</TD><TD>ZHANG_TLX_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>ZHANG_TLX_TARGETS_DN</TD><TD>108</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,NR4A1</TD></TR>
<TR><TD>2.377e-02</TD><TD>-3.74</TD><TD>MORF_MLLT10</TD><TD>MSigDB lists</TD><TD>MORF_MLLT10</TD><TD>282</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,MAP2,SULT2B1</TD></TR>
<TR><TD>2.387e-02</TD><TD>-3.74</TD><TD>MODULE_180</TD><TD>MSigDB lists</TD><TD>MODULE_180</TD><TD>109</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SULT2B1,SYTL2</TD></TR>
<TR><TD>2.388e-02</TD><TD>-3.73</TD><TD>ion channel complex</TD><TD>cellular component</TD><TD>GO:0034702</TD><TD>287</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>CNTNAP2,PDE4D,NETO2</TD></TR>
<TR><TD>2.389e-02</TD><TD>-3.73</TD><TD>integrin binding</TD><TD>molecular function</TD><TD>GO:0005178</TD><TD>104</TD><TD>2</TD><TD>16491</TD><TD>38</TD>
<TD>TIMP2,CTGF</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>DORN_ADENOVIRUS_INFECTION_32HR_UP</TD><TD>MSigDB lists</TD><TD>DORN_ADENOVIRUS_INFECTION_32HR_UP</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>BIOCARTA_VITCB_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_VITCB_PATHWAY</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>INTERLEUKIN_2_PRODUCTION</TD><TD>MSigDB lists</TD><TD>INTERLEUKIN_2_PRODUCTION</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>2.390e-02</TD><TD>-3.73</TD><TD>MOROSETTI_FACIOSCAPULOHUMERAL_MUSCULAR_DISTROPHY_DN</TD><TD>MSigDB lists</TD><TD>MOROSETTI_FACIOSCAPULOHUMERAL_MUSCULAR_DISTROPHY_DN</TD><TD>11</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM3</TD></TR>
<TR><TD>2.393e-02</TD><TD>-3.73</TD><TD>cellular component organization or biogenesis</TD><TD>biological process</TD><TD>GO:0071840</TD><TD>5468</TD><TD>19</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,HSPG2,ATP9A,COL4A5,SLC1A3,CNTNAP2,FGF19,SYTL2,COL12A1,MECOM,IGF1R,CTGF,PDLIM3,PLOD2,MAP2,TOX2,TRPC1,SUN3,PDE4D</TD></TR>
<TR><TD>2.411e-02</TD><TD>-3.72</TD><TD>TAATTA_V$CHX10_01</TD><TD>MSigDB lists</TD><TD>TAATTA_V$CHX10_01</TD><TD>757</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,FGF19,TSC22D3,COL12A1,MECOM</TD></TR>
<TR><TD>2.427e-02</TD><TD>-3.72</TD><TD>V$COMP1_01</TD><TD>MSigDB lists</TD><TD>V$COMP1_01</TD><TD>110</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,SLC1A3</TD></TR>
<TR><TD>2.428e-02</TD><TD>-3.72</TD><TD>Calx_beta</TD><TD>smart domains</TD><TD>SM00237</TD><TD>8</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>FRAS1</TD></TR>
<TR><TD>2.432e-02</TD><TD>-3.72</TD><TD>ion channel binding</TD><TD>molecular function</TD><TD>GO:0044325</TD><TD>105</TD><TD>2</TD><TD>16491</TD><TD>38</TD>
<TD>TRPC1,PDE4D</TD></TR>
<TR><TD>2.436e-02</TD><TD>-3.71</TD><TD>Oxidation of Branched Chain Fatty Acids</TD><TD>SMPDB pathways</TD><TD>SMP00030</TD><TD>8</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.443e-02</TD><TD>-3.71</TD><TD>MORF_ARL3</TD><TD>MSigDB lists</TD><TD>MORF_ARL3</TD><TD>285</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,MAP2,SULT2B1</TD></TR>
<TR><TD>2.444e-02</TD><TD>-3.71</TD><TD>renal system development</TD><TD>biological process</TD><TD>GO:0072001</TD><TD>271</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,FRAS1,MECOM</TD></TR>
<TR><TD>2.452e-02</TD><TD>-3.71</TD><TD>metal ion homeostasis</TD><TD>biological process</TD><TD>GO:0055065</TD><TD>482</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CD55,MFI2,ATP2C2</TD></TR>
<TR><TD>2.463e-02</TD><TD>-3.70</TD><TD>HSPE1 (heat shock 10kDa protein 1)</TD><TD>protein interactions</TD><TD>3336</TD><TD>115</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2,ALDH2</TD></TR>
<TR><TD>2.469e-02</TD><TD>-3.70</TD><TD>CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP</TD><TD>MSigDB lists</TD><TD>CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP</TD><TD>111</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TSC22D3,AIM1</TD></TR>
<TR><TD>2.486e-02</TD><TD>-3.69</TD><TD>Laminin_G_1</TD><TD>pfam domains</TD><TD>PF00054</TD><TD>11</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>HSPG2</TD></TR>
<TR><TD>2.488e-02</TD><TD>-3.69</TD><TD>GTGCCAA,MIR-96</TD><TD>MSigDB lists</TD><TD>GTGCCAA,MIR-96</TD><TD>287</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PLOD2,MYRIP,TSC22D3</TD></TR>
<TR><TD>2.488e-02</TD><TD>-3.69</TD><TD>Alzheimer&#39;s disease(PMID:22159054)</TD><TD>GWAS genes</TD><TD>Alzheimer&#39;s disease(PMID:22159054)</TD><TD>5</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.488e-02</TD><TD>-3.69</TD><TD>Immune response to smallpox vaccine (IL-6)(PMID:22610502)</TD><TD>GWAS genes</TD><TD>Immune response to smallpox vaccine (IL-6)(PMID:22610502)</TD><TD>5</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.488e-02</TD><TD>-3.69</TD><TD>Diastolic blood pressure(PMID:19430483)</TD><TD>GWAS genes</TD><TD>Diastolic blood pressure(PMID:19430483)</TD><TD>5</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.488e-02</TD><TD>-3.69</TD><TD>Hair morphology(PMID:19896111)</TD><TD>GWAS genes</TD><TD>Hair morphology(PMID:19896111)</TD><TD>5</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>FRAS1</TD></TR>
<TR><TD>2.488e-02</TD><TD>-3.69</TD><TD>Dupuytren&#39;s disease(PMID:21732829)</TD><TD>GWAS genes</TD><TD>Dupuytren&#39;s disease(PMID:21732829)</TD><TD>5</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>TIMP2</TD></TR>
<TR><TD>2.495e-02</TD><TD>-3.69</TD><TD>carbohydrate binding</TD><TD>molecular function</TD><TD>GO:0030246</TD><TD>274</TD><TD>3</TD><TD>16491</TD><TD>38</TD>
<TD>GALNT3,PLOD2,AIM1</TD></TR>
<TR><TD>2.497e-02</TD><TD>-3.69</TD><TD>SHC-related events triggered by IGF1R</TD><TD>REACTOME pathways</TD><TD>R-HSA-2428933</TD><TD>9</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.497e-02</TD><TD>-3.69</TD><TD>AKT phosphorylates targets in the nucleus</TD><TD>REACTOME pathways</TD><TD>R-HSA-198693</TD><TD>9</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.506e-02</TD><TD>-3.69</TD><TD>insulin receptor substrate binding</TD><TD>molecular function</TD><TD>GO:0043560</TD><TD>11</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.506e-02</TD><TD>-3.69</TD><TD>store-operated calcium channel activity</TD><TD>molecular function</TD><TD>GO:0015279</TD><TD>11</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>TRPC1</TD></TR>
<TR><TD>2.510e-02</TD><TD>-3.68</TD><TD>ZHANG_TLX_TARGETS_60HR_UP</TD><TD>MSigDB lists</TD><TD>ZHANG_TLX_TARGETS_60HR_UP</TD><TD>288</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,HSPG2,NR4A1</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>negative regulation of humoral immune response</TD><TD>biological process</TD><TD>GO:0002921</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CD55</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>cellular response to epinephrine stimulus</TD><TD>biological process</TD><TD>GO:0071872</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>negative regulation of substrate adhesion-dependent cell spreading</TD><TD>biological process</TD><TD>GO:1900025</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MFI2</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>negative regulation of protein activation cascade</TD><TD>biological process</TD><TD>GO:2000258</TD><TD>11</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CD55</TD></TR>
<TR><TD>2.516e-02</TD><TD>-3.68</TD><TD>BBS10 (Bardet-Biedl syndrome 10)</TD><TD>protein interactions</TD><TD>79738</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.516e-02</TD><TD>-3.68</TD><TD>SPDEF (SAM pointed domain containing ETS transcription factor)</TD><TD>protein interactions</TD><TD>25803</TD><TD>12</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.542e-02</TD><TD>-3.67</TD><TD>EGF</TD><TD>smart domains</TD><TD>SM00181</TD><TD>209</TD><TD>3</TD><TD>9131</TD><TD>28</TD>
<TD>CNTNAP2,HSPG2,FRAS1</TD></TR>
<TR><TD>2.552e-02</TD><TD>-3.67</TD><TD>LEE_NEURAL_CREST_STEM_CELL_DN</TD><TD>MSigDB lists</TD><TD>LEE_NEURAL_CREST_STEM_CELL_DN</TD><TD>113</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,CNTNAP2</TD></TR>
<TR><TD>2.554e-02</TD><TD>-3.67</TD><TD>thyroid-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>thyroid-carcinoma</TD><TD>4286</TD><TD>15</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ZNF432,IGF1R,PDLIM3,MAP2,FRAS1,TSC22D3,ATP2C2,AIM1,NETO2,COL4A5,PDE4D,MYRIP,COL12A1,SYTL2</TD></TR>
<TR><TD>2.560e-02</TD><TD>-3.67</TD><TD>human chr4q32.1</TD><TD>chromosome location</TD><TD>human chr4q32.1</TD><TD>17</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>FAM198B</TD></TR>
<TR><TD>2.560e-02</TD><TD>-3.67</TD><TD>human chr3q26.2</TD><TD>chromosome location</TD><TD>human chr3q26.2</TD><TD>17</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.590e-02</TD><TD>-3.65</TD><TD>response to chemical</TD><TD>biological process</TD><TD>GO:0042221</TD><TD>3971</TD><TD>15</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,ALDH2,CTGF,IGF1R,PLOD2,MAP2,NR4A1,TOX2,TRPC1,COL4A5,IL18,PDE4D,SLC1A3,SULT2B1,FGF19</TD></TR>
<TR><TD>2.597e-02</TD><TD>-3.65</TD><TD>MODULE_11</TD><TD>MSigDB lists</TD><TD>MODULE_11</TD><TD>516</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CNTNAP2,SLC1A3,MAP2,ATP9A</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>INTERFERON_GAMMA_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>INTERFERON_GAMMA_BIOSYNTHETIC_PROCESS</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>DORN_ADENOVIRUS_INFECTION_24HR_UP</TD><TD>MSigDB lists</TD><TD>DORN_ADENOVIRUS_INFECTION_24HR_UP</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>POSITIVE_REGULATION_OF_T_CELL_PROLIFERATION</TD><TD>MSigDB lists</TD><TD>POSITIVE_REGULATION_OF_T_CELL_PROLIFERATION</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>REACTOME_FGFR4_LIGAND_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_FGFR4_LIGAND_BINDING_AND_ACTIVATION</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF19</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>MODULE_190</TD><TD>MSigDB lists</TD><TD>MODULE_190</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>BOYERINAS_ONCOFETAL_TARGETS_OF_LET7A1</TD><TD>MSigDB lists</TD><TD>BOYERINAS_ONCOFETAL_TARGETS_OF_LET7A1</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>ACETYLGALACTOSAMINYLTRANSFERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>ACETYLGALACTOSAMINYLTRANSFERASE_ACTIVITY</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3</TD></TR>
<TR><TD>2.605e-02</TD><TD>-3.65</TD><TD>HASINA_NOL7_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>HASINA_NOL7_TARGETS_DN</TD><TD>12</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD55</TD></TR>
<TR><TD>2.636e-02</TD><TD>-3.64</TD><TD>MORF_CD8A</TD><TD>MSigDB lists</TD><TD>MORF_CD8A</TD><TD>115</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,MAP2</TD></TR>
<TR><TD>2.638e-02</TD><TD>-3.64</TD><TD>single-organism catabolic process</TD><TD>biological process</TD><TD>GO:0044712</TD><TD>1004</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>COL4A5,PDE4D,ALDH2,SLC1A3,PLOD2,COL12A1</TD></TR>
<TR><TD>2.647e-02</TD><TD>-3.63</TD><TD>DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN</TD><TD>MSigDB lists</TD><TD>DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN</TD><TD>294</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,AIM1,SYTL2</TD></TR>
<TR><TD>2.676e-02</TD><TD>-3.62</TD><TD>BENPORATH_ES_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>BENPORATH_ES_WITH_H3K27ME3</TD><TD>1059</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,LONRF3,SOX8,COL12A1,AIM1,MECOM</TD></TR>
<TR><TD>2.679e-02</TD><TD>-3.62</TD><TD>ENK_UV_RESPONSE_KERATINOCYTE_UP</TD><TD>MSigDB lists</TD><TD>ENK_UV_RESPONSE_KERATINOCYTE_UP</TD><TD>521</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,TAGLN2,CTGF,SULT2B1</TD></TR>
<TR><TD>2.690e-02</TD><TD>-3.62</TD><TD>neuron projection morphogenesis</TD><TD>biological process</TD><TD>GO:0048812</TD><TD>741</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,COL4A5,IGF1R,MAP2,FGF19</TD></TR>
<TR><TD>2.691e-02</TD><TD>-3.62</TD><TD>MAPK signaling pathway</TD><TD>KEGG pathways</TD><TD>ko04010</TD><TD>255</TD><TD>3</TD><TD>6908</TD><TD>18</TD>
<TD>NR4A1,FGF19,MECOM</TD></TR>
<TR><TD>2.691e-02</TD><TD>-3.62</TD><TD>MAPK signaling pathway</TD><TD>KEGG pathways</TD><TD>hsa04010</TD><TD>255</TD><TD>3</TD><TD>6908</TD><TD>18</TD>
<TD>NR4A1,FGF19,MECOM</TD></TR>
<TR><TD>2.691e-02</TD><TD>-3.62</TD><TD>extracellular membrane-bounded organelle</TD><TD>cellular component</TD><TD>GO:0065010</TD><TD>2742</TD><TD>11</TD><TD>17570</TD><TD>38</TD>
<TD>GALNT3,CD55,TIMP2,ALDH2,MFI2,HSPG2,PLOD2,IL18,TAGLN2,SULT2B1,COL12A1</TD></TR>
<TR><TD>2.691e-02</TD><TD>-3.62</TD><TD>extracellular exosome</TD><TD>cellular component</TD><TD>GO:0070062</TD><TD>2742</TD><TD>11</TD><TD>17570</TD><TD>38</TD>
<TD>GALNT3,CD55,TIMP2,ALDH2,MFI2,HSPG2,PLOD2,IL18,TAGLN2,SULT2B1,COL12A1</TD></TR>
<TR><TD>2.708e-02</TD><TD>-3.61</TD><TD>human chrXq22</TD><TD>chromosome location</TD><TD>human chrXq22</TD><TD>18</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.712e-02</TD><TD>-3.61</TD><TD>adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-virilizing_syndrome_producing</TD><TD>COSMIC cancer mutations</TD><TD>adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-virilizing_syndrome_producing</TD><TD>305</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,COL12A1,SYTL2</TD></TR>
<TR><TD>2.712e-02</TD><TD>-3.61</TD><TD>secretory</TD><TD>COSMIC cancer mutations</TD><TD>secretory</TD><TD>120</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,PLOD2</TD></TR>
<TR><TD>2.712e-02</TD><TD>-3.61</TD><TD>meninges-meningioma-secretory</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-secretory</TD><TD>120</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,PLOD2</TD></TR>
<TR><TD>2.723e-02</TD><TD>-3.60</TD><TD>FGF7 (fibroblast growth factor 7)</TD><TD>protein interactions</TD><TD>2252</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>2.723e-02</TD><TD>-3.60</TD><TD>TXNDC16 (thioredoxin domain containing 16)</TD><TD>protein interactions</TD><TD>57544</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>2.723e-02</TD><TD>-3.60</TD><TD>ITPR2 (inositol 1,4,5-trisphosphate receptor, type 2)</TD><TD>protein interactions</TD><TD>3709</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TRPC1</TD></TR>
<TR><TD>2.723e-02</TD><TD>-3.60</TD><TD>ZMYM6 (zinc finger, MYM-type 6)</TD><TD>protein interactions</TD><TD>9204</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TIMP2</TD></TR>
<TR><TD>2.723e-02</TD><TD>-3.60</TD><TD>PGBD1 (piggyBac transposable element derived 1)</TD><TD>protein interactions</TD><TD>84547</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.723e-02</TD><TD>-3.60</TD><TD>CTGF (connective tissue growth factor)</TD><TD>protein interactions</TD><TD>1490</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>2.723e-02</TD><TD>-3.60</TD><TD>PVRIG (poliovirus receptor related immunoglobulin domain containing)</TD><TD>protein interactions</TD><TD>79037</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>FRAS1</TD></TR>
<TR><TD>2.723e-02</TD><TD>-3.60</TD><TD>ALDH6A1 (aldehyde dehydrogenase 6 family, member A1)</TD><TD>protein interactions</TD><TD>4329</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.723e-02</TD><TD>-3.60</TD><TD>HOXC11 (homeobox C11)</TD><TD>protein interactions</TD><TD>3227</TD><TD>13</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SOX8</TD></TR>
<TR><TD>2.724e-02</TD><TD>-3.60</TD><TD>Corticotropin-releasing hormone</TD><TD>WikiPathways</TD><TD>WP2355</TD><TD>90</TD><TD>2</TD><TD>4455</TD><TD>13</TD>
<TD>IL18,NR4A1</TD></TR>
<TR><TD>2.732e-02</TD><TD>-3.60</TD><TD>positive regulation of cell activation</TD><TD>biological process</TD><TD>GO:0050867</TD><TD>283</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55,CTGF</TD></TR>
<TR><TD>2.738e-02</TD><TD>-3.60</TD><TD>Beta-Alanine Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00007</TD><TD>9</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.738e-02</TD><TD>-3.60</TD><TD>Carnosinuria- carnosinemia</TD><TD>SMPDB pathways</TD><TD>SMP00493</TD><TD>9</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.738e-02</TD><TD>-3.60</TD><TD>GABA-Transaminase Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00351</TD><TD>9</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.738e-02</TD><TD>-3.60</TD><TD>Ureidopropionase deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00492</TD><TD>9</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.739e-02</TD><TD>-3.60</TD><TD>ethanol oxidation</TD><TD>biological process</TD><TD>GO:0006069</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>ALDH2</TD></TR>
<TR><TD>2.739e-02</TD><TD>-3.60</TD><TD>regulation of metalloenzyme activity</TD><TD>biological process</TD><TD>GO:0048552</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2</TD></TR>
<TR><TD>2.739e-02</TD><TD>-3.60</TD><TD>regulation of extracellular matrix disassembly</TD><TD>biological process</TD><TD>GO:0010715</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MFI2</TD></TR>
<TR><TD>2.739e-02</TD><TD>-3.60</TD><TD>iron ion import</TD><TD>biological process</TD><TD>GO:0097286</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MFI2</TD></TR>
<TR><TD>2.739e-02</TD><TD>-3.60</TD><TD>negative regulation of skeletal muscle tissue development</TD><TD>biological process</TD><TD>GO:0048642</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>2.739e-02</TD><TD>-3.60</TD><TD>enteric nervous system development</TD><TD>biological process</TD><TD>GO:0048484</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>2.739e-02</TD><TD>-3.60</TD><TD>ureter development</TD><TD>biological process</TD><TD>GO:0072189</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>2.739e-02</TD><TD>-3.60</TD><TD>neuronal ion channel clustering</TD><TD>biological process</TD><TD>GO:0045161</TD><TD>12</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.765e-02</TD><TD>-3.59</TD><TD>KIM_WT1_TARGETS_8HR_DN</TD><TD>MSigDB lists</TD><TD>KIM_WT1_TARGETS_8HR_DN</TD><TD>118</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,CTGF</TD></TR>
<TR><TD>2.765e-02</TD><TD>-3.59</TD><TD>V$ATF6_01</TD><TD>MSigDB lists</TD><TD>V$ATF6_01</TD><TD>118</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,NR4A1</TD></TR>
<TR><TD>2.765e-02</TD><TD>-3.59</TD><TD>REACTOME_SIGNALING_BY_PDGF</TD><TD>MSigDB lists</TD><TD>REACTOME_SIGNALING_BY_PDGF</TD><TD>118</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,NR4A1</TD></TR>
<TR><TD>2.771e-02</TD><TD>-3.59</TD><TD>Role of second messengers in netrin-1 signaling</TD><TD>REACTOME pathways</TD><TD>R-HSA-418890</TD><TD>10</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>TRPC1</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>extracellular vesicle</TD><TD>cellular component</TD><TD>GO:1903561</TD><TD>2755</TD><TD>11</TD><TD>17570</TD><TD>38</TD>
<TD>GALNT3,CD55,TIMP2,ALDH2,MFI2,HSPG2,PLOD2,IL18,TAGLN2,SULT2B1,COL12A1</TD></TR>
<TR><TD>2.778e-02</TD><TD>-3.58</TD><TD>extracellular organelle</TD><TD>cellular component</TD><TD>GO:0043230</TD><TD>2755</TD><TD>11</TD><TD>17570</TD><TD>38</TD>
<TD>GALNT3,CD55,TIMP2,ALDH2,MFI2,HSPG2,PLOD2,IL18,TAGLN2,SULT2B1,COL12A1</TD></TR>
<TR><TD>2.798e-02</TD><TD>-3.58</TD><TD>membrane-bounded vesicle</TD><TD>cellular component</TD><TD>GO:0031988</TD><TD>3503</TD><TD>13</TD><TD>17570</TD><TD>38</TD>
<TD>GALNT3,CD55,TIMP2,ALDH2,MFI2,HSPG2,PLOD2,IL18,TAGLN2,MYRIP,SULT2B1,SYTL2,COL12A1</TD></TR>
<TR><TD>2.809e-02</TD><TD>-3.57</TD><TD>lymphoid_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>lymphoid_neoplasm</TD><TD>12854</TD><TD>33</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,TSC22D3,ATP9A,ATP2C2,COL4A5,FAM198B,SLC1A3,CNTNAP2,FGF19,SYTL2,MECOM,ZNF432,CTGF,IGF1R,FRAS1,AIM1,TOX2,TRPC1,SUN3,PDE4D,MYRIP,AMOTL2,CD55,MFI2,LONRF3,NR4A1,COL12A1,GALNT3,PDLIM3,MAP2,PLOD2,NETO2,SOX8</TD></TR>
<TR><TD>2.812e-02</TD><TD>-3.57</TD><TD>MORF_ERCC4</TD><TD>MSigDB lists</TD><TD>MORF_ERCC4</TD><TD>301</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,MAP2,SULT2B1</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>3_5_CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>3_5_CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>WANG_RESPONSE_TO_PACLITAXEL_VIA_MAPK8_UP</TD><TD>MSigDB lists</TD><TD>WANG_RESPONSE_TO_PACLITAXEL_VIA_MAPK8_UP</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>HASINA_NOL7_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HASINA_NOL7_TARGETS_UP</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>LEE_SP4_THYMOCYTE</TD><TD>MSigDB lists</TD><TD>LEE_SP4_THYMOCYTE</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>EXTRINSIC_TO_PLASMA_MEMBRANE</TD><TD>MSigDB lists</TD><TD>EXTRINSIC_TO_PLASMA_MEMBRANE</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SYTL2</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>KEGG_SULFUR_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_SULFUR_METABOLISM</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>chr6q12</TD><TD>MSigDB lists</TD><TD>chr6q12</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL12A1</TD></TR>
<TR><TD>2.819e-02</TD><TD>-3.57</TD><TD>BIOCARTA_ACE2_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_ACE2_PATHWAY</TD><TD>13</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>2.847e-02</TD><TD>-3.56</TD><TD>CHICAS_RB1_TARGETS_CONFLUENT</TD><TD>MSigDB lists</TD><TD>CHICAS_RB1_TARGETS_CONFLUENT</TD><TD>531</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>FAM198B,TIMP2,SYTL2,MECOM</TD></TR>
<TR><TD>2.848e-02</TD><TD>-3.56</TD><TD>positive regulation of JNK cascade</TD><TD>biological process</TD><TD>GO:0046330</TD><TD>114</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,FGF19</TD></TR>
<TR><TD>2.852e-02</TD><TD>-3.56</TD><TD>TOOKER_GEMCITABINE_RESISTANCE_DN</TD><TD>MSigDB lists</TD><TD>TOOKER_GEMCITABINE_RESISTANCE_DN</TD><TD>120</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,PLOD2</TD></TR>
<TR><TD>2.852e-02</TD><TD>-3.56</TD><TD>ZHU_CMV_ALL_UP</TD><TD>MSigDB lists</TD><TD>ZHU_CMV_ALL_UP</TD><TD>120</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,NR4A1</TD></TR>
<TR><TD>2.857e-02</TD><TD>-3.56</TD><TD>human chr3q24</TD><TD>chromosome location</TD><TD>human chr3q24</TD><TD>19</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.860e-02</TD><TD>-3.55</TD><TD>CCCNNGGGAR_V$OLF1_01</TD><TD>MSigDB lists</TD><TD>CCCNNGGGAR_V$OLF1_01</TD><TD>303</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>FAM198B,SYTL2,MECOM</TD></TR>
<TR><TD>2.863e-02</TD><TD>-3.55</TD><TD>regulation of biological quality</TD><TD>biological process</TD><TD>GO:0065008</TD><TD>3288</TD><TD>13</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,ALDH2,CTGF,MFI2,ATP9A,ATP2C2,TRPC1,SUN3,PDE4D,SLC1A3,SOX8,SYTL2,MECOM</TD></TR>
<TR><TD>2.874e-02</TD><TD>-3.55</TD><TD>bone-humerus-other-chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-other-chondroblastoma</TD><TD>312</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,FRAS1,ATP2C2</TD></TR>
<TR><TD>2.884e-02</TD><TD>-3.55</TD><TD>negative regulation of protein metabolic process</TD><TD>biological process</TD><TD>GO:0051248</TD><TD>1025</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,TIMP2,PDE4D,IGF1R,SYTL2,MECOM</TD></TR>
<TR><TD>2.906e-02</TD><TD>-3.54</TD><TD>ion binding</TD><TD>molecular function</TD><TD>GO:0043167</TD><TD>5991</TD><TD>20</TD><TD>16491</TD><TD>38</TD>
<TD>TIMP2,LONRF3,MFI2,HSPG2,ATP9A,NR4A1,ATP2C2,SLC1A3,SYTL2,MECOM,GALNT3,ZNF432,IGF1R,CTGF,PDLIM3,PLOD2,FRAS1,TRPC1,PDE4D,MYRIP</TD></TR>
<TR><TD>2.908e-02</TD><TD>-3.54</TD><TD>RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_DN</TD><TD>MSigDB lists</TD><TD>RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_DN</TD><TD>305</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,TIMP2,CD55</TD></TR>
<TR><TD>2.929e-02</TD><TD>-3.53</TD><TD>SH2B1 (SH2B adaptor protein 1)</TD><TD>protein interactions</TD><TD>25970</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.929e-02</TD><TD>-3.53</TD><TD>COLGALT1 (collagen beta(1-O)galactosyltransferase 1)</TD><TD>protein interactions</TD><TD>79709</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PLOD2</TD></TR>
<TR><TD>2.929e-02</TD><TD>-3.53</TD><TD>SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1)</TD><TD>protein interactions</TD><TD>710</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>2.929e-02</TD><TD>-3.53</TD><TD>TMEM189-UBE2V1 (TMEM189-UBE2V1 readthrough)</TD><TD>protein interactions</TD><TD>387522</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>2.929e-02</TD><TD>-3.53</TD><TD>BMP1 (bone morphogenetic protein 1)</TD><TD>protein interactions</TD><TD>649</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>2.929e-02</TD><TD>-3.53</TD><TD>TIMP3 (TIMP metallopeptidase inhibitor 3)</TD><TD>protein interactions</TD><TD>7078</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TIMP2</TD></TR>
<TR><TD>2.929e-02</TD><TD>-3.53</TD><TD>FBN1 (fibrillin 1)</TD><TD>protein interactions</TD><TD>2200</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>2.929e-02</TD><TD>-3.53</TD><TD>TGFB3 (transforming growth factor beta 3)</TD><TD>protein interactions</TD><TD>7043</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CTGF</TD></TR>
<TR><TD>2.929e-02</TD><TD>-3.53</TD><TD>CD14 (CD14 molecule)</TD><TD>protein interactions</TD><TD>929</TD><TD>14</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>2.933e-02</TD><TD>-3.53</TD><TD>DOUGLAS_BMI1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>DOUGLAS_BMI1_TARGETS_UP</TD><TD>536</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>CNTNAP2,SLC1A3,TIMP2,NR4A1</TD></TR>
<TR><TD>2.933e-02</TD><TD>-3.53</TD><TD>MODULE_19</TD><TD>MSigDB lists</TD><TD>MODULE_19</TD><TD>306</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,HSPG2,NR4A1</TD></TR>
<TR><TD>2.940e-02</TD><TD>-3.53</TD><TD>REACTOME_SIGNALING_BY_FGFR_IN_DISEASE</TD><TD>MSigDB lists</TD><TD>REACTOME_SIGNALING_BY_FGFR_IN_DISEASE</TD><TD>122</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>2.941e-02</TD><TD>-3.53</TD><TD>positive regulation of lymphocyte proliferation</TD><TD>biological process</TD><TD>GO:0050671</TD><TD>116</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>2.945e-02</TD><TD>-3.53</TD><TD>P-type_ATPase_N</TD><TD>interpro domains</TD><TD>IPR032631</TD><TD>14</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ATP9A</TD></TR>
<TR><TD>2.945e-02</TD><TD>-3.53</TD><TD>P-type_ATPase_IV</TD><TD>interpro domains</TD><TD>IPR006539</TD><TD>14</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ATP9A</TD></TR>
<TR><TD>2.945e-02</TD><TD>-3.53</TD><TD>Neurexin-like</TD><TD>interpro domains</TD><TD>IPR003585</TD><TD>14</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.945e-02</TD><TD>-3.53</TD><TD>P_typ_ATPase_c</TD><TD>interpro domains</TD><TD>IPR032630</TD><TD>14</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ATP9A</TD></TR>
<TR><TD>2.945e-02</TD><TD>-3.53</TD><TD>Glyco_hormone_CN</TD><TD>interpro domains</TD><TD>IPR006208</TD><TD>14</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>2.956e-02</TD><TD>-3.52</TD><TD>neurexin family protein binding</TD><TD>molecular function</TD><TD>GO:0042043</TD><TD>13</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>SYTL2</TD></TR>
<TR><TD>2.956e-02</TD><TD>-3.52</TD><TD>L-glutamate transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0005313</TD><TD>13</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>2.957e-02</TD><TD>-3.52</TD><TD>negative regulation of phosphate metabolic process</TD><TD>biological process</TD><TD>GO:0045936</TD><TD>511</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,IGF1R,SYTL2,MECOM</TD></TR>
<TR><TD>2.957e-02</TD><TD>-3.52</TD><TD>negative regulation of phosphorus metabolic process</TD><TD>biological process</TD><TD>GO:0010563</TD><TD>511</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,IGF1R,SYTL2,MECOM</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>positive regulation of steroid biosynthetic process</TD><TD>biological process</TD><TD>GO:0010893</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>glial cell fate commitment</TD><TD>biological process</TD><TD>GO:0021781</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>cytokine production involved in immune response</TD><TD>biological process</TD><TD>GO:0002367</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CD55</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>positive regulation of interleukin-17 production</TD><TD>biological process</TD><TD>GO:0032740</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>male sex determination</TD><TD>biological process</TD><TD>GO:0030238</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>thalamus development</TD><TD>biological process</TD><TD>GO:0021794</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>positive regulation of granulocyte macrophage colony-stimulating factor production</TD><TD>biological process</TD><TD>GO:0032725</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>response to epinephrine</TD><TD>biological process</TD><TD>GO:0071871</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>regulation of cell communication by electrical coupling</TD><TD>biological process</TD><TD>GO:0010649</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>melanin biosynthetic process</TD><TD>biological process</TD><TD>GO:0042438</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1</TD></TR>
<TR><TD>2.964e-02</TD><TD>-3.52</TD><TD>L-glutamate transmembrane transport</TD><TD>biological process</TD><TD>GO:0089711</TD><TD>13</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>2.979e-02</TD><TD>-3.51</TD><TD>Magnesium levels(PMID:20700443)</TD><TD>GWAS genes</TD><TD>Magnesium levels(PMID:20700443)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>MECOM</TD></TR>
<TR><TD>2.979e-02</TD><TD>-3.51</TD><TD>Conduct disorder (symptom count)(PMID:20585324)</TD><TD>GWAS genes</TD><TD>Conduct disorder (symptom count)(PMID:20585324)</TD><TD>6</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>TOX2</TD></TR>
<TR><TD>2.984e-02</TD><TD>-3.51</TD><TD>MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_DN</TD><TD>MSigDB lists</TD><TD>MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_DN</TD><TD>123</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,ATP9A</TD></TR>
<TR><TD>2.984e-02</TD><TD>-3.51</TD><TD>ACTGTAG,MIR-139</TD><TD>MSigDB lists</TD><TD>ACTGTAG,MIR-139</TD><TD>123</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,MAP2</TD></TR>
<TR><TD>2.986e-02</TD><TD>-3.51</TD><TD>fibroblast growth factor receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0008543</TD><TD>293</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,NR4A1,FGF19</TD></TR>
<TR><TD>2.987e-02</TD><TD>-3.51</TD><TD>fibril</TD><TD>cellular component</TD><TD>GO:0043205</TD><TD>14</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>2.988e-02</TD><TD>-3.51</TD><TD>response to estradiol</TD><TD>biological process</TD><TD>GO:0032355</TD><TD>117</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,MAP2</TD></TR>
<TR><TD>2.988e-02</TD><TD>-3.51</TD><TD>positive regulation of mononuclear cell proliferation</TD><TD>biological process</TD><TD>GO:0032946</TD><TD>117</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>3.007e-02</TD><TD>-3.50</TD><TD>KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN</TD><TD>MSigDB lists</TD><TD>KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN</TD><TD>309</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,TIMP2,MAP2</TD></TR>
<TR><TD>3.018e-02</TD><TD>-3.50</TD><TD>growth factor binding</TD><TD>molecular function</TD><TD>GO:0019838</TD><TD>118</TD><TD>2</TD><TD>16491</TD><TD>38</TD>
<TD>IGF1R,CTGF</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>MATZUK_OVULATION</TD><TD>MSigDB lists</TD><TD>MATZUK_OVULATION</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>SABATES_COLORECTAL_ADENOMA_SIZE_DN</TD><TD>MSigDB lists</TD><TD>SABATES_COLORECTAL_ADENOMA_SIZE_DN</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>VICENT_METASTASIS_UP</TD><TD>MSigDB lists</TD><TD>VICENT_METASTASIS_UP</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>AIM1</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>REACTOME_REGULATION_OF_COMPLEMENT_CASCADE</TD><TD>MSigDB lists</TD><TD>REACTOME_REGULATION_OF_COMPLEMENT_CASCADE</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD55</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>VANDESLUIS_COMMD1_TARGETS_GROUP_2_UP</TD><TD>MSigDB lists</TD><TD>VANDESLUIS_COMMD1_TARGETS_GROUP_2_UP</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF19</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>DORN_ADENOVIRUS_INFECTION_48HR_UP</TD><TD>MSigDB lists</TD><TD>DORN_ADENOVIRUS_INFECTION_48HR_UP</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>TSUNODA_CISPLATIN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>TSUNODA_CISPLATIN_RESISTANCE_UP</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>INSOLUBLE_FRACTION</TD><TD>MSigDB lists</TD><TD>INSOLUBLE_FRACTION</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>MODULE_14</TD><TD>MSigDB lists</TD><TD>MODULE_14</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>CYCLIC_NUCLEOTIDE_PHOSPHODIESTERASE_ACTIVITY</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>PROTEIN_TETRAMERIZATION</TD><TD>MSigDB lists</TD><TD>PROTEIN_TETRAMERIZATION</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>VISALA_RESPONSE_TO_HEAT_SHOCK_AND_AGING_UP</TD><TD>MSigDB lists</TD><TD>VISALA_RESPONSE_TO_HEAT_SHOCK_AND_AGING_UP</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>INTERFERON_GAMMA_PRODUCTION</TD><TD>MSigDB lists</TD><TD>INTERFERON_GAMMA_PRODUCTION</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>BIOCARTA_PLATELETAPP_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_PLATELETAPP_PATHWAY</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.032e-02</TD><TD>-3.50</TD><TD>REACTOME_CYTOSOLIC_SULFONATION_OF_SMALL_MOLECULES</TD><TD>MSigDB lists</TD><TD>REACTOME_CYTOSOLIC_SULFONATION_OF_SMALL_MOLECULES</TD><TD>14</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>3.035e-02</TD><TD>-3.49</TD><TD>cytokine production</TD><TD>biological process</TD><TD>GO:0001816</TD><TD>118</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>3.038e-02</TD><TD>-3.49</TD><TD>PI-3K cascade:FGFR4</TD><TD>REACTOME pathways</TD><TD>R-HSA-5654720</TD><TD>98</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>3.038e-02</TD><TD>-3.49</TD><TD>PIP3 activates AKT signaling</TD><TD>REACTOME pathways</TD><TD>R-HSA-1257604</TD><TD>98</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>3.038e-02</TD><TD>-3.49</TD><TD>PI-3K cascade:FGFR2</TD><TD>REACTOME pathways</TD><TD>R-HSA-5654695</TD><TD>98</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>3.038e-02</TD><TD>-3.49</TD><TD>PI3K events in ERBB2 signaling</TD><TD>REACTOME pathways</TD><TD>R-HSA-1963642</TD><TD>98</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>3.038e-02</TD><TD>-3.49</TD><TD>PI3K events in ERBB4 signaling</TD><TD>REACTOME pathways</TD><TD>R-HSA-1250342</TD><TD>98</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>3.038e-02</TD><TD>-3.49</TD><TD>PI-3K cascade:FGFR1</TD><TD>REACTOME pathways</TD><TD>R-HSA-5654689</TD><TD>98</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>3.038e-02</TD><TD>-3.49</TD><TD>PI-3K cascade:FGFR3</TD><TD>REACTOME pathways</TD><TD>R-HSA-5654710</TD><TD>98</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>3.039e-02</TD><TD>-3.49</TD><TD>cellular calcium ion homeostasis</TD><TD>biological process</TD><TD>GO:0006874</TD><TD>295</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CD55,ATP2C2</TD></TR>
<TR><TD>3.066e-02</TD><TD>-3.48</TD><TD>ATPase activity, coupled to movement of substances</TD><TD>molecular function</TD><TD>GO:0043492</TD><TD>119</TD><TD>2</TD><TD>16491</TD><TD>38</TD>
<TD>ATP9A,ATP2C2</TD></TR>
<TR><TD>3.074e-02</TD><TD>-3.48</TD><TD>RASHI_RESPONSE_TO_IONIZING_RADIATION_2</TD><TD>MSigDB lists</TD><TD>RASHI_RESPONSE_TO_IONIZING_RADIATION_2</TD><TD>125</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,TIMP2</TD></TR>
<TR><TD>3.076e-02</TD><TD>-3.48</TD><TD>recycling endosome</TD><TD>cellular component</TD><TD>GO:0055037</TD><TD>127</TD><TD>2</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,ATP9A</TD></TR>
<TR><TD>3.082e-02</TD><TD>-3.48</TD><TD>FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL</TD><TD>312</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,IGF1R,AIM1</TD></TR>
<TR><TD>3.095e-02</TD><TD>-3.48</TD><TD>Stimuli-sensing channels</TD><TD>REACTOME pathways</TD><TD>R-HSA-2672351</TD><TD>99</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>TRPC1,TSC22D3</TD></TR>
<TR><TD>3.108e-02</TD><TD>-3.47</TD><TD>IGFBP_N_1</TD><TD>prosite domains</TD><TD>PS00222</TD><TD>11</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.108e-02</TD><TD>-3.47</TD><TD>RECEPTOR_TYR_KIN_II</TD><TD>prosite domains</TD><TD>PS00239</TD><TD>11</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>3.113e-02</TD><TD>-3.47</TD><TD>regulation of protein phosphorylation</TD><TD>biological process</TD><TD>GO:0001932</TD><TD>1334</TD><TD>7</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,TIMP2,PDE4D,CTGF,IGF1R,FGF19,MECOM</TD></TR>
<TR><TD>3.120e-02</TD><TD>-3.47</TD><TD>PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN</TD><TD>MSigDB lists</TD><TD>PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN</TD><TD>126</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,TSC22D3</TD></TR>
<TR><TD>3.122e-02</TD><TD>-3.47</TD><TD>cell migration</TD><TD>biological process</TD><TD>GO:0016477</TD><TD>771</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,SOX8,CTGF,NR4A1,FGF19</TD></TR>
<TR><TD>3.130e-02</TD><TD>-3.46</TD><TD>SRC (SRC proto-oncogene, non-receptor tyrosine kinase)</TD><TD>protein interactions</TD><TD>6714</TD><TD>326</TD><TD>3</TD><TD>16036</TD><TD>34</TD>
<TD>PDE4D,IGF1R,MAP2</TD></TR>
<TR><TD>3.135e-02</TD><TD>-3.46</TD><TD>SULT1E1 (sulfotransferase family 1E member 1)</TD><TD>protein interactions</TD><TD>6783</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>3.135e-02</TD><TD>-3.46</TD><TD>GRM1 (glutamate receptor, metabotropic 1)</TD><TD>protein interactions</TD><TD>2911</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TRPC1</TD></TR>
<TR><TD>3.135e-02</TD><TD>-3.46</TD><TD>PRELP (proline/arginine-rich end leucine-rich repeat protein)</TD><TD>protein interactions</TD><TD>5549</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>3.135e-02</TD><TD>-3.46</TD><TD>TRPC4 (transient receptor potential cation channel, subfamily C, member 4)</TD><TD>protein interactions</TD><TD>7223</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TRPC1</TD></TR>
<TR><TD>3.135e-02</TD><TD>-3.46</TD><TD>MARK1 (MAP/microtubule affinity-regulating kinase 1)</TD><TD>protein interactions</TD><TD>4139</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>MAP2</TD></TR>
<TR><TD>3.135e-02</TD><TD>-3.46</TD><TD>HHEX (hematopoietically expressed homeobox)</TD><TD>protein interactions</TD><TD>3087</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SOX8</TD></TR>
<TR><TD>3.135e-02</TD><TD>-3.46</TD><TD>ATOX1 (antioxidant 1 copper chaperone)</TD><TD>protein interactions</TD><TD>475</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>3.135e-02</TD><TD>-3.46</TD><TD>TRPC6 (transient receptor potential cation channel, subfamily C, member 6)</TD><TD>protein interactions</TD><TD>7225</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TRPC1</TD></TR>
<TR><TD>3.135e-02</TD><TD>-3.46</TD><TD>SLC12A4 (solute carrier family 12 (potassium/chloride transporter), member 4)</TD><TD>protein interactions</TD><TD>6560</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>3.135e-02</TD><TD>-3.46</TD><TD>SLC25A24 (solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 24)</TD><TD>protein interactions</TD><TD>29957</TD><TD>15</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>3.152e-02</TD><TD>-3.46</TD><TD>G_crystallin-rel</TD><TD>interpro domains</TD><TD>IPR011024</TD><TD>15</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>AIM1</TD></TR>
<TR><TD>3.152e-02</TD><TD>-3.46</TD><TD>Beta/gamma_crystallin</TD><TD>interpro domains</TD><TD>IPR001064</TD><TD>15</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>AIM1</TD></TR>
<TR><TD>3.153e-02</TD><TD>-3.46</TD><TD>lower_third</TD><TD>COSMIC cancer mutations</TD><TD>lower_third</TD><TD>8323</TD><TD>24</TD><TD>17775</TD><TD>38</TD>
<TD>MFI2,LONRF3,HSPG2,NR4A1,ATP2C2,COL4A5,CNTNAP2,COL12A1,SYTL2,MECOM,GALNT3,ZNF432,CTGF,IGF1R,MAP2,FRAS1,TOX2,AIM1,NETO2,TRPC1,SUN3,PDE4D,SOX8,MYRIP</TD></TR>
<TR><TD>3.153e-02</TD><TD>-3.46</TD><TD>PhoLip_ATPase_C</TD><TD>pfam domains</TD><TD>PF16212</TD><TD>14</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>ATP9A</TD></TR>
<TR><TD>3.153e-02</TD><TD>-3.46</TD><TD>PhoLip_ATPase_N</TD><TD>pfam domains</TD><TD>PF16209</TD><TD>14</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>ATP9A</TD></TR>
<TR><TD>3.153e-02</TD><TD>-3.46</TD><TD>Cys_knot</TD><TD>pfam domains</TD><TD>PF00007</TD><TD>14</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.178e-02</TD><TD>-3.45</TD><TD>positive regulation of leukocyte proliferation</TD><TD>biological process</TD><TD>GO:0070665</TD><TD>121</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>3.178e-02</TD><TD>-3.45</TD><TD>mesenchymal cell development</TD><TD>biological process</TD><TD>GO:0014031</TD><TD>121</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,FGF19</TD></TR>
<TR><TD>3.179e-02</TD><TD>-3.45</TD><TD>metalloendopeptidase inhibitor activity</TD><TD>molecular function</TD><TD>GO:0008191</TD><TD>14</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>TIMP2</TD></TR>
<TR><TD>3.179e-02</TD><TD>-3.45</TD><TD>metalloenzyme inhibitor activity</TD><TD>molecular function</TD><TD>GO:0048551</TD><TD>14</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>TIMP2</TD></TR>
<TR><TD>3.179e-02</TD><TD>-3.45</TD><TD>acidic amino acid transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0015172</TD><TD>14</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>3.183e-02</TD><TD>-3.45</TD><TD>transmembrane transporter complex</TD><TD>cellular component</TD><TD>GO:1902495</TD><TD>321</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>CNTNAP2,PDE4D,NETO2</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>melanin metabolic process</TD><TD>biological process</TD><TD>GO:0006582</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>sleep</TD><TD>biological process</TD><TD>GO:0030431</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>insulin-like growth factor receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0048009</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>regulation of granulocyte macrophage colony-stimulating factor production</TD><TD>biological process</TD><TD>GO:0032645</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>dicarboxylic acid biosynthetic process</TD><TD>biological process</TD><TD>GO:0043650</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>cAMP catabolic process</TD><TD>biological process</TD><TD>GO:0006198</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>vocalization behavior</TD><TD>biological process</TD><TD>GO:0071625</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>ethanol metabolic process</TD><TD>biological process</TD><TD>GO:0006067</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>L-amino acid import</TD><TD>biological process</TD><TD>GO:0043092</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>3.189e-02</TD><TD>-3.45</TD><TD>hematopoietic stem cell proliferation</TD><TD>biological process</TD><TD>GO:0071425</TD><TD>14</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MECOM</TD></TR>
<TR><TD>3.192e-02</TD><TD>-3.44</TD><TD>SM22CALPONIN</TD><TD>prints domains</TD><TD>PR00888</TD><TD>11</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>3.211e-02</TD><TD>-3.44</TD><TD>NRL_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>NRL_DN.V1_DN</TD><TD>128</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,NR4A1</TD></TR>
<TR><TD>3.211e-02</TD><TD>-3.44</TD><TD>chr1q32</TD><TD>MSigDB lists</TD><TD>chr1q32</TD><TD>128</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,ASCL5</TD></TR>
<TR><TD>3.211e-02</TD><TD>-3.44</TD><TD>PI3K/AKT activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-198203</TD><TD>101</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>3.228e-02</TD><TD>-3.43</TD><TD>regulation of MAPK cascade</TD><TD>biological process</TD><TD>GO:0043408</TD><TD>778</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,CTGF,IGF1R,FGF19,MECOM</TD></TR>
<TR><TD>3.229e-02</TD><TD>-3.43</TD><TD>humerus</TD><TD>COSMIC cancer mutations</TD><TD>humerus</TD><TD>568</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,FRAS1,ATP2C2,AIM1</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>MODULE_563</TD><TD>MSigDB lists</TD><TD>MODULE_563</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>BIOCARTA_LONGEVITY_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_LONGEVITY_PATHWAY</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>VETTER_TARGETS_OF_PRKCA_AND_ETS1_UP</TD><TD>MSigDB lists</TD><TD>VETTER_TARGETS_OF_PRKCA_AND_ETS1_UP</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>BIOCARTA_AKAPCENTROSOME_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_AKAPCENTROSOME_PATHWAY</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>MODULE_516</TD><TD>MSigDB lists</TD><TD>MODULE_516</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>REGULATION_OF_T_CELL_PROLIFERATION</TD><TD>MSigDB lists</TD><TD>REGULATION_OF_T_CELL_PROLIFERATION</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>chr2q34</TD><TD>MSigDB lists</TD><TD>chr2q34</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>DEMAGALHAES_AGING_DN</TD><TD>MSigDB lists</TD><TD>DEMAGALHAES_AGING_DN</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>SCHURINGA_STAT5A_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>SCHURINGA_STAT5A_TARGETS_DN</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>AIM1</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_ALDEHYDE_OR_OXO_GROUP_OF_DONORSNAD_OR_NADP_AS_ACCEPTOR</TD><TD>MSigDB lists</TD><TD>OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_ALDEHYDE_OR_OXO_GROUP_OF_DONORSNAD_OR_NADP_AS_ACCEPTOR</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.245e-02</TD><TD>-3.43</TD><TD>MAHADEVAN_GIST_MORPHOLOGICAL_SWITCH</TD><TD>MSigDB lists</TD><TD>MAHADEVAN_GIST_MORPHOLOGICAL_SWITCH</TD><TD>15</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.257e-02</TD><TD>-3.42</TD><TD>CATRRAGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>CATRRAGC_UNKNOWN</TD><TD>129</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LONRF3,MAP2</TD></TR>
<TR><TD>3.270e-02</TD><TD>-3.42</TD><TD>GAB1 signalosome</TD><TD>REACTOME pathways</TD><TD>R-HSA-180292</TD><TD>102</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>3.275e-02</TD><TD>-3.42</TD><TD>regulation of lipid biosynthetic process</TD><TD>biological process</TD><TD>GO:0046890</TD><TD>123</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,FGF19</TD></TR>
<TR><TD>3.284e-02</TD><TD>-3.42</TD><TD>receptor complex</TD><TD>cellular component</TD><TD>GO:0043235</TD><TD>325</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>TRPC1,IGF1R,NETO2</TD></TR>
<TR><TD>3.301e-02</TD><TD>-3.41</TD><TD>human chr20q13.2</TD><TD>chromosome location</TD><TD>human chr20q13.2</TD><TD>22</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>ATP9A</TD></TR>
<TR><TD>3.303e-02</TD><TD>-3.41</TD><TD>POOLA_INVASIVE_BREAST_CANCER_DN</TD><TD>MSigDB lists</TD><TD>POOLA_INVASIVE_BREAST_CANCER_DN</TD><TD>130</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,IGF1R</TD></TR>
<TR><TD>3.303e-02</TD><TD>-3.41</TD><TD>HOELZEL_NF1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HOELZEL_NF1_TARGETS_UP</TD><TD>130</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM3,MAP2</TD></TR>
<TR><TD>3.315e-02</TD><TD>-3.41</TD><TD>typical</TD><TD>COSMIC cancer mutations</TD><TD>typical</TD><TD>330</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>COL4A5,CNTNAP2,PLOD2</TD></TR>
<TR><TD>3.315e-02</TD><TD>-3.41</TD><TD>lung-carcinoid-endocrine_tumour-typical</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoid-endocrine_tumour-typical</TD><TD>330</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>COL4A5,CNTNAP2,PLOD2</TD></TR>
<TR><TD>3.315e-02</TD><TD>-3.41</TD><TD>virilizing_syndrome_producing</TD><TD>COSMIC cancer mutations</TD><TD>virilizing_syndrome_producing</TD><TD>330</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,COL12A1,SYTL2</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>Ethanol oxidation</TD><TD>REACTOME pathways</TD><TD>R-HSA-71384</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>Defective EXT2 causes exostoses 2</TD><TD>REACTOME pathways</TD><TD>R-HSA-3656237</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>HSPG2</TD></TR>
<TR><TD>3.316e-02</TD><TD>-3.41</TD><TD>Defective EXT1 causes exostoses 1, TRPS2 and CHDS</TD><TD>REACTOME pathways</TD><TD>R-HSA-3656253</TD><TD>12</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>HSPG2</TD></TR>
<TR><TD>3.324e-02</TD><TD>-3.40</TD><TD>adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains</TD><TD>biological process</TD><TD>GO:0002460</TD><TD>124</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>3.336e-02</TD><TD>-3.40</TD><TD>transporter complex</TD><TD>cellular component</TD><TD>GO:1990351</TD><TD>327</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>PDE4D,CNTNAP2,NETO2</TD></TR>
<TR><TD>3.337e-02</TD><TD>-3.40</TD><TD>response to lipid</TD><TD>biological process</TD><TD>GO:0033993</TD><TD>785</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,PDE4D,CTGF,MAP2,NR4A1</TD></TR>
<TR><TD>3.340e-02</TD><TD>-3.40</TD><TD>QPCT (glutaminyl-peptide cyclotransferase)</TD><TD>protein interactions</TD><TD>25797</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>FRAS1</TD></TR>
<TR><TD>3.340e-02</TD><TD>-3.40</TD><TD>PDGFA (platelet-derived growth factor alpha polypeptide)</TD><TD>protein interactions</TD><TD>5154</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>3.340e-02</TD><TD>-3.40</TD><TD>GRB14 (growth factor receptor bound protein 14)</TD><TD>protein interactions</TD><TD>2888</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>3.340e-02</TD><TD>-3.40</TD><TD>BCL2A1 (BCL2-related protein A1)</TD><TD>protein interactions</TD><TD>597</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.340e-02</TD><TD>-3.40</TD><TD>IGF1 (insulin-like growth factor 1 (somatomedin C))</TD><TD>protein interactions</TD><TD>3479</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>3.340e-02</TD><TD>-3.40</TD><TD>Bub1 (budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae))</TD><TD>protein interactions</TD><TD>12235</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.340e-02</TD><TD>-3.40</TD><TD>OSM (oncostatin M)</TD><TD>protein interactions</TD><TD>5008</TD><TD>16</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.350e-02</TD><TD>-3.40</TD><TD>ONDER_CDH1_TARGETS_1_UP</TD><TD>MSigDB lists</TD><TD>ONDER_CDH1_TARGETS_1_UP</TD><TD>131</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,TSC22D3</TD></TR>
<TR><TD>3.350e-02</TD><TD>-3.40</TD><TD>ALK_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>ALK_DN.V1_DN</TD><TD>131</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CNTNAP2,ATP2C2</TD></TR>
<TR><TD>3.350e-02</TD><TD>-3.40</TD><TD>CRX_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>CRX_DN.V1_DN</TD><TD>131</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,PLOD2</TD></TR>
<TR><TD>3.358e-02</TD><TD>-3.39</TD><TD>Ald_DH_CS_CYS</TD><TD>interpro domains</TD><TD>IPR016160</TD><TD>16</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.358e-02</TD><TD>-3.39</TD><TD>Ald_DH_CS_GLU</TD><TD>interpro domains</TD><TD>IPR029510</TD><TD>16</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.358e-02</TD><TD>-3.39</TD><TD>Pro_4_hyd_alph</TD><TD>interpro domains</TD><TD>IPR006620</TD><TD>16</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.358e-02</TD><TD>-3.39</TD><TD>ATPase_P-typ_TM_dom</TD><TD>interpro domains</TD><TD>IPR023298</TD><TD>16</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>3.361e-02</TD><TD>-3.39</TD><TD>DACOSTA_UV_RESPONSE_VIA_ERCC3_DN</TD><TD>MSigDB lists</TD><TD>DACOSTA_UV_RESPONSE_VIA_ERCC3_DN</TD><TD>827</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,CTGF,IGF1R,PLOD2,MECOM</TD></TR>
<TR><TD>3.374e-02</TD><TD>-3.39</TD><TD>neurotransmitter secretion</TD><TD>biological process</TD><TD>GO:0007269</TD><TD>125</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3,SYTL2</TD></TR>
<TR><TD>3.374e-02</TD><TD>-3.39</TD><TD>stem cell development</TD><TD>biological process</TD><TD>GO:0048864</TD><TD>125</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,FGF19</TD></TR>
<TR><TD>3.375e-02</TD><TD>-3.39</TD><TD>Crystall</TD><TD>pfam domains</TD><TD>PF00030</TD><TD>15</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>AIM1</TD></TR>
<TR><TD>3.388e-02</TD><TD>-3.38</TD><TD>Role of LAT2/NTAL/LAB on calcium mobilization</TD><TD>REACTOME pathways</TD><TD>R-HSA-2730905</TD><TD>104</TD><TD>2</TD><TD>8202</TD><TD>23</TD>
<TD>NR4A1,FGF19</TD></TR>
<TR><TD>3.390e-02</TD><TD>-3.38</TD><TD>calcium ion homeostasis</TD><TD>biological process</TD><TD>GO:0055074</TD><TD>308</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CD55,ATP2C2</TD></TR>
<TR><TD>3.391e-02</TD><TD>-3.38</TD><TD>KEGG_PATHWAYS_IN_CANCER</TD><TD>MSigDB lists</TD><TD>KEGG_PATHWAYS_IN_CANCER</TD><TD>324</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R,FGF19,MECOM</TD></TR>
<TR><TD>3.397e-02</TD><TD>-3.38</TD><TD>V$HMEF2_Q6</TD><TD>MSigDB lists</TD><TD>V$HMEF2_Q6</TD><TD>132</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,NR4A1</TD></TR>
<TR><TD>3.397e-02</TD><TD>-3.38</TD><TD>XU_GH1_AUTOCRINE_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>XU_GH1_AUTOCRINE_TARGETS_DN</TD><TD>132</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL12A1,NETO2</TD></TR>
<TR><TD>3.401e-02</TD><TD>-3.38</TD><TD>chemotaxis</TD><TD>biological process</TD><TD>GO:0006935</TD><TD>789</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,COL4A5,PDE4D,NR4A1,FGF19</TD></TR>
<TR><TD>3.401e-02</TD><TD>-3.38</TD><TD>taxis</TD><TD>biological process</TD><TD>GO:0042330</TD><TD>789</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,COL4A5,PDE4D,NR4A1,FGF19</TD></TR>
<TR><TD>3.403e-02</TD><TD>-3.38</TD><TD>protein anchor</TD><TD>molecular function</TD><TD>GO:0043495</TD><TD>15</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>SUN3</TD></TR>
<TR><TD>3.403e-02</TD><TD>-3.38</TD><TD>metalloenzyme regulator activity</TD><TD>molecular function</TD><TD>GO:0010576</TD><TD>15</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>TIMP2</TD></TR>
<TR><TD>3.413e-02</TD><TD>-3.38</TD><TD>Sertoli cell development</TD><TD>biological process</TD><TD>GO:0060009</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>3.413e-02</TD><TD>-3.38</TD><TD>cell migration involved in sprouting angiogenesis</TD><TD>biological process</TD><TD>GO:0002042</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.413e-02</TD><TD>-3.38</TD><TD>positive regulation of extracellular matrix organization</TD><TD>biological process</TD><TD>GO:1903055</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MFI2</TD></TR>
<TR><TD>3.413e-02</TD><TD>-3.38</TD><TD>metanephric nephron tubule development</TD><TD>biological process</TD><TD>GO:0072234</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>3.413e-02</TD><TD>-3.38</TD><TD>response to vitamin E</TD><TD>biological process</TD><TD>GO:0033197</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>3.413e-02</TD><TD>-3.38</TD><TD>regulation of interleukin-5 production</TD><TD>biological process</TD><TD>GO:0032674</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.413e-02</TD><TD>-3.38</TD><TD>neurotransmitter uptake</TD><TD>biological process</TD><TD>GO:0001504</TD><TD>15</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>ATPase activity, coupled</TD><TD>molecular function</TD><TD>GO:0042623</TD><TD>310</TD><TD>3</TD><TD>16491</TD><TD>38</TD>
<TD>LONRF3,ATP9A,ATP2C2</TD></TR>
<TR><TD>3.421e-02</TD><TD>-3.38</TD><TD>regulation of phosphate metabolic process</TD><TD>biological process</TD><TD>GO:0019220</TD><TD>1669</TD><TD>8</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,CTGF,IGF1R,IL18,PDE4D,FGF19,SYTL2,MECOM</TD></TR>
<TR><TD>3.435e-02</TD><TD>-3.37</TD><TD>lung-carcinoma-small_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-small_cell_carcinoma</TD><TD>10319</TD><TD>28</TD><TD>17775</TD><TD>38</TD>
<TD>ALDH2,CD55,MFI2,LONRF3,HSPG2,ATP9A,NR4A1,TSC22D3,COL4A5,CNTNAP2,FAM198B,FGF19,COL12A1,SYTL2,MECOM,GALNT3,ZNF432,CTGF,PDLIM3,IGF1R,PLOD2,MAP2,FRAS1,AIM1,NETO2,TRPC1,PDE4D,MYRIP</TD></TR>
<TR><TD>3.438e-02</TD><TD>-3.37</TD><TD>cation homeostasis</TD><TD>biological process</TD><TD>GO:0055080</TD><TD>536</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CD55,MFI2,ATP2C2</TD></TR>
<TR><TD>3.444e-02</TD><TD>-3.37</TD><TD>MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>133</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>MFI2,SULT2B1</TD></TR>
<TR><TD>3.444e-02</TD><TD>-3.37</TD><TD>V$AHRARNT_01</TD><TD>MSigDB lists</TD><TD>V$AHRARNT_01</TD><TD>133</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,NR4A1</TD></TR>
<TR><TD>3.444e-02</TD><TD>-3.37</TD><TD>TTTGTAG,MIR-520D</TD><TD>MSigDB lists</TD><TD>TTTGTAG,MIR-520D</TD><TD>326</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,CNTNAP2,PDE4D</TD></TR>
<TR><TD>3.446e-02</TD><TD>-3.37</TD><TD>cellular divalent inorganic cation homeostasis</TD><TD>biological process</TD><TD>GO:0072503</TD><TD>310</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CD55,ATP2C2</TD></TR>
<TR><TD>3.454e-02</TD><TD>-3.37</TD><TD>calcium ion transmembrane transporter activity</TD><TD>molecular function</TD><TD>GO:0015085</TD><TD>127</TD><TD>2</TD><TD>16491</TD><TD>38</TD>
<TD>TRPC1,ATP2C2</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>DASU_IL6_SIGNALING_SCAR_DN</TD><TD>MSigDB lists</TD><TD>DASU_IL6_SIGNALING_SCAR_DN</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>MODULE_178</TD><TD>MSigDB lists</TD><TD>MODULE_178</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>LEE_LIVER_CANCER_HEPATOBLAST</TD><TD>MSigDB lists</TD><TD>LEE_LIVER_CANCER_HEPATOBLAST</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>CAIRO_HEPATOBLASTOMA_POOR_SURVIVAL</TD><TD>MSigDB lists</TD><TD>CAIRO_HEPATOBLASTOMA_POOR_SURVIVAL</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G56_DN</TD><TD>MSigDB lists</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G56_DN</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>REACTOME_CHYLOMICRON_MEDIATED_LIPID_TRANSPORT</TD><TD>MSigDB lists</TD><TD>REACTOME_CHYLOMICRON_MEDIATED_LIPID_TRANSPORT</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>LUND_SILENCED_BY_METHYLATION</TD><TD>MSigDB lists</TD><TD>LUND_SILENCED_BY_METHYLATION</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>3.458e-02</TD><TD>-3.36</TD><TD>AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_DN</TD><TD>MSigDB lists</TD><TD>AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_DN</TD><TD>16</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2</TD></TR>
<TR><TD>3.462e-02</TD><TD>-3.36</TD><TD>small_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>small_cell_carcinoma</TD><TD>10324</TD><TD>28</TD><TD>17775</TD><TD>38</TD>
<TD>ALDH2,CD55,MFI2,LONRF3,HSPG2,ATP9A,NR4A1,TSC22D3,COL4A5,CNTNAP2,FAM198B,FGF19,COL12A1,SYTL2,MECOM,GALNT3,ZNF432,CTGF,PDLIM3,IGF1R,PLOD2,MAP2,FRAS1,AIM1,NETO2,TRPC1,PDE4D,MYRIP</TD></TR>
<TR><TD>3.468e-02</TD><TD>-3.36</TD><TD>Esophageal cancer(PMID:21642993)</TD><TD>GWAS genes</TD><TD>Esophageal cancer(PMID:21642993)</TD><TD>7</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.468e-02</TD><TD>-3.36</TD><TD>Renal function-related traits (sCR)(PMID:22797727)</TD><TD>GWAS genes</TD><TD>Renal function-related traits (sCR)(PMID:22797727)</TD><TD>7</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.468e-02</TD><TD>-3.36</TD><TD>Systolic blood pressure(PMID:19430479)</TD><TD>GWAS genes</TD><TD>Systolic blood pressure(PMID:19430479)</TD><TD>7</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>MECOM</TD></TR>
<TR><TD>3.471e-02</TD><TD>-3.36</TD><TD>IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_DN</TD><TD>MSigDB lists</TD><TD>IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_DN</TD><TD>327</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM3,PLOD2,MAP2</TD></TR>
<TR><TD>3.473e-02</TD><TD>-3.36</TD><TD>cellular response to lipopolysaccharide</TD><TD>biological process</TD><TD>GO:0071222</TD><TD>127</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,PDE4D</TD></TR>
<TR><TD>3.473e-02</TD><TD>-3.36</TD><TD>embryonic limb morphogenesis</TD><TD>biological process</TD><TD>GO:0030326</TD><TD>127</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>FRAS1,MECOM</TD></TR>
<TR><TD>3.473e-02</TD><TD>-3.36</TD><TD>embryonic appendage morphogenesis</TD><TD>biological process</TD><TD>GO:0035113</TD><TD>127</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>FRAS1,MECOM</TD></TR>
<TR><TD>3.477e-02</TD><TD>-3.36</TD><TD>Glutamatergic synapse</TD><TD>KEGG pathways</TD><TD>hsa04724</TD><TD>114</TD><TD>2</TD><TD>6908</TD><TD>18</TD>
<TD>TRPC1,SLC1A3</TD></TR>
<TR><TD>3.477e-02</TD><TD>-3.36</TD><TD>Glutamatergic synapse</TD><TD>KEGG pathways</TD><TD>ko04724</TD><TD>114</TD><TD>2</TD><TD>6908</TD><TD>18</TD>
<TD>TRPC1,SLC1A3</TD></TR>
<TR><TD>3.492e-02</TD><TD>-3.35</TD><TD>PROVENZANI_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>PROVENZANI_METASTASIS_DN</TD><TD>134</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,PDE4D</TD></TR>
<TR><TD>3.492e-02</TD><TD>-3.35</TD><TD>V$DR3_Q4</TD><TD>MSigDB lists</TD><TD>V$DR3_Q4</TD><TD>134</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TSC22D3,COL12A1</TD></TR>
<TR><TD>3.492e-02</TD><TD>-3.35</TD><TD>SMID_BREAST_CANCER_ERBB2_UP</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_ERBB2_UP</TD><TD>134</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ATP2C2,AIM1</TD></TR>
<TR><TD>3.520e-02</TD><TD>-3.35</TD><TD>plasma membrane</TD><TD>cellular component</TD><TD>GO:0005886</TD><TD>4806</TD><TD>16</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,CD55,MFI2,HSPG2,ATP9A,ATP2C2,SLC1A3,CNTNAP2,SYTL2,CTGF,IGF1R,FRAS1,NETO2,TRPC1,PDE4D,MYRIP</TD></TR>
<TR><TD>3.539e-02</TD><TD>-3.34</TD><TD>PENG_LEUCINE_DEPRIVATION_UP</TD><TD>MSigDB lists</TD><TD>PENG_LEUCINE_DEPRIVATION_UP</TD><TD>135</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,AIM1</TD></TR>
<TR><TD>3.546e-02</TD><TD>-3.34</TD><TD>BRMS1L (breast cancer metastasis-suppressor 1-like)</TD><TD>protein interactions</TD><TD>84312</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>3.546e-02</TD><TD>-3.34</TD><TD>ECM1 (extracellular matrix protein 1)</TD><TD>protein interactions</TD><TD>1893</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>3.546e-02</TD><TD>-3.34</TD><TD>SERPINA4 (serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4)</TD><TD>protein interactions</TD><TD>5267</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.546e-02</TD><TD>-3.34</TD><TD>FECH (ferrochelatase)</TD><TD>protein interactions</TD><TD>2235</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TIMP2</TD></TR>
<TR><TD>3.546e-02</TD><TD>-3.34</TD><TD>PYHIN1 (pyrin and HIN domain family, member 1)</TD><TD>protein interactions</TD><TD>149628</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AIM1</TD></TR>
<TR><TD>3.546e-02</TD><TD>-3.34</TD><TD>Yap1 (yes-associated protein 1)</TD><TD>protein interactions</TD><TD>22601</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>3.546e-02</TD><TD>-3.34</TD><TD>SLC35F6 (solute carrier family 35, member F6)</TD><TD>protein interactions</TD><TD>54978</TD><TD>17</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.562e-02</TD><TD>-3.33</TD><TD>regulation of phosphorus metabolic process</TD><TD>biological process</TD><TD>GO:0051174</TD><TD>1682</TD><TD>8</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,CTGF,IGF1R,IL18,PDE4D,FGF19,SYTL2,MECOM</TD></TR>
<TR><TD>3.562e-02</TD><TD>-3.33</TD><TD>lung-left_upper_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-left_upper_lobe-carcinoma-adenocarcinoma</TD><TD>586</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,MAP2,FRAS1,TOX2</TD></TR>
<TR><TD>3.565e-02</TD><TD>-3.33</TD><TD>ATPase_P-typ_cation-transptr_C</TD><TD>interpro domains</TD><TD>IPR006068</TD><TD>17</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>3.574e-02</TD><TD>-3.33</TD><TD>central_nervous_system-diencephalon-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-diencephalon-glioma-astrocytoma_Grade_I</TD><TD>17</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.579e-02</TD><TD>-3.33</TD><TD>REACTOME_GENERIC_TRANSCRIPTION_PATHWAY</TD><TD>MSigDB lists</TD><TD>REACTOME_GENERIC_TRANSCRIPTION_PATHWAY</TD><TD>331</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ZNF432,CTGF,NR4A1</TD></TR>
<TR><TD>3.587e-02</TD><TD>-3.33</TD><TD>PDGF_ERK_DN.V1_UP</TD><TD>MSigDB lists</TD><TD>PDGF_ERK_DN.V1_UP</TD><TD>136</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,MAP2</TD></TR>
<TR><TD>3.587e-02</TD><TD>-3.33</TD><TD>QI_HYPOXIA</TD><TD>MSigDB lists</TD><TD>QI_HYPOXIA</TD><TD>136</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PLOD2,COL12A1</TD></TR>
<TR><TD>3.588e-02</TD><TD>-3.33</TD><TD>cellular response to fibroblast growth factor stimulus</TD><TD>biological process</TD><TD>GO:0044344</TD><TD>315</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,NR4A1,FGF19</TD></TR>
<TR><TD>3.592e-02</TD><TD>-3.33</TD><TD>SYSTEM_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>SYSTEM_DEVELOPMENT</TD><TD>842</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,SOX8,CTGF,FGF19,COL12A1</TD></TR>
<TR><TD>3.599e-02</TD><TD>-3.32</TD><TD>oesophagus-lower_third-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-lower_third-carcinoma-squamous_cell_carcinoma</TD><TD>3665</TD><TD>13</TD><TD>17775</TD><TD>38</TD>
<TD>GALNT3,ZNF432,HSPG2,MAP2,FRAS1,ATP2C2,NETO2,COL4A5,CNTNAP2,SOX8,COL12A1,SYTL2,MECOM</TD></TR>
<TR><TD>3.600e-02</TD><TD>-3.32</TD><TD>left_upper_lobe</TD><TD>COSMIC cancer mutations</TD><TD>left_upper_lobe</TD><TD>588</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,MAP2,FRAS1,TOX2</TD></TR>
<TR><TD>3.623e-02</TD><TD>-3.32</TD><TD>negative regulation of macromolecule metabolic process</TD><TD>biological process</TD><TD>GO:0010605</TD><TD>2342</TD><TD>10</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,TIMP2,CTGF,IGF1R,TSC22D3,PDE4D,SOX8,FGF19,SYTL2,MECOM</TD></TR>
<TR><TD>3.625e-02</TD><TD>-3.32</TD><TD>phospholipid-translocating ATPase activity</TD><TD>molecular function</TD><TD>GO:0004012</TD><TD>16</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>ATP9A</TD></TR>
<TR><TD>3.636e-02</TD><TD>-3.31</TD><TD>striatum development</TD><TD>biological process</TD><TD>GO:0021756</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.636e-02</TD><TD>-3.31</TD><TD>respiratory burst</TD><TD>biological process</TD><TD>GO:0045730</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CD55</TD></TR>
<TR><TD>3.636e-02</TD><TD>-3.31</TD><TD>adenylate cyclase-activating adrenergic receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0071880</TD><TD>16</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.639e-02</TD><TD>-3.31</TD><TD>SOX2 (SRY box 2)</TD><TD>protein interactions</TD><TD>6657</TD><TD>346</TD><TD>3</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2,SOX8,MECOM</TD></TR>
<TR><TD>3.640e-02</TD><TD>-3.31</TD><TD>Androgen and Estrogen Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00068</TD><TD>12</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>3.640e-02</TD><TD>-3.31</TD><TD>17-Beta Hydroxysteroid Dehydrogenase III Deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00356</TD><TD>12</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>3.640e-02</TD><TD>-3.31</TD><TD>Aromatase deficiency</TD><TD>SMPDB pathways</TD><TD>SMP00565</TD><TD>12</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>3.663e-02</TD><TD>-3.31</TD><TD>CTCK_1</TD><TD>prosite domains</TD><TD>PS01185</TD><TD>13</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>LIU_VAV3_PROSTATE_CARCINOGENESIS_DN</TD><TD>MSigDB lists</TD><TD>LIU_VAV3_PROSTATE_CARCINOGENESIS_DN</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>SIMBULAN_PARP1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>SIMBULAN_PARP1_TARGETS_DN</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>TOMIDA_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>TOMIDA_METASTASIS_DN</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>LAMB_CCND1_TARGETS</TD><TD>MSigDB lists</TD><TD>LAMB_CCND1_TARGETS</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_DN</TD><TD>MSigDB lists</TD><TD>SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_DN</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>MODULE_474</TD><TD>MSigDB lists</TD><TD>MODULE_474</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>PID_ANTHRAX_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_ANTHRAX_PATHWAY</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>KYNG_WERNER_SYNDROM_UP</TD><TD>MSigDB lists</TD><TD>KYNG_WERNER_SYNDROM_UP</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>ONDER_CDH1_TARGETS_3_UP</TD><TD>MSigDB lists</TD><TD>ONDER_CDH1_TARGETS_3_UP</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>MODULE_444</TD><TD>MSigDB lists</TD><TD>MODULE_444</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>L_AMINO_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY</TD><TD>MSigDB lists</TD><TD>L_AMINO_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>NIELSEN_MALIGNAT_FIBROUS_HISTIOCYTOMA_DN</TD><TD>MSigDB lists</TD><TD>NIELSEN_MALIGNAT_FIBROUS_HISTIOCYTOMA_DN</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_UP</TD><TD>MSigDB lists</TD><TD>GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_UP</TD><TD>17</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>3.675e-02</TD><TD>-3.30</TD><TD>positive regulation of stress-activated MAPK cascade</TD><TD>biological process</TD><TD>GO:0032874</TD><TD>131</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,FGF19</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>GOZGIT_ESR1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>GOZGIT_ESR1_TARGETS_UP</TD><TD>138</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,COL12A1</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>YAUCH_HEDGEHOG_SIGNALING_PARACRINE_UP</TD><TD>MSigDB lists</TD><TD>YAUCH_HEDGEHOG_SIGNALING_PARACRINE_UP</TD><TD>138</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,SLC1A3</TD></TR>
<TR><TD>3.684e-02</TD><TD>-3.30</TD><TD>MEISSNER_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MEISSNER_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>138</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,FGF19</TD></TR>
<TR><TD>3.689e-02</TD><TD>-3.30</TD><TD>MEMBRANE_FRACTION</TD><TD>MSigDB lists</TD><TD>MEMBRANE_FRACTION</TD><TD>335</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,SLC1A3,SYTL2</TD></TR>
<TR><TD>3.717e-02</TD><TD>-3.29</TD><TD>RXR and RAR heterodimerization with other nuclear receptor</TD><TD>Pathway Interaction DB</TD><TD>rxr_vdr_pathway</TD><TD>14</TD><TD>1</TD><TD>2227</TD><TD>6</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.726e-02</TD><TD>-3.29</TD><TD>positive regulation of stress-activated protein kinase signaling cascade</TD><TD>biological process</TD><TD>GO:0070304</TD><TD>132</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,FGF19</TD></TR>
<TR><TD>3.726e-02</TD><TD>-3.29</TD><TD>cell maturation</TD><TD>biological process</TD><TD>GO:0048469</TD><TD>132</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2,SOX8</TD></TR>
<TR><TD>3.732e-02</TD><TD>-3.29</TD><TD>REACTOME_BIOLOGICAL_OXIDATIONS</TD><TD>MSigDB lists</TD><TD>REACTOME_BIOLOGICAL_OXIDATIONS</TD><TD>139</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,SULT2B1</TD></TR>
<TR><TD>3.732e-02</TD><TD>-3.29</TD><TD>V$STAT3_02</TD><TD>MSigDB lists</TD><TD>V$STAT3_02</TD><TD>139</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,NR4A1</TD></TR>
<TR><TD>3.733e-02</TD><TD>-3.29</TD><TD>response to fibroblast growth factor</TD><TD>biological process</TD><TD>GO:0071774</TD><TD>320</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,NR4A1,FGF19</TD></TR>
<TR><TD>3.740e-02</TD><TD>-3.29</TD><TD>cellular response to organic substance</TD><TD>biological process</TD><TD>GO:0071310</TD><TD>2021</TD><TD>9</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,CTGF,IGF1R,PLOD2,MAP2,NR4A1,IL18,PDE4D,FGF19</TD></TR>
<TR><TD>3.750e-02</TD><TD>-3.28</TD><TD>NOV (nephroblastoma overexpressed)</TD><TD>protein interactions</TD><TD>4856</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.750e-02</TD><TD>-3.28</TD><TD>GOLGA8F (golgin A8 family, member F)</TD><TD>protein interactions</TD><TD>100132565</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.750e-02</TD><TD>-3.28</TD><TD>MMP1 (matrix metallopeptidase 1)</TD><TD>protein interactions</TD><TD>4312</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SOX8</TD></TR>
<TR><TD>3.750e-02</TD><TD>-3.28</TD><TD>ARHGEF5 (Rho guanine nucleotide exchange factor 5)</TD><TD>protein interactions</TD><TD>7984</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.750e-02</TD><TD>-3.28</TD><TD>Wwtr1 (WW domain containing transcription regulator 1)</TD><TD>protein interactions</TD><TD>97064</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>3.750e-02</TD><TD>-3.28</TD><TD>MPP5 (membrane protein, palmitoylated 5)</TD><TD>protein interactions</TD><TD>64398</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>3.750e-02</TD><TD>-3.28</TD><TD>ROBO2 (roundabout guidance receptor 2)</TD><TD>protein interactions</TD><TD>6092</TD><TD>18</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>inorganic ion homeostasis</TD><TD>biological process</TD><TD>GO:0098771</TD><TD>552</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CD55,MFI2,ATP2C2</TD></TR>
<TR><TD>3.770e-02</TD><TD>-3.28</TD><TD>scalp</TD><TD>COSMIC cancer mutations</TD><TD>scalp</TD><TD>2188</TD><TD>9</TD><TD>17775</TD><TD>38</TD>
<TD>ZNF432,MAP2,ATP9A,ATP2C2,AIM1,FAM198B,SULT2B1,SYTL2,MECOM</TD></TR>
<TR><TD>3.774e-02</TD><TD>-3.28</TD><TD>regulation of protein modification process</TD><TD>biological process</TD><TD>GO:0031399</TD><TD>1701</TD><TD>8</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,CTGF,IGF1R,IL18,PDE4D,FGF19,SYTL2,MECOM</TD></TR>
<TR><TD>3.781e-02</TD><TD>-3.28</TD><TD>diencephalon</TD><TD>COSMIC cancer mutations</TD><TD>diencephalon</TD><TD>18</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.788e-02</TD><TD>-3.27</TD><TD>transition metal ion binding</TD><TD>molecular function</TD><TD>GO:0046914</TD><TD>1395</TD><TD>7</TD><TD>16491</TD><TD>38</TD>
<TD>GALNT3,PDLIM3,LONRF3,MFI2,PLOD2,MYRIP,NR4A1</TD></TR>
<TR><TD>3.816e-02</TD><TD>-3.27</TD><TD>Cation_ATPase_C</TD><TD>pfam domains</TD><TD>PF00689</TD><TD>17</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>3.817e-02</TD><TD>-3.27</TD><TD>Golgi apparatus part</TD><TD>cellular component</TD><TD>GO:0044431</TD><TD>870</TD><TD>5</TD><TD>17570</TD><TD>38</TD>
<TD>GALNT3,FAM198B,HSPG2,ATP9A,ATP2C2</TD></TR>
<TR><TD>3.824e-02</TD><TD>-3.26</TD><TD>axolemma</TD><TD>cellular component</TD><TD>GO:0030673</TD><TD>18</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>3.824e-02</TD><TD>-3.26</TD><TD>exocyst</TD><TD>cellular component</TD><TD>GO:0000145</TD><TD>18</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>MYRIP</TD></TR>
<TR><TD>3.826e-02</TD><TD>-3.26</TD><TD>prostate-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>prostate-carcinoma</TD><TD>9403</TD><TD>26</TD><TD>17775</TD><TD>38</TD>
<TD>AMOTL2,ALDH2,CD55,HSPG2,ATP9A,NR4A1,ATP2C2,COL4A5,CNTNAP2,SLC1A3,FGF19,COL12A1,SYTL2,MECOM,GALNT3,IGF1R,PLOD2,MAP2,FRAS1,TOX2,AIM1,NETO2,SUN3,PDE4D,SOX8,MYRIP</TD></TR>
<TR><TD>3.829e-02</TD><TD>-3.26</TD><TD>mitophagy in response to mitochondrial depolarization</TD><TD>biological process</TD><TD>GO:0098779</TD><TD>134</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3,PLOD2</TD></TR>
<TR><TD>3.829e-02</TD><TD>-3.26</TD><TD>cellular response to molecule of bacterial origin</TD><TD>biological process</TD><TD>GO:0071219</TD><TD>134</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,PDE4D</TD></TR>
<TR><TD>3.829e-02</TD><TD>-3.26</TD><TD>mesenchymal cell differentiation</TD><TD>biological process</TD><TD>GO:0048762</TD><TD>134</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,FGF19</TD></TR>
<TR><TD>3.829e-02</TD><TD>-3.26</TD><TD>response to mitochondrial depolarisation</TD><TD>biological process</TD><TD>GO:0098780</TD><TD>134</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3,PLOD2</TD></TR>
<TR><TD>3.833e-02</TD><TD>-3.26</TD><TD>response to peptide hormone</TD><TD>biological process</TD><TD>GO:0043434</TD><TD>555</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,IGF1R,NR4A1,FGF19</TD></TR>
<TR><TD>3.858e-02</TD><TD>-3.25</TD><TD>FGFR4 ligand binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-190322</TD><TD>14</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>FGF19</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>neurotransmitter biosynthetic process</TD><TD>biological process</TD><TD>GO:0042136</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>cyclic nucleotide catabolic process</TD><TD>biological process</TD><TD>GO:0009214</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>negative regulation of T cell apoptotic process</TD><TD>biological process</TD><TD>GO:0070233</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>metanephric nephron epithelium development</TD><TD>biological process</TD><TD>GO:0072243</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>amino acid import</TD><TD>biological process</TD><TD>GO:0043090</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>metanephric tubule development</TD><TD>biological process</TD><TD>GO:0072170</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>interferon-gamma production</TD><TD>biological process</TD><TD>GO:0032609</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>3.859e-02</TD><TD>-3.25</TD><TD>cytokine biosynthetic process</TD><TD>biological process</TD><TD>GO:0042089</TD><TD>17</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>3.867e-02</TD><TD>-3.25</TD><TD>regulation of response to stress</TD><TD>biological process</TD><TD>GO:0080134</TD><TD>1397</TD><TD>7</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55,SLC1A3,CTGF,IGF1R,FGF19,MECOM</TD></TR>
<TR><TD>3.873e-02</TD><TD>-3.25</TD><TD>apical part of cell</TD><TD>cellular component</TD><TD>GO:0045177</TD><TD>347</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,PDE4D,MYRIP</TD></TR>
<TR><TD>3.880e-02</TD><TD>-3.25</TD><TD>GSE37416_CTRL_VS_0H_F_TULARENSIS_LVS_NEUTROPHIL_DN</TD><TD>MSigDB lists</TD><TD>GSE37416_CTRL_VS_0H_F_TULARENSIS_LVS_NEUTROPHIL_DN</TD><TD>142</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SOX8,COL12A1</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>STAMBOLSKY_BOUND_BY_MUTATED_TP53</TD><TD>MSigDB lists</TD><TD>STAMBOLSKY_BOUND_BY_MUTATED_TP53</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FRAS1</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>MODULE_478</TD><TD>MSigDB lists</TD><TD>MODULE_478</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PLOD2</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>MAINA_VHL_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>MAINA_VHL_TARGETS_DN</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>NIELSEN_MALIGNAT_FIBROUS_HISTIOCYTOMA_UP</TD><TD>MSigDB lists</TD><TD>NIELSEN_MALIGNAT_FIBROUS_HISTIOCYTOMA_UP</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_DN</TD><TD>MSigDB lists</TD><TD>HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_DN</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>BIOCARTA_TEL_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_TEL_PATHWAY</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>DAZARD_UV_RESPONSE_CLUSTER_G28</TD><TD>MSigDB lists</TD><TD>DAZARD_UV_RESPONSE_CLUSTER_G28</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>LANDIS_ERBB2_BREAST_PRENEOPLASTIC_UP</TD><TD>MSigDB lists</TD><TD>LANDIS_ERBB2_BREAST_PRENEOPLASTIC_UP</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3</TD></TR>
<TR><TD>3.882e-02</TD><TD>-3.25</TD><TD>T_CELL_PROLIFERATION</TD><TD>MSigDB lists</TD><TD>T_CELL_PROLIFERATION</TD><TD>18</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>3.889e-02</TD><TD>-3.25</TD><TD>human chrXq22.3</TD><TD>chromosome location</TD><TD>human chrXq22.3</TD><TD>26</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>3.913e-02</TD><TD>-3.24</TD><TD>CTAWWWATA_V$RSRFC4_Q2</TD><TD>MSigDB lists</TD><TD>CTAWWWATA_V$RSRFC4_Q2</TD><TD>343</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2,NR4A1,SYTL2</TD></TR>
<TR><TD>3.930e-02</TD><TD>-3.24</TD><TD>GREGORY_SYNTHETIC_LETHAL_WITH_IMATINIB</TD><TD>MSigDB lists</TD><TD>GREGORY_SYNTHETIC_LETHAL_WITH_IMATINIB</TD><TD>143</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PLOD2,ATP2C2</TD></TR>
<TR><TD>3.930e-02</TD><TD>-3.24</TD><TD>SMITH_TERT_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SMITH_TERT_TARGETS_UP</TD><TD>143</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,CD55</TD></TR>
<TR><TD>3.930e-02</TD><TD>-3.24</TD><TD>NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON</TD><TD>MSigDB lists</TD><TD>NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON</TD><TD>143</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FGF19,SYTL2</TD></TR>
<TR><TD>3.954e-02</TD><TD>-3.23</TD><TD>Immune reponse to smallpox (secreted IL-1beta)(PMID:22610502)</TD><TD>GWAS genes</TD><TD>Immune reponse to smallpox (secreted IL-1beta)(PMID:22610502)</TD><TD>8</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>MECOM</TD></TR>
<TR><TD>3.955e-02</TD><TD>-3.23</TD><TD>EGR2 (early growth response 2)</TD><TD>protein interactions</TD><TD>1959</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SOX8</TD></TR>
<TR><TD>3.955e-02</TD><TD>-3.23</TD><TD>TRAPPC10 (trafficking protein particle complex 10)</TD><TD>protein interactions</TD><TD>7109</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>3.955e-02</TD><TD>-3.23</TD><TD>TGFB2 (transforming growth factor beta 2)</TD><TD>protein interactions</TD><TD>7042</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CTGF</TD></TR>
<TR><TD>3.955e-02</TD><TD>-3.23</TD><TD>ZNF579 (zinc finger protein 579)</TD><TD>protein interactions</TD><TD>163033</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>3.955e-02</TD><TD>-3.23</TD><TD>FGFR4 (fibroblast growth factor receptor 4)</TD><TD>protein interactions</TD><TD>2264</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>FGF19</TD></TR>
<TR><TD>3.955e-02</TD><TD>-3.23</TD><TD>TRPC4AP (transient receptor potential cation channel, subfamily C, member 4 associated protein)</TD><TD>protein interactions</TD><TD>26133</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TRPC1</TD></TR>
<TR><TD>3.955e-02</TD><TD>-3.23</TD><TD>VAV3 (vav 3 guanine nucleotide exchange factor)</TD><TD>protein interactions</TD><TD>10451</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>3.955e-02</TD><TD>-3.23</TD><TD>TRPC5 (transient receptor potential cation channel, subfamily C, member 5)</TD><TD>protein interactions</TD><TD>7224</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TRPC1</TD></TR>
<TR><TD>3.955e-02</TD><TD>-3.23</TD><TD>NID2 (nidogen 2 (osteonidogen))</TD><TD>protein interactions</TD><TD>22795</TD><TD>19</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>Ald_DH_N</TD><TD>interpro domains</TD><TD>IPR016162</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>PUA-like_domain</TD><TD>interpro domains</TD><TD>IPR015947</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>LONRF3</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>Aldehyde_DH_dom</TD><TD>interpro domains</TD><TD>IPR015590</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>ATPase_P-typ_cation-transptr_N</TD><TD>interpro domains</TD><TD>IPR004014</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>Ald_DH/histidinol_DH</TD><TD>interpro domains</TD><TD>IPR016161</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>PDEase</TD><TD>interpro domains</TD><TD>IPR023088</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PDE4D</TD></TR>
<TR><TD>3.976e-02</TD><TD>-3.22</TD><TD>Ald_DH_C</TD><TD>interpro domains</TD><TD>IPR016163</TD><TD>19</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>3.980e-02</TD><TD>-3.22</TD><TD>V$FREAC4_01</TD><TD>MSigDB lists</TD><TD>V$FREAC4_01</TD><TD>144</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2,NR4A1</TD></TR>
<TR><TD>3.985e-02</TD><TD>-3.22</TD><TD>postsynapse</TD><TD>cellular component</TD><TD>GO:0098794</TD><TD>351</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>SLC1A3,MAP2,NETO2</TD></TR>
<TR><TD>4.005e-02</TD><TD>-3.22</TD><TD>GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP</TD><TD>MSigDB lists</TD><TD>GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP</TD><TD>592</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,CD55,ALDH2,NR4A1</TD></TR>
<TR><TD>4.011e-02</TD><TD>-3.22</TD><TD>central_nervous_system-brainstem-glioma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brainstem-glioma</TD><TD>356</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,MYRIP,FRAS1</TD></TR>
<TR><TD>4.032e-02</TD><TD>-3.21</TD><TD>rough endoplasmic reticulum membrane</TD><TD>cellular component</TD><TD>GO:0030867</TD><TD>19</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.035e-02</TD><TD>-3.21</TD><TD>soft_tissue-striated_muscle-rhabdomyosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-striated_muscle-rhabdomyosarcoma</TD><TD>610</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>COL4A5,IGF1R,COL12A1,NETO2</TD></TR>
<TR><TD>4.036e-02</TD><TD>-3.21</TD><TD>Cation_ATPase_N</TD><TD>pfam domains</TD><TD>PF00690</TD><TD>18</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>4.039e-02</TD><TD>-3.21</TD><TD>calcium ion transmembrane transport</TD><TD>biological process</TD><TD>GO:0070588</TD><TD>138</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,ATP2C2</TD></TR>
<TR><TD>4.062e-02</TD><TD>-3.20</TD><TD>divalent inorganic cation homeostasis</TD><TD>biological process</TD><TD>GO:0072507</TD><TD>331</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CD55,ATP2C2</TD></TR>
<TR><TD>4.070e-02</TD><TD>-3.20</TD><TD>G-protein alpha-subunit binding</TD><TD>molecular function</TD><TD>GO:0001965</TD><TD>18</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.070e-02</TD><TD>-3.20</TD><TD>aldehyde dehydrogenase (NAD) activity</TD><TD>molecular function</TD><TD>GO:0004029</TD><TD>18</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.080e-02</TD><TD>-3.20</TD><TD>GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_0.5H_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_0.5H_CD4_TCELL_UP</TD><TD>146</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FAM198B,SOX8</TD></TR>
<TR><TD>4.082e-02</TD><TD>-3.20</TD><TD>pericardium development</TD><TD>biological process</TD><TD>GO:0060039</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.082e-02</TD><TD>-3.20</TD><TD>regulation of protein kinase A signaling</TD><TD>biological process</TD><TD>GO:0010738</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.082e-02</TD><TD>-3.20</TD><TD>regulation of cardiac conduction</TD><TD>biological process</TD><TD>GO:1903779</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.082e-02</TD><TD>-3.20</TD><TD>T-helper 1 type immune response</TD><TD>biological process</TD><TD>GO:0042088</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>4.082e-02</TD><TD>-3.20</TD><TD>positive regulation of protein processing</TD><TD>biological process</TD><TD>GO:0010954</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MFI2</TD></TR>
<TR><TD>4.082e-02</TD><TD>-3.20</TD><TD>regulation of hormone biosynthetic process</TD><TD>biological process</TD><TD>GO:0046885</TD><TD>18</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.083e-02</TD><TD>-3.20</TD><TD>regulation of cellular protein metabolic process</TD><TD>biological process</TD><TD>GO:0032268</TD><TD>2389</TD><TD>10</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,TIMP2,CTGF,MFI2,IGF1R,IL18,PDE4D,FGF19,SYTL2,MECOM</TD></TR>
<TR><TD>4.087e-02</TD><TD>-3.20</TD><TD>breast-carcinoma-ductal_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma-ductal_carcinoma</TD><TD>15563</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,ATP9A,TSC22D3,ATP2C2,COL4A5,IL18,CNTNAP2,SLC1A3,FAM198B,FGF19,SYTL2,MECOM,ZNF432,CTGF,IGF1R,FRAS1,TOX2,AIM1,TRPC1,SUN3,TAGLN2,PDE4D,MYRIP,SULT2B1,AMOTL2,CD55,ALDH2,LONRF3,MFI2,NR4A1,COL12A1,GALNT3,PDLIM3,PLOD2,MAP2,NETO2,SOX8</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>ZIRN_TRETINOIN_RESPONSE_UP</TD><TD>MSigDB lists</TD><TD>ZIRN_TRETINOIN_RESPONSE_UP</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>GTCAACC,MIR-380-5P</TD><TD>MSigDB lists</TD><TD>GTCAACC,MIR-380-5P</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FRAS1</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>MODULE_305</TD><TD>MSigDB lists</TD><TD>MODULE_305</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>WEST_ADRENOCORTICAL_CARCINOMA_VS_ADENOMA_UP</TD><TD>MSigDB lists</TD><TD>WEST_ADRENOCORTICAL_CARCINOMA_VS_ADENOMA_UP</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>LONRF3</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>chr3q24</TD><TD>MSigDB lists</TD><TD>chr3q24</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>AMUNDSON_GAMMA_RADIATION_RESISTANCE</TD><TD>MSigDB lists</TD><TD>AMUNDSON_GAMMA_RADIATION_RESISTANCE</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>BIOCARTA_NKCELLS_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_NKCELLS_PATHWAY</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>VERRECCHIA_RESPONSE_TO_TGFB1_C1</TD><TD>MSigDB lists</TD><TD>VERRECCHIA_RESPONSE_TO_TGFB1_C1</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>V$EVI1_06</TD><TD>MSigDB lists</TD><TD>V$EVI1_06</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>WANG_THOC1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>WANG_THOC1_TARGETS_DN</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SOX8</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_DN</TD><TD>MSigDB lists</TD><TD>MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_DN</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>BUCKANOVICH_T_LYMPHOCYTE_HOMING_ON_TUMOR_DN</TD><TD>MSigDB lists</TD><TD>BUCKANOVICH_T_LYMPHOCYTE_HOMING_ON_TUMOR_DN</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ATP9A</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>DELLA_RESPONSE_TO_TSA_AND_BUTYRATE</TD><TD>MSigDB lists</TD><TD>DELLA_RESPONSE_TO_TSA_AND_BUTYRATE</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>BIOCARTA_TH1TH2_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_TH1TH2_PATHWAY</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>NIELSEN_GIST_AND_SYNOVIAL_SARCOMA_UP</TD><TD>MSigDB lists</TD><TD>NIELSEN_GIST_AND_SYNOVIAL_SARCOMA_UP</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>INSULIN_RECEPTOR_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>INSULIN_RECEPTOR_SIGNALING_PATHWAY</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.093e-02</TD><TD>-3.20</TD><TD>chr7p12</TD><TD>MSigDB lists</TD><TD>chr7p12</TD><TD>19</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SUN3</TD></TR>
<TR><TD>4.109e-02</TD><TD>-3.19</TD><TD>NFKB1 (nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)</TD><TD>protein interactions</TD><TD>4790</TD><TD>152</TD><TD>2</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1,TSC22D3</TD></TR>
<TR><TD>4.113e-02</TD><TD>-3.19</TD><TD>neuron projection</TD><TD>cellular component</TD><TD>GO:0043005</TD><TD>888</TD><TD>5</TD><TD>17570</TD><TD>38</TD>
<TD>TIMP2,CNTNAP2,SLC1A3,IGF1R,MAP2</TD></TR>
<TR><TD>4.115e-02</TD><TD>-3.19</TD><TD>GRUETZMANN_PANCREATIC_CANCER_UP</TD><TD>MSigDB lists</TD><TD>GRUETZMANN_PANCREATIC_CANCER_UP</TD><TD>350</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,CD55,PLOD2</TD></TR>
<TR><TD>4.126e-02</TD><TD>-3.19</TD><TD>response to abiotic stimulus</TD><TD>biological process</TD><TD>GO:0009628</TD><TD>1116</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2,SLC1A3,CTGF,HSPG2,PLOD2,TSC22D3</TD></TR>
<TR><TD>4.129e-02</TD><TD>-3.19</TD><TD>chronic_myelomonocytic_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>chronic_myelomonocytic_leukaemia</TD><TD>151</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>SYTL2,MECOM</TD></TR>
<TR><TD>4.129e-02</TD><TD>-3.19</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_myelomonocytic_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_myelomonocytic_leukaemia</TD><TD>151</TD><TD>2</TD><TD>17775</TD><TD>38</TD>
<TD>SYTL2,MECOM</TD></TR>
<TR><TD>4.131e-02</TD><TD>-3.19</TD><TD>CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_DN</TD><TD>MSigDB lists</TD><TD>CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_DN</TD><TD>147</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,CTGF</TD></TR>
<TR><TD>4.145e-02</TD><TD>-3.18</TD><TD>regulation of T cell proliferation</TD><TD>biological process</TD><TD>GO:0042129</TD><TD>140</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,CD55</TD></TR>
<TR><TD>4.145e-02</TD><TD>-3.18</TD><TD>negative regulation of MAPK cascade</TD><TD>biological process</TD><TD>GO:0043409</TD><TD>140</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,MECOM</TD></TR>
<TR><TD>4.145e-02</TD><TD>-3.18</TD><TD>regulation of cAMP metabolic process</TD><TD>biological process</TD><TD>GO:0030814</TD><TD>140</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,PDE4D</TD></TR>
<TR><TD>4.159e-02</TD><TD>-3.18</TD><TD>EIF5A2 (eukaryotic translation initiation factor 5A2)</TD><TD>protein interactions</TD><TD>56648</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>4.159e-02</TD><TD>-3.18</TD><TD>KCNA2 (potassium channel, voltage gated shaker related subfamily A, member 2)</TD><TD>protein interactions</TD><TD>3737</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.159e-02</TD><TD>-3.18</TD><TD>MATN2 (matrilin 2)</TD><TD>protein interactions</TD><TD>4147</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.159e-02</TD><TD>-3.18</TD><TD>RNF123 (ring finger protein 123)</TD><TD>protein interactions</TD><TD>63891</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.159e-02</TD><TD>-3.18</TD><TD>NXPH2 (neurexophilin 2)</TD><TD>protein interactions</TD><TD>11249</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>FRAS1</TD></TR>
<TR><TD>4.159e-02</TD><TD>-3.18</TD><TD>MTHFD1L (methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like)</TD><TD>protein interactions</TD><TD>25902</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>4.159e-02</TD><TD>-3.18</TD><TD>SERPINE2 (serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2)</TD><TD>protein interactions</TD><TD>5270</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.159e-02</TD><TD>-3.18</TD><TD>KCNIP3 (Kv channel interacting protein 3, calsenilin)</TD><TD>protein interactions</TD><TD>30818</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.159e-02</TD><TD>-3.18</TD><TD>MYO5B (myosin VB)</TD><TD>protein interactions</TD><TD>4645</TD><TD>20</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>4.166e-02</TD><TD>-3.18</TD><TD>anchored component of membrane</TD><TD>cellular component</TD><TD>GO:0031225</TD><TD>150</TD><TD>2</TD><TD>17570</TD><TD>38</TD>
<TD>CD55,MFI2</TD></TR>
<TR><TD>4.174e-02</TD><TD>-3.18</TD><TD>MONNIER_POSTRADIATION_TUMOR_ESCAPE_DN</TD><TD>MSigDB lists</TD><TD>MONNIER_POSTRADIATION_TUMOR_ESCAPE_DN</TD><TD>352</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF,FGF19,TSC22D3</TD></TR>
<TR><TD>4.181e-02</TD><TD>-3.17</TD><TD>IGFBP-like</TD><TD>interpro domains</TD><TD>IPR000867</TD><TD>20</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.182e-02</TD><TD>-3.17</TD><TD>POSITIVE_REGULATION_OF_CELL_PROLIFERATION</TD><TD>MSigDB lists</TD><TD>POSITIVE_REGULATION_OF_CELL_PROLIFERATION</TD><TD>148</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,IGF1R</TD></TR>
<TR><TD>4.182e-02</TD><TD>-3.17</TD><TD>GSE29614_CTRL_VS_DAY7_TIV_FLU_VACCINE_PBMC_UP</TD><TD>MSigDB lists</TD><TD>GSE29614_CTRL_VS_DAY7_TIV_FLU_VACCINE_PBMC_UP</TD><TD>148</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,FGF19</TD></TR>
<TR><TD>4.190e-02</TD><TD>-3.17</TD><TD>neuron part</TD><TD>cellular component</TD><TD>GO:0097458</TD><TD>1197</TD><TD>6</TD><TD>17570</TD><TD>38</TD>
<TD>TIMP2,CNTNAP2,SLC1A3,IGF1R,MYRIP,MAP2</TD></TR>
<TR><TD>4.192e-02</TD><TD>-3.17</TD><TD>salivary_gland-mouth_roof-carcinoma-adenoid_cystic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-mouth_roof-carcinoma-adenoid_cystic_carcinoma</TD><TD>20</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>MAP2</TD></TR>
<TR><TD>4.204e-02</TD><TD>-3.17</TD><TD>SANSOM_APC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>SANSOM_APC_TARGETS_DN</TD><TD>353</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,COL4A5,SULT2B1</TD></TR>
<TR><TD>4.211e-02</TD><TD>-3.17</TD><TD>4.1m</TD><TD>smart domains</TD><TD>SM00294</TD><TD>14</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.211e-02</TD><TD>-3.17</TD><TD>SEA</TD><TD>smart domains</TD><TD>SM00200</TD><TD>14</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.215e-02</TD><TD>-3.17</TD><TD>CRYSTALLIN_BETA_GAMMA</TD><TD>prosite domains</TD><TD>PS50915</TD><TD>15</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>AIM1</TD></TR>
<TR><TD>4.216e-02</TD><TD>-3.17</TD><TD>cell periphery</TD><TD>cellular component</TD><TD>GO:0071944</TD><TD>4907</TD><TD>16</TD><TD>17570</TD><TD>38</TD>
<TD>AMOTL2,CD55,MFI2,HSPG2,ATP9A,ATP2C2,SLC1A3,CNTNAP2,SYTL2,IGF1R,CTGF,FRAS1,NETO2,TRPC1,PDE4D,MYRIP</TD></TR>
<TR><TD>4.233e-02</TD><TD>-3.16</TD><TD>ACACTGG,MIR-199A,MIR-199B</TD><TD>MSigDB lists</TD><TD>ACACTGG,MIR-199A,MIR-199B</TD><TD>149</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,CTGF</TD></TR>
<TR><TD>4.233e-02</TD><TD>-3.16</TD><TD>GSE29614_DAY3_VS_DAY7_TIV_FLU_VACCINE_PBMC_UP</TD><TD>MSigDB lists</TD><TD>GSE29614_DAY3_VS_DAY7_TIV_FLU_VACCINE_PBMC_UP</TD><TD>149</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM3,FGF19</TD></TR>
<TR><TD>4.238e-02</TD><TD>-3.16</TD><TD>Histidinemia</TD><TD>SMPDB pathways</TD><TD>SMP00191</TD><TD>14</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.238e-02</TD><TD>-3.16</TD><TD>Histidine Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP00044</TD><TD>14</TD><TD>1</TD><TD>978</TD><TD>3</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.239e-02</TD><TD>-3.16</TD><TD>regulation of phosphorylation</TD><TD>biological process</TD><TD>GO:0042325</TD><TD>1425</TD><TD>7</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,TIMP2,PDE4D,CTGF,IGF1R,FGF19,MECOM</TD></TR>
<TR><TD>4.242e-02</TD><TD>-3.16</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.20.1110.10</TD><TD>16</TD><TD>1</TD><TD>9988</TD><TD>27</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>Aldedh</TD><TD>pfam domains</TD><TD>PF00171</TD><TD>19</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.264e-02</TD><TD>-3.15</TD><TD>mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>mantle_cell_lymphoma</TD><TD>2976</TD><TD>11</TD><TD>17775</TD><TD>38</TD>
<TD>CTGF,PDLIM3,PLOD2,MAP2,FRAS1,TSC22D3,COL4A5,SLC1A3,CNTNAP2,SOX8,MYRIP</TD></TR>
<TR><TD>4.272e-02</TD><TD>-3.15</TD><TD>single-multicellular organism process</TD><TD>biological process</TD><TD>GO:0044707</TD><TD>6192</TD><TD>20</TD><TD>16441</TD><TD>38</TD>
<TD>CD55,TIMP2,HSPG2,NR4A1,IL18,COL4A5,SLC1A3,CNTNAP2,FGF19,COL12A1,MECOM,CTGF,IGF1R,PDLIM3,MAP2,FRAS1,TOX2,TRPC1,PDE4D,SOX8</TD></TR>
<TR><TD>4.284e-02</TD><TD>-3.15</TD><TD>LU_AGING_BRAIN_DN</TD><TD>MSigDB lists</TD><TD>LU_AGING_BRAIN_DN</TD><TD>150</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,MAP2</TD></TR>
<TR><TD>4.284e-02</TD><TD>-3.15</TD><TD>RUIZ_TNC_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>RUIZ_TNC_TARGETS_UP</TD><TD>150</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,ATP9A</TD></TR>
<TR><TD>4.289e-02</TD><TD>-3.15</TD><TD>perinuclear region of cytoplasm</TD><TD>cellular component</TD><TD>GO:0048471</TD><TD>615</TD><TD>4</TD><TD>17570</TD><TD>38</TD>
<TD>GALNT3,CTGF,MYRIP,ATP9A</TD></TR>
<TR><TD>4.291e-02</TD><TD>-3.15</TD><TD>ionotropic glutamate receptor binding</TD><TD>molecular function</TD><TD>GO:0035255</TD><TD>19</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.291e-02</TD><TD>-3.15</TD><TD>adrenergic receptor binding</TD><TD>molecular function</TD><TD>GO:0031690</TD><TD>19</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.295e-02</TD><TD>-3.15</TD><TD>Fatty Acid Omega Oxidation</TD><TD>WikiPathways</TD><TD>WP206</TD><TD>15</TD><TD>1</TD><TD>4455</TD><TD>13</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>camera-type eye photoreceptor cell differentiation</TD><TD>biological process</TD><TD>GO:0060219</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>3'-phosphoadenosine 5'-phosphosulfate metabolic process</TD><TD>biological process</TD><TD>GO:0050427</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>positive regulation of protein maturation</TD><TD>biological process</TD><TD>GO:1903319</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>MFI2</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>positive regulation of natural killer cell activation</TD><TD>biological process</TD><TD>GO:0032816</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>cytokine metabolic process</TD><TD>biological process</TD><TD>GO:0042107</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>IL18</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>nephron tubule formation</TD><TD>biological process</TD><TD>GO:0072079</TD><TD>19</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>CHEMELLO_SOLEUS_VS_EDL_MYOFIBERS_DN</TD><TD>MSigDB lists</TD><TD>CHEMELLO_SOLEUS_VS_EDL_MYOFIBERS_DN</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM3</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>REACTOME_SIGNALING_BY_HIPPO</TD><TD>MSigDB lists</TD><TD>REACTOME_SIGNALING_BY_HIPPO</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>MODULE_362</TD><TD>MSigDB lists</TD><TD>MODULE_362</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>POSITIVE_REGULATION_OF_T_CELL_ACTIVATION</TD><TD>MSigDB lists</TD><TD>POSITIVE_REGULATION_OF_T_CELL_ACTIVATION</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>NIKOLSKY_BREAST_CANCER_15Q26_AMPLICON</TD><TD>MSigDB lists</TD><TD>NIKOLSKY_BREAST_CANCER_15Q26_AMPLICON</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>MODULE_186</TD><TD>MSigDB lists</TD><TD>MODULE_186</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>chr3q28</TD><TD>MSigDB lists</TD><TD>chr3q28</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MFI2</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>MODULE_58</TD><TD>MSigDB lists</TD><TD>MODULE_58</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD55</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>BIOCARTA_IGF1MTOR_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_IGF1MTOR_PATHWAY</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>TIAN_TNF_SIGNALING_NOT_VIA_NFKB</TD><TD>MSigDB lists</TD><TD>TIAN_TNF_SIGNALING_NOT_VIA_NFKB</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>REACTOME_HS_GAG_DEGRADATION</TD><TD>MSigDB lists</TD><TD>REACTOME_HS_GAG_DEGRADATION</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>NIELSEN_LEIOMYOSARCOMA_CNN1_DN</TD><TD>MSigDB lists</TD><TD>NIELSEN_LEIOMYOSARCOMA_CNN1_DN</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FRAS1</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>GESERICK_TERT_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>GESERICK_TERT_TARGETS_DN</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.304e-02</TD><TD>-3.15</TD><TD>BIOCARTA_AMI_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_AMI_PATHWAY</TD><TD>20</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.315e-02</TD><TD>-3.14</TD><TD>hepatocellular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>hepatocellular_carcinoma</TD><TD>15590</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,ATP9A,TSC22D3,ATP2C2,COL4A5,IL18,CNTNAP2,SLC1A3,FAM198B,FGF19,SYTL2,MECOM,ZNF432,CTGF,IGF1R,FRAS1,TOX2,AIM1,TRPC1,SUN3,TAGLN2,PDE4D,MYRIP,SULT2B1,AMOTL2,CD55,ALDH2,LONRF3,MFI2,NR4A1,COL12A1,GALNT3,PDLIM3,PLOD2,MAP2,NETO2,SOX8</TD></TR>
<TR><TD>4.315e-02</TD><TD>-3.14</TD><TD>liver-carcinoma-hepatocellular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>liver-carcinoma-hepatocellular_carcinoma</TD><TD>15590</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,ATP9A,TSC22D3,ATP2C2,COL4A5,IL18,CNTNAP2,SLC1A3,FAM198B,FGF19,SYTL2,MECOM,ZNF432,CTGF,IGF1R,FRAS1,TOX2,AIM1,TRPC1,SUN3,TAGLN2,PDE4D,MYRIP,SULT2B1,AMOTL2,CD55,ALDH2,LONRF3,MFI2,NR4A1,COL12A1,GALNT3,PDLIM3,PLOD2,MAP2,NETO2,SOX8</TD></TR>
<TR><TD>4.329e-02</TD><TD>-3.14</TD><TD>BGCRYSTALLIN</TD><TD>prints domains</TD><TD>PR01367</TD><TD>15</TD><TD>1</TD><TD>4759</TD><TD>14</TD>
<TD>AIM1</TD></TR>
<TR><TD>4.335e-02</TD><TD>-3.14</TD><TD>chondrosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>chondrosarcoma</TD><TD>1221</TD><TD>6</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,PLOD2,MAP2,FRAS1,AIM1,SYTL2</TD></TR>
<TR><TD>4.336e-02</TD><TD>-3.14</TD><TD>GAVIN_FOXP3_TARGETS_CLUSTER_P3</TD><TD>MSigDB lists</TD><TD>GAVIN_FOXP3_TARGETS_CLUSTER_P3</TD><TD>151</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,SYTL2</TD></TR>
<TR><TD>4.345e-02</TD><TD>-3.14</TD><TD>ion homeostasis</TD><TD>biological process</TD><TD>GO:0050801</TD><TD>578</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CD55,MFI2,ATP2C2</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>SLC2A1 (solute carrier family 2 (facilitated glucose transporter), member 1)</TD><TD>protein interactions</TD><TD>6513</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>TINAGL1 (tubulointerstitial nephritis antigen-like 1)</TD><TD>protein interactions</TD><TD>64129</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>TRPC1 (transient receptor potential cation channel, subfamily C, member 1)</TD><TD>protein interactions</TD><TD>7220</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TRPC1</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>SOCS2 (suppressor of cytokine signaling 2)</TD><TD>protein interactions</TD><TD>8835</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>MPP1 (membrane protein, palmitoylated 1)</TD><TD>protein interactions</TD><TD>4354</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>ITGA3 (integrin alpha 3)</TD><TD>protein interactions</TD><TD>3675</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TIMP2</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>TPP2 (tripeptidyl peptidase II)</TD><TD>protein interactions</TD><TD>7174</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>ARHGEF12 (Rho guanine nucleotide exchange factor (GEF) 12)</TD><TD>protein interactions</TD><TD>23365</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>IGKC (immunoglobulin kappa constant)</TD><TD>protein interactions</TD><TD>3514</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>CARKD (carbohydrate kinase domain containing)</TD><TD>protein interactions</TD><TD>55739</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>IGF2 (insulin-like growth factor 2)</TD><TD>protein interactions</TD><TD>3481</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.362e-02</TD><TD>-3.13</TD><TD>NDUFS7 (NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-coenzyme Q reductase))</TD><TD>protein interactions</TD><TD>374291</TD><TD>21</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>4.385e-02</TD><TD>-3.13</TD><TD>Oxoglu/Fe-dep_dioxygenase</TD><TD>interpro domains</TD><TD>IPR005123</TD><TD>21</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.385e-02</TD><TD>-3.13</TD><TD>PDEase_catalytic_dom</TD><TD>interpro domains</TD><TD>IPR002073</TD><TD>21</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.385e-02</TD><TD>-3.13</TD><TD>Netrin_domain</TD><TD>interpro domains</TD><TD>IPR001134</TD><TD>21</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>4.385e-02</TD><TD>-3.13</TD><TD>PDEase_CS</TD><TD>interpro domains</TD><TD>IPR023174</TD><TD>21</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.391e-02</TD><TD>-3.13</TD><TD>cellular response to endogenous stimulus</TD><TD>biological process</TD><TD>GO:0071495</TD><TD>1133</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,CTGF,IGF1R,PLOD2,NR4A1,FGF19</TD></TR>
<TR><TD>4.396e-02</TD><TD>-3.12</TD><TD>organ development</TD><TD>biological process</TD><TD>GO:0048513</TD><TD>2766</TD><TD>11</TD><TD>16441</TD><TD>38</TD>
<TD>IGF1R,CTGF,HSPG2,PDLIM3,FRAS1,TOX2,CNTNAP2,PDE4D,SOX8,FGF19,MECOM</TD></TR>
<TR><TD>4.438e-02</TD><TD>-3.11</TD><TD>Information processing speed(PMID:21130836)</TD><TD>GWAS genes</TD><TD>Information processing speed(PMID:21130836)</TD><TD>9</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>MYRIP</TD></TR>
<TR><TD>4.440e-02</TD><TD>-3.11</TD><TD>RODRIGUES_NTN1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>RODRIGUES_NTN1_TARGETS_DN</TD><TD>153</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2,NR4A1</TD></TR>
<TR><TD>4.440e-02</TD><TD>-3.11</TD><TD>TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP</TD><TD>MSigDB lists</TD><TD>TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP</TD><TD>153</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SLC1A3,NETO2</TD></TR>
<TR><TD>4.444e-02</TD><TD>-3.11</TD><TD>pleura-mesothelioma-epithelial</TD><TD>COSMIC cancer mutations</TD><TD>pleura-mesothelioma-epithelial</TD><TD>371</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,IGF1R,TOX2</TD></TR>
<TR><TD>4.447e-02</TD><TD>-3.11</TD><TD>costamere</TD><TD>cellular component</TD><TD>GO:0043034</TD><TD>21</TD><TD>1</TD><TD>17570</TD><TD>38</TD>
<TD>TRPC1</TD></TR>
<TR><TD>4.474e-02</TD><TD>-3.11</TD><TD>human chr16q24.1</TD><TD>chromosome location</TD><TD>human chr16q24.1</TD><TD>30</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>ATP2C2</TD></TR>
<TR><TD>4.475e-02</TD><TD>-3.11</TD><TD>IGFBP</TD><TD>pfam domains</TD><TD>PF00219</TD><TD>20</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.485e-02</TD><TD>-3.10</TD><TD>negative regulation of protein modification process</TD><TD>biological process</TD><TD>GO:0031400</TD><TD>584</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,IGF1R,SYTL2,MECOM</TD></TR>
<TR><TD>4.490e-02</TD><TD>-3.10</TD><TD>ALDEHYDE_DEHYDR_GLU</TD><TD>prosite domains</TD><TD>PS00687</TD><TD>16</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.490e-02</TD><TD>-3.10</TD><TD>FA58C_2</TD><TD>prosite domains</TD><TD>PS01286</TD><TD>16</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.490e-02</TD><TD>-3.10</TD><TD>ALDEHYDE_DEHYDR_CYS</TD><TD>prosite domains</TD><TD>PS00070</TD><TD>16</TD><TD>1</TD><TD>11866</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.492e-02</TD><TD>-3.10</TD><TD>SNF5_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>SNF5_DN.V1_DN</TD><TD>154</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ATP9A,SYTL2</TD></TR>
<TR><TD>4.492e-02</TD><TD>-3.10</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_1H_ACT_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_1H_ACT_CD4_TCELL_DN</TD><TD>154</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>LONRF3,COL12A1</TD></TR>
<TR><TD>4.492e-02</TD><TD>-3.10</TD><TD>HALLMARK_UV_RESPONSE_UP</TD><TD>MSigDB lists</TD><TD>HALLMARK_UV_RESPONSE_UP</TD><TD>154</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDLIM3,NR4A1</TD></TR>
<TR><TD>4.492e-02</TD><TD>-3.10</TD><TD>GTGACTT,MIR-224</TD><TD>MSigDB lists</TD><TD>GTGACTT,MIR-224</TD><TD>154</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,NR4A1</TD></TR>
<TR><TD>4.503e-02</TD><TD>-3.10</TD><TD>SMID_BREAST_CANCER_BASAL_UP</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_UP</TD><TD>615</TD><TD>4</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,CTGF,MAP2,PLOD2</TD></TR>
<TR><TD>4.503e-02</TD><TD>-3.10</TD><TD>epithelial</TD><TD>COSMIC cancer mutations</TD><TD>epithelial</TD><TD>373</TD><TD>3</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,IGF1R,TOX2</TD></TR>
<TR><TD>4.506e-02</TD><TD>-3.10</TD><TD>XTALbg</TD><TD>smart domains</TD><TD>SM00247</TD><TD>15</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>AIM1</TD></TR>
<TR><TD>4.508e-02</TD><TD>-3.10</TD><TD>metal ion transport</TD><TD>biological process</TD><TD>GO:0030001</TD><TD>585</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,CTGF,MFI2,ATP2C2</TD></TR>
<TR><TD>4.512e-02</TD><TD>-3.10</TD><TD>polypeptide N-acetylgalactosaminyltransferase activity</TD><TD>molecular function</TD><TD>GO:0004653</TD><TD>20</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>GALNT3</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_ALDEHYDE_OR_OXO_GROUP_OF_DONORS</TD><TD>MSigDB lists</TD><TD>OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_ALDEHYDE_OR_OXO_GROUP_OF_DONORS</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>CEBALLOS_TARGETS_OF_TP53_AND_MYC_UP</TD><TD>MSigDB lists</TD><TD>CEBALLOS_TARGETS_OF_TP53_AND_MYC_UP</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD55</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>HUI_MAPK14_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HUI_MAPK14_TARGETS_UP</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>FINETTI_BREAST_CANCERS_KINOME_BLUE</TD><TD>MSigDB lists</TD><TD>FINETTI_BREAST_CANCERS_KINOME_BLUE</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>MODULE_253</TD><TD>MSigDB lists</TD><TD>MODULE_253</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>YANG_MUC2_TARGETS_DUODENUM_3MO_DN</TD><TD>MSigDB lists</TD><TD>YANG_MUC2_TARGETS_DUODENUM_3MO_DN</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>BIOCARTA_CYTOKINE_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_CYTOKINE_PATHWAY</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>NUMATA_CSF3_SIGNALING_VIA_STAT3</TD><TD>MSigDB lists</TD><TD>NUMATA_CSF3_SIGNALING_VIA_STAT3</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>VERNELL_RETINOBLASTOMA_PATHWAY_DN</TD><TD>MSigDB lists</TD><TD>VERNELL_RETINOBLASTOMA_PATHWAY_DN</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A</TD><TD>MSigDB lists</TD><TD>SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>MACLACHLAN_BRCA1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>MACLACHLAN_BRCA1_TARGETS_UP</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>BIOCARTA_IGF1_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_IGF1_PATHWAY</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>MODULE_562</TD><TD>MSigDB lists</TD><TD>MODULE_562</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>4.515e-02</TD><TD>-3.10</TD><TD>BIOCARTA_IL12_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_IL12_PATHWAY</TD><TD>21</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>4.519e-02</TD><TD>-3.10</TD><TD>localization of cell</TD><TD>biological process</TD><TD>GO:0051674</TD><TD>853</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,SOX8,CTGF,NR4A1,FGF19</TD></TR>
<TR><TD>4.519e-02</TD><TD>-3.10</TD><TD>cell motility</TD><TD>biological process</TD><TD>GO:0048870</TD><TD>853</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,SOX8,CTGF,NR4A1,FGF19</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>regulation of lipopolysaccharide-mediated signaling pathway</TD><TD>biological process</TD><TD>GO:0031664</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CD55</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>metanephric epithelium development</TD><TD>biological process</TD><TD>GO:0072207</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>cartilage condensation</TD><TD>biological process</TD><TD>GO:0001502</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>L-glutamate transport</TD><TD>biological process</TD><TD>GO:0015813</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>adrenergic receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0071875</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>glutamine family amino acid biosynthetic process</TD><TD>biological process</TD><TD>GO:0009084</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>phospholipid translocation</TD><TD>biological process</TD><TD>GO:0045332</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>ATP9A</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>positive regulation of branching involved in ureteric bud morphogenesis</TD><TD>biological process</TD><TD>GO:0090190</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>secondary metabolite biosynthetic process</TD><TD>biological process</TD><TD>GO:0044550</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>cell aggregation</TD><TD>biological process</TD><TD>GO:0098743</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.525e-02</TD><TD>-3.10</TD><TD>purine ribonucleoside bisphosphate metabolic process</TD><TD>biological process</TD><TD>GO:0034035</TD><TD>20</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>4.545e-02</TD><TD>-3.09</TD><TD>chr20q13</TD><TD>MSigDB lists</TD><TD>chr20q13</TD><TD>155</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ATP9A,TOX2</TD></TR>
<TR><TD>4.552e-02</TD><TD>-3.09</TD><TD>cell morphogenesis</TD><TD>biological process</TD><TD>GO:0000902</TD><TD>1143</TD><TD>6</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,COL4A5,SLC1A3,IGF1R,MAP2,FGF19</TD></TR>
<TR><TD>4.565e-02</TD><TD>-3.09</TD><TD>LAMA1 (laminin, alpha 1)</TD><TD>protein interactions</TD><TD>284217</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.565e-02</TD><TD>-3.09</TD><TD>MECOM (MDS1 and EVI1 complex locus)</TD><TD>protein interactions</TD><TD>2122</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.565e-02</TD><TD>-3.09</TD><TD>PTRH2 (peptidyl-tRNA hydrolase 2)</TD><TD>protein interactions</TD><TD>51651</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>4.565e-02</TD><TD>-3.09</TD><TD>PDGFB (platelet-derived growth factor beta polypeptide)</TD><TD>protein interactions</TD><TD>5155</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.565e-02</TD><TD>-3.09</TD><TD>SCNN1B (sodium channel, non voltage gated 1 beta subunit)</TD><TD>protein interactions</TD><TD>6338</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TSC22D3</TD></TR>
<TR><TD>4.565e-02</TD><TD>-3.09</TD><TD>GNG5 (guanine nucleotide binding protein (G protein), gamma 5)</TD><TD>protein interactions</TD><TD>2787</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>4.565e-02</TD><TD>-3.09</TD><TD>TRAPPC3 (trafficking protein particle complex 3)</TD><TD>protein interactions</TD><TD>27095</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>4.565e-02</TD><TD>-3.09</TD><TD>FGG (fibrinogen gamma chain)</TD><TD>protein interactions</TD><TD>2266</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.565e-02</TD><TD>-3.09</TD><TD>GPHA2 (glycoprotein hormone alpha 2)</TD><TD>protein interactions</TD><TD>170589</TD><TD>22</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>FRAS1</TD></TR>
<TR><TD>4.589e-02</TD><TD>-3.08</TD><TD>SEA_dom</TD><TD>interpro domains</TD><TD>IPR000082</TD><TD>22</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.589e-02</TD><TD>-3.08</TD><TD>Fibroblast_GF_fam</TD><TD>interpro domains</TD><TD>IPR002209</TD><TD>22</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>FGF19</TD></TR>
<TR><TD>4.599e-02</TD><TD>-3.08</TD><TD>large_cell</TD><TD>COSMIC cancer mutations</TD><TD>large_cell</TD><TD>15622</TD><TD>37</TD><TD>17775</TD><TD>38</TD>
<TD>HSPG2,ATP9A,TSC22D3,ATP2C2,COL4A5,IL18,CNTNAP2,SLC1A3,FAM198B,FGF19,SYTL2,MECOM,ZNF432,CTGF,IGF1R,FRAS1,TOX2,AIM1,TRPC1,SUN3,TAGLN2,PDE4D,MYRIP,SULT2B1,AMOTL2,CD55,ALDH2,LONRF3,MFI2,NR4A1,COL12A1,GALNT3,PDLIM3,PLOD2,MAP2,NETO2,SOX8</TD></TR>
<TR><TD>4.620e-02</TD><TD>-3.07</TD><TD>human chr11q23.1</TD><TD>chromosome location</TD><TD>human chr11q23.1</TD><TD>31</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>IL18</TD></TR>
<TR><TD>4.627e-02</TD><TD>-3.07</TD><TD>response to peptide</TD><TD>biological process</TD><TD>GO:1901652</TD><TD>590</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,IGF1R,NR4A1,FGF19</TD></TR>
<TR><TD>4.631e-02</TD><TD>-3.07</TD><TD>negative regulation of protein phosphorylation</TD><TD>biological process</TD><TD>GO:0001933</TD><TD>349</TD><TD>3</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D,IGF1R,MECOM</TD></TR>
<TR><TD>4.637e-02</TD><TD>-3.07</TD><TD>appendage morphogenesis</TD><TD>biological process</TD><TD>GO:0035107</TD><TD>149</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>FRAS1,MECOM</TD></TR>
<TR><TD>4.637e-02</TD><TD>-3.07</TD><TD>limb morphogenesis</TD><TD>biological process</TD><TD>GO:0035108</TD><TD>149</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>FRAS1,MECOM</TD></TR>
<TR><TD>4.650e-02</TD><TD>-3.07</TD><TD>GSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_2H_DN</TD><TD>MSigDB lists</TD><TD>GSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_2H_DN</TD><TD>157</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>SUN3,NR4A1</TD></TR>
<TR><TD>4.666e-02</TD><TD>-3.06</TD><TD>BLALOCK_ALZHEIMERS_DISEASE_DN</TD><TD>MSigDB lists</TD><TD>BLALOCK_ALZHEIMERS_DISEASE_DN</TD><TD>1209</TD><TD>6</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,FAM198B,CNTNAP2,ALDH2,PDE4D,NETO2</TD></TR>
<TR><TD>4.666e-02</TD><TD>-3.06</TD><TD>Chylomicron-mediated lipid transport</TD><TD>REACTOME pathways</TD><TD>R-HSA-174800</TD><TD>17</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.693e-02</TD><TD>-3.06</TD><TD>regulation of muscle cell differentiation</TD><TD>biological process</TD><TD>GO:0051147</TD><TD>150</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,SOX8</TD></TR>
<TR><TD>4.694e-02</TD><TD>-3.06</TD><TD>PDEase_I</TD><TD>pfam domains</TD><TD>PF00233</TD><TD>21</TD><TD>1</TD><TD>16629</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.721e-02</TD><TD>-3.05</TD><TD>ear</TD><TD>COSMIC cancer mutations</TD><TD>ear</TD><TD>642</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,FRAS1,TOX2,NETO2</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>TARTE_PLASMA_CELL_VS_PLASMABLAST_UP</TD><TD>MSigDB lists</TD><TD>TARTE_PLASMA_CELL_VS_PLASMABLAST_UP</TD><TD>370</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2,NR4A1,TSC22D3</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>DAZARD_UV_RESPONSE_CLUSTER_G4</TD><TD>MSigDB lists</TD><TD>DAZARD_UV_RESPONSE_CLUSTER_G4</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>MODULE_372</TD><TD>MSigDB lists</TD><TD>MODULE_372</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SOX8</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>HINATA_NFKB_TARGETS_KERATINOCYTE_DN</TD><TD>MSigDB lists</TD><TD>HINATA_NFKB_TARGETS_KERATINOCYTE_DN</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>KEGG_BETA_ALANINE_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_BETA_ALANINE_METABOLISM</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_DN</TD><TD>MSigDB lists</TD><TD>MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_DN</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD55</TD></TR>
<TR><TD>4.725e-02</TD><TD>-3.05</TD><TD>REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION</TD><TD>22</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>FGF19</TD></TR>
<TR><TD>4.732e-02</TD><TD>-3.05</TD><TD>L-ascorbic acid binding</TD><TD>molecular function</TD><TD>GO:0031418</TD><TD>21</TD><TD>1</TD><TD>16491</TD><TD>38</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.743e-02</TD><TD>-3.05</TD><TD>large_intestine-colon-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-colon-adenoma</TD><TD>643</TD><TD>4</TD><TD>17775</TD><TD>38</TD>
<TD>CNTNAP2,PDLIM3,HSPG2,MAP2</TD></TR>
<TR><TD>4.746e-02</TD><TD>-3.05</TD><TD>cartilage development involved in endochondral bone morphogenesis</TD><TD>biological process</TD><TD>GO:0060351</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.746e-02</TD><TD>-3.05</TD><TD>negative regulation of heart contraction</TD><TD>biological process</TD><TD>GO:0045822</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.746e-02</TD><TD>-3.05</TD><TD>Sertoli cell differentiation</TD><TD>biological process</TD><TD>GO:0060008</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>4.746e-02</TD><TD>-3.05</TD><TD>negative regulation of peptidyl-serine phosphorylation</TD><TD>biological process</TD><TD>GO:0033137</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.746e-02</TD><TD>-3.05</TD><TD>regulation of membrane protein ectodomain proteolysis</TD><TD>biological process</TD><TD>GO:0051043</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2</TD></TR>
<TR><TD>4.746e-02</TD><TD>-3.05</TD><TD>lipid translocation</TD><TD>biological process</TD><TD>GO:0034204</TD><TD>21</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>ATP9A</TD></TR>
<TR><TD>4.749e-02</TD><TD>-3.05</TD><TD>cellular response to biotic stimulus</TD><TD>biological process</TD><TD>GO:0071216</TD><TD>151</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,PDE4D</TD></TR>
<TR><TD>4.757e-02</TD><TD>-3.05</TD><TD>IWANAGA_CARCINOGENESIS_BY_KRAS_UP</TD><TD>MSigDB lists</TD><TD>IWANAGA_CARCINOGENESIS_BY_KRAS_UP</TD><TD>159</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3,CD55</TD></TR>
<TR><TD>4.757e-02</TD><TD>-3.05</TD><TD>GSE2706_UNSTIM_VS_2H_LPS_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE2706_UNSTIM_VS_2H_LPS_DC_UP</TD><TD>159</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>ZNF432,TSC22D3</TD></TR>
<TR><TD>4.757e-02</TD><TD>-3.05</TD><TD>HALLMARK_APOPTOSIS</TD><TD>MSigDB lists</TD><TD>HALLMARK_APOPTOSIS</TD><TD>159</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>IL18,TIMP2</TD></TR>
<TR><TD>4.766e-02</TD><TD>-3.04</TD><TD>human chr3q23</TD><TD>chromosome location</TD><TD>human chr3q23</TD><TD>32</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>TRPC1</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>COTL1 (coactosin-like F-actin binding protein 1)</TD><TD>protein interactions</TD><TD>23406</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>NID1 (nidogen 1)</TD><TD>protein interactions</TD><TD>4811</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>HDGFRP2 (hepatoma-derived growth factor-related protein 2)</TD><TD>protein interactions</TD><TD>84717</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>MMP14 (matrix metallopeptidase 14 (membrane-inserted))</TD><TD>protein interactions</TD><TD>4323</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TIMP2</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>RAD51D (RAD51 paralog D)</TD><TD>protein interactions</TD><TD>5892</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>ITGA2 (integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor))</TD><TD>protein interactions</TD><TD>3673</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>IL9R (interleukin 9 receptor)</TD><TD>protein interactions</TD><TD>3581</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NETO2</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>SPARC (secreted protein, acidic, cysteine-rich (osteonectin))</TD><TD>protein interactions</TD><TD>6678</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>HSPG2</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>SYNJ2BP (synaptojanin 2 binding protein)</TD><TD>protein interactions</TD><TD>55333</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>CALML5 (calmodulin-like 5)</TD><TD>protein interactions</TD><TD>51806</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>ALDH2</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>PAX3 (paired box 3)</TD><TD>protein interactions</TD><TD>5077</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>SOX8</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>TRPC3 (transient receptor potential cation channel, subfamily C, member 3)</TD><TD>protein interactions</TD><TD>7222</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TRPC1</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>PPP3R1 (protein phosphatase 3, regulatory subunit B, alpha)</TD><TD>protein interactions</TD><TD>5534</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>PPBP (pro-platelet basic protein)</TD><TD>protein interactions</TD><TD>5473</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.768e-02</TD><TD>-3.04</TD><TD>TRAPPC9 (trafficking protein particle complex 9)</TD><TD>protein interactions</TD><TD>83696</TD><TD>23</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>4.772e-02</TD><TD>-3.04</TD><TD>positive regulation of MAPK cascade</TD><TD>biological process</TD><TD>GO:0043410</TD><TD>596</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>TIMP2,CTGF,IGF1R,FGF19</TD></TR>
<TR><TD>4.780e-02</TD><TD>-3.04</TD><TD>response to oxygen-containing compound</TD><TD>biological process</TD><TD>GO:1901700</TD><TD>1463</TD><TD>7</TD><TD>16441</TD><TD>38</TD>
<TD>IL18,PDE4D,CTGF,IGF1R,MAP2,NR4A1,FGF19</TD></TR>
<TR><TD>4.793e-02</TD><TD>-3.04</TD><TD>IL-1_fam/FGF_fam</TD><TD>interpro domains</TD><TD>IPR028142</TD><TD>23</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>FGF19</TD></TR>
<TR><TD>4.793e-02</TD><TD>-3.04</TD><TD>TIMP-like_OB-fold</TD><TD>interpro domains</TD><TD>IPR008993</TD><TD>23</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>4.793e-02</TD><TD>-3.04</TD><TD>FA58C</TD><TD>interpro domains</TD><TD>IPR000421</TD><TD>23</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.799e-02</TD><TD>-3.04</TD><TD>P4Hc</TD><TD>smart domains</TD><TD>SM00702</TD><TD>16</TD><TD>1</TD><TD>9131</TD><TD>28</TD>
<TD>PLOD2</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>cartilage development</TD><TD>biological process</TD><TD>GO:0051216</TD><TD>152</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>CTGF,HSPG2</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>macromitophagy</TD><TD>biological process</TD><TD>GO:0000423</TD><TD>152</TD><TD>2</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3,PLOD2</TD></TR>
<TR><TD>4.806e-02</TD><TD>-3.04</TD><TD>mouth_roof</TD><TD>COSMIC cancer mutations</TD><TD>mouth_roof</TD><TD>23</TD><TD>1</TD><TD>17775</TD><TD>38</TD>
<TD>MAP2</TD></TR>
<TR><TD>4.811e-02</TD><TD>-3.03</TD><TD>SOLUBLE_FRACTION</TD><TD>MSigDB lists</TD><TD>SOLUBLE_FRACTION</TD><TD>160</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,PDE4D</TD></TR>
<TR><TD>4.811e-02</TD><TD>-3.03</TD><TD>CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP</TD><TD>MSigDB lists</TD><TD>CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP</TD><TD>160</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5,TSC22D3</TD></TR>
<TR><TD>4.811e-02</TD><TD>-3.03</TD><TD>MORF_PPP2R5B</TD><TD>MSigDB lists</TD><TD>MORF_PPP2R5B</TD><TD>160</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>PDE4D,SULT2B1</TD></TR>
<TR><TD>4.848e-02</TD><TD>-3.03</TD><TD>MODULE_2</TD><TD>MSigDB lists</TD><TD>MODULE_2</TD><TD>374</TD><TD>3</TD><TD>17758</TD><TD>39</TD>
<TD>HSPG2,NR4A1,ATP9A</TD></TR>
<TR><TD>4.850e-02</TD><TD>-3.03</TD><TD>neuronal cell body</TD><TD>cellular component</TD><TD>GO:0043025</TD><TD>380</TD><TD>3</TD><TD>17570</TD><TD>38</TD>
<TD>TIMP2,SLC1A3,MAP2</TD></TR>
<TR><TD>4.855e-02</TD><TD>-3.03</TD><TD>Complement Activation, Classical Pathway</TD><TD>WikiPathways</TD><TD>WP545</TD><TD>17</TD><TD>1</TD><TD>4455</TD><TD>13</TD>
<TD>CD55</TD></TR>
<TR><TD>4.864e-02</TD><TD>-3.02</TD><TD>GSE11057_NAIVE_VS_CENT_MEMORY_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE11057_NAIVE_VS_CENT_MEMORY_CD4_TCELL_UP</TD><TD>161</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>CD55,IGF1R</TD></TR>
<TR><TD>4.910e-02</TD><TD>-3.01</TD><TD>CTTTAAR_UNKNOWN</TD><TD>MSigDB lists</TD><TD>CTTTAAR_UNKNOWN</TD><TD>918</TD><TD>5</TD><TD>17758</TD><TD>39</TD>
<TD>TAGLN2,SLC1A3,MAP2,TOX2,MECOM</TD></TR>
<TR><TD>4.911e-02</TD><TD>-3.01</TD><TD>human chr3p22.1</TD><TD>chromosome location</TD><TD>human chr3p22.1</TD><TD>33</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>MYRIP</TD></TR>
<TR><TD>4.911e-02</TD><TD>-3.01</TD><TD>human chr17q25</TD><TD>chromosome location</TD><TD>human chr17q25</TD><TD>33</TD><TD>1</TD><TD>26250</TD><TD>40</TD>
<TD>TIMP2</TD></TR>
<TR><TD>4.919e-02</TD><TD>-3.01</TD><TD>ESC_V6.5_UP_EARLY.V1_UP</TD><TD>MSigDB lists</TD><TD>ESC_V6.5_UP_EARLY.V1_UP</TD><TD>162</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>FGF19,SYTL2</TD></TR>
<TR><TD>4.919e-02</TD><TD>-3.01</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_24H_ACT_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_24H_ACT_CD4_TCELL_DN</TD><TD>162</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TRPC1,TOX2</TD></TR>
<TR><TD>4.919e-02</TD><TD>-3.01</TD><TD>GCNP_SHH_UP_EARLY.V1_DN</TD><TD>MSigDB lists</TD><TD>GCNP_SHH_UP_EARLY.V1_DN</TD><TD>162</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>AMOTL2,AIM1</TD></TR>
<TR><TD>4.919e-02</TD><TD>-3.01</TD><TD>secretion</TD><TD>biological process</TD><TD>GO:0046903</TD><TD>602</TD><TD>4</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,SLC1A3,CTGF,SYTL2</TD></TR>
<TR><TD>4.920e-02</TD><TD>-3.01</TD><TD>Renal function-related traits (BUN)(PMID:22797727)</TD><TD>GWAS genes</TD><TD>Renal function-related traits (BUN)(PMID:22797727)</TD><TD>10</TD><TD>1</TD><TD>2389</TD><TD>12</TD>
<TD>MECOM</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>Cytosolic sulfonation of small molecules</TD><TD>REACTOME pathways</TD><TD>R-HSA-156584</TD><TD>18</TD><TD>1</TD><TD>8202</TD><TD>23</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>BIOCARTA_INTRINSIC_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_INTRINSIC_PATHWAY</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>MODULE_222</TD><TD>MSigDB lists</TD><TD>MODULE_222</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>DEBOSSCHER_NFKB_TARGETS_REPRESSED_BY_GLUCOCORTICOIDS</TD><TD>MSigDB lists</TD><TD>DEBOSSCHER_NFKB_TARGETS_REPRESSED_BY_GLUCOCORTICOIDS</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>IIZUKA_LIVER_CANCER_PROGRESSION_L0_L1_UP</TD><TD>MSigDB lists</TD><TD>IIZUKA_LIVER_CANCER_PROGRESSION_L0_L1_UP</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>SULT2B1</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>BIOCARTA_IGF1R_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_IGF1R_PATHWAY</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>POSITIVE_REGULATION_OF_LYMPHOCYTE_ACTIVATION</TD><TD>MSigDB lists</TD><TD>POSITIVE_REGULATION_OF_LYMPHOCYTE_ACTIVATION</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>IL18</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>MODULE_168</TD><TD>MSigDB lists</TD><TD>MODULE_168</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRESSION</TD><TD>MSigDB lists</TD><TD>REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRESSION</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>JEON_SMAD6_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>JEON_SMAD6_TARGETS_UP</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>TIMP2</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>MODULE_196</TD><TD>MSigDB lists</TD><TD>MODULE_196</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>MAP2</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>MODULE_130</TD><TD>MSigDB lists</TD><TD>MODULE_130</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>CD55</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>COLLAGEN</TD><TD>MSigDB lists</TD><TD>COLLAGEN</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>COL4A5</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>WAGNER_APO2_SENSITIVITY</TD><TD>MSigDB lists</TD><TD>WAGNER_APO2_SENSITIVITY</TD><TD>23</TD><TD>1</TD><TD>17758</TD><TD>39</TD>
<TD>GALNT3</TD></TR>
<TR><TD>4.966e-02</TD><TD>-3.00</TD><TD>metanephric nephron morphogenesis</TD><TD>biological process</TD><TD>GO:0072273</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>4.966e-02</TD><TD>-3.00</TD><TD>regulation of osteoblast proliferation</TD><TD>biological process</TD><TD>GO:0033688</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8</TD></TR>
<TR><TD>4.966e-02</TD><TD>-3.00</TD><TD>subpallium development</TD><TD>biological process</TD><TD>GO:0021544</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>CNTNAP2</TD></TR>
<TR><TD>4.966e-02</TD><TD>-3.00</TD><TD>acidic amino acid transport</TD><TD>biological process</TD><TD>GO:0015800</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>SLC1A3</TD></TR>
<TR><TD>4.966e-02</TD><TD>-3.00</TD><TD>positive regulation of heart rate</TD><TD>biological process</TD><TD>GO:0010460</TD><TD>22</TD><TD>1</TD><TD>16441</TD><TD>38</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>LTA4H (leukotriene A4 hydrolase)</TD><TD>protein interactions</TD><TD>4048</TD><TD>24</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>SNX12 (sorting nexin 12)</TD><TD>protein interactions</TD><TD>29934</TD><TD>24</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>NDUFB7 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa)</TD><TD>protein interactions</TD><TD>4713</TD><TD>24</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>CD55</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>ITPR3 (inositol 1,4,5-trisphosphate receptor, type 3)</TD><TD>protein interactions</TD><TD>3710</TD><TD>24</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TRPC1</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>MAGOHB (mago homolog B, exon junction complex core component)</TD><TD>protein interactions</TD><TD>55110</TD><TD>24</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>AMOTL2</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>GOLGA8EP (golgin A8 family, member E, pseudogene)</TD><TD>protein interactions</TD><TD>390535</TD><TD>24</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>PDE4D</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>INS (insulin)</TD><TD>protein interactions</TD><TD>3630</TD><TD>24</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>IGF1R</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>GK (glycerol kinase)</TD><TD>protein interactions</TD><TD>2710</TD><TD>24</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>NR4A1</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>EHD2 (EH domain containing 2)</TD><TD>protein interactions</TD><TD>30846</TD><TD>24</TD><TD>1</TD><TD>16036</TD><TD>34</TD>
<TD>TAGLN2</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>organ morphogenesis</TD><TD>biological process</TD><TD>GO:0009887</TD><TD>876</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>SOX8,CTGF,IGF1R,HSPG2,FRAS1</TD></TR>
<TR><TD>4.970e-02</TD><TD>-3.00</TD><TD>positive regulation of transport</TD><TD>biological process</TD><TD>GO:0051050</TD><TD>876</TD><TD>5</TD><TD>16441</TD><TD>38</TD>
<TD>TRPC1,IL18,MYRIP,FGF19,SYTL2</TD></TR>
<TR><TD>4.973e-02</TD><TD>-3.00</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP</TD><TD>MSigDB lists</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP</TD><TD>163</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>AIM1,NETO2</TD></TR>
<TR><TD>4.973e-02</TD><TD>-3.00</TD><TD>GSE17974_0H_VS_24H_IN_VITRO_ACT_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_0H_VS_24H_IN_VITRO_ACT_CD4_TCELL_UP</TD><TD>163</TD><TD>2</TD><TD>17758</TD><TD>39</TD>
<TD>TSC22D3,AIM1</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>Cys_knot_C</TD><TD>interpro domains</TD><TD>IPR006207</TD><TD>24</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>CTGF</TD></TR>
<TR><TD>4.996e-02</TD><TD>-3.00</TD><TD>HD/PDEase_dom</TD><TD>interpro domains</TD><TD>IPR003607</TD><TD>24</TD><TD>1</TD><TD>18293</TD><TD>39</TD>
<TD>PDE4D</TD></TR>
</TABLE>
</BODY></HTML>
